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Abstract
Angiogenesis, the growth of new capillaries from preexisting blood vessels, is 
essential for tumour growth and the development of metastases. Vascular endothelial 
growth factor is the most potent angiogenic factor identified to date Tamoxifen has 
been shown to inhibit angiogenesis m a manner independent of the oestrogen 
receptor. The expression of VEGF in breast cancer, possible regulators, and 
evidence for a VEGF related inhibition of angiogenesis by tamoxifen was examined. 
BT474 and MDA-MB-231 cells are breast cancer cell lines of primary and metastatic 
origin, respectively. Both cell lines expressed VEGF protein and mRNA with the 
MDA-MB-231 cell line producing 5 fold more VEGF than the BT474 cell line 
VEGF protein was elevated in breast tumour tissue as compared to matched normal 
tissue. Serum VEGF levels were significantly elevated m patients with breast cancer 
compared to patients with benign fibroadenomas and age-matched healthy controls 
The expression of TGF(3-1 was found to be associated with the expression of VEGF 
m the serum and tumour tissue of breast cancer patients. TGFp-1 increased 
expression of VEGF by both breast cancer cell lines. Tamoxifen significantly 
decreased serum levels of VEGF m breast cancer patients independently of oestrogen 
receptor status. Tamoxifen did not reduce VEGF production by either breast cancer 
cell lines or by macrophages, important contributors of breast tumour VEGF. 
Tamoxifen decreased monocyte transendothelial migration in vitro From these 
results we conclude that the expression pattern of VEGF suggest a role for this factor 
m breast cancer. TGFp-1 is a regulator of VEGF expression m breast cancer. 
Tamoxifen reduces serum VEGF levels and in an in vivo situation this may be 
achieved by reducing endothelial migration and tumour recruitment of macrophages 
and, thereby reducing overall tumour production of VEGF.
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CHAPTER 1
INTRODUCTION
1
1.1 Cancer epidemiology
According to the World Health Organisation approximately 6.6 million people world­
wide died of cancer in 1995 alone (WHO, 1996). Cancer is the second biggest killer 
with only heart disease killing more people each year. In Ireland there were nearly 
20,000 cancer cases and approximately 7,500 cancer deaths in 1995 (Irish Cancer 
Registry, 1996). In this country the risk of developing cancer before 75 years is 39% for 
men and 35% for women while the risk of dying of cancer before 75 years is 17% for 
men and 13% for women
World-wide, breast cancer is the commonest malignancy amongst women with 
approximately 570 000 new cases each year (McPherson et al., 1994). In Ireland it is 
the most common cancer m women accounting for 16% of all cancer cases. There were 
over 1,500 cases and over 600 deaths from breast cancer m Ireland m 1995 Currently, 
the risk of developing breast cancer before the age of 75 is 7.3% and the risk of death 
before 75 years is 2.8%. The mortality rate for patients diagnosed with breast cancer is 
41%.
1.2 Pathophysiology of breast cancer
Each breast is composed of 15 - 20 lobes, each of which then has a number of lobules. 
The lobules are connected to lobes via ducts. The most common form of breast cancer 
is ductal cancer, comprising 65% - 80% of all cases (American Joint Committee on 
Cancer, 1992). Lobular cancer is the second most common and there are a variety of 
other less common pathologies. Nearly all breast cancer is of epithelial origin although 
there are some rarer forms denved from connective tissue. Metastasis is a major feature 
of breast cancer. The most common site of metastases is to the axillary lymph nodes 
and other sites including the bram, liver, skeleton, skin and lungs. Approximately 60% 
of breast cancer cases are oestrogen receptor (ER) positive Oestrogen is believed to be 
mitogemc to all early stage breast cancer but as the disease advances many tumours lose 
this dependency and no longer express the oestrogen receptor.
1.3 Aetiology and treatment
No single factor has been definitively shown to initiate the malignant transformation of 
normal breast tissue. Epidemiological studies have identified a number of risk factors 
including age, early onset of menarche, late onset of menopause, elderly pnmi para (late
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age of first birth), positive family history, exposure to ionising radiation, obesity and a 
high fat intake and previous benign disease. Up to 10% of cases are thought to be due 
to genetic predisposition. Most of these cases are due to inherited mutations in the 
BRCA1, BRCA2 and p53 genes (McPherson et al., 1994).
Breast cancer is a very heterogeneous disease and the type of therapy chosen will 
depend on a number of factors including the stage and histology of the lesion, age, 
menopausal status and overall health. At present the main treatment options are 
surgery, radiation therapy, chemotherapy and hormonal therapy. Surgical removal of 
the tumour is the most common treatment and is usually accompanied by adjuvant 
hormonal or chemo-therapy.
1.4 Cancer growth
The number of cells within a multi-cellular organism is tightly controlled by a complex 
mechanism of signals that control the proliferation, differentiation and survival of 
individual cells. Deregulation of these cellular processes may result in changes in the 
number of cells. In cancer a single cell clone undergoes a series of genetic changes that 
gradually result in increasingly deregulated growth. Genetic changes in a subset of 
genes, the oncogenes and tumour suppressor genes cause this deregulated proliferation 
of cells. Initially, a single cell is altered and proliferates too rapidly. Over time a 
hyperplastic lesion may be further altered until the proliferative rate, state of 
differentiation and relationship with the microenvironment result in a fully developed 
neoplasm capable of metastasising to distant organs. This uncoordinated growth of a 
heterogeneous population of tumour cells will ultimately result in organ destruction and 
loss of function leading to death. However, in addition to tumour cells, solid tumours 
contain non-transformed host cells including fibroblasts, smooth muscle cells, pericytes, 
immune cells and endothelial cells. Survival of the tumour cells requires the support of 
these host cells. One of the most striking examples of tumour dependence on host cells 
is seen in the reliance of tumours on host vasculature.
Similar to normal tissue, tumours require the delivery of oxygen and nutrients 
and the removal of toxic waste products. As the tumour expands its oxygen and nutrient 
requirements can no longer be met by simple diffusion from nearby blood vessels. 
Solid tumours induce the growth of new blood vessels into the tumour to provide 
oxygen and nutrients to the tumour tissue. Endothelial cells also support tumour growth
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by releasing vanous paracrine growth factors, such as insulm-like growth factor (IGF) 
and granulocyte-colony stimulating factor (GMCSF) (Folkman, 1995) There is clear 
evidence that most solid tumours are dependent on the growth of new blood vessels, a 
process called angiogenesis. The evidence that tumour growth is angiogenesis 
dependent is comprehensively reviewed by (Folkman, 1990) and some examples are 
outlined here. A mouse sarcoma implanted sub-cutaneously, m transparent chambers, 
did not grow until the development of new blood vessels after which growth was nearly 
exponential (Algire et a l , 1945). Similarly, a rat sarcoma implanted on the chick 
embryo chonoallanotoic membrane did not grow for the first 72 hr when there was no 
blood vessel supply but tumour growth increased rapidly withm the first 24 hr of the in­
growth of blood vessels (Ingber et al., 1986). When a rabbit epithelioma was suspended 
m the anterior chamber of the eye, where it is physiologically impossible to attract new 
blood vessels, it remained viable but over 34 days did not grow beyond 1 mm3. When it 
was subsequently re-implanted on the ms, where it could induce new blood vessels, it 
reached 16,000 times its original volume within 2 weeks (Gimbrone et al., 1972) More 
recent experiments have show that avascular tumours remain small reaching a steady 
state size of approximately 2 mm2, upon which the lesion forms a dense population of 
cells in which the rate of proliferation of tumour cells is balanced by the rate of 
apoptosis and necrosis of cells (Holmgren et a l , 1995). These lesions are asymptomatic 
and are usually clinically undetectable until incidental discovery m post-mortem 
examinations (Folkman, 1995).
1.5 Angiogenesis
The vascular system is a very complex integrated organ providing essential transport 
functions such as the oxygenation and nutrition of all tissues, removal of the by­
products of metabolism, the circulation of cells that mediate host defence, the transport 
of proteins and cells involved m wound healing, inflammatory response, homeostasis 
and thrombolysis. The vasculature is composed of around 1012 endothelial cells lining 
the mside of blood vessels covering an area of approximately 1000 m2 in a 70 kg adult 
(Jaffe, 1987). At any time the cells in normal tissue are m close proximity to the 
endothelial cell of a blood vessel, which supplies all the necessary nutrients and removal 
of waste products. In the absence of neovasculansation, a tumour cell that is 
proliferating rapidly will soon be at some distance from the nearest endothelial cell due
to the increasing bulk of the tumour mass. Without nutrition and oxygenation by the 
vasculature its fate, and that of all its progeny, is starvation and death by necrosis or 
apoptosis.
Under normal physiological conditions, there is little need for new blood vessel 
formation, except in a few tightly controlled situations, such as wound healing, and the 
vasculature remains quiescent. However, the vasculature retains the ability to form new 
blood vessels, for example following injury (Edgington, 1995). The vasculature is 
formed in one of two ways, vasculogenesis and angiogenesis (Noden, 1989). 
Vasculogenesis is the process whereby simple angioblast cells, in the mesoderm, 
differentiate into endothelial cells and form primitive blood vessels (Risau and Flamme,
1995). Angiogenesis, however, is the sprouting of new capillaries from a pre-existing 
blood vessel (Wilting and Christ, 1996). Within the growing embryo the vasculature is 
formed by a combination of vasculogenesis and angiogenesis (Noden, 1989). In adults, 
however, angiogenesis is the sole method for new blood vessel formation (Tischer et al.,
1991).
1.6 Physiological and pathological angiogenesis
Angiogenesis occurs in a highly regulated fashion during normal physiological events. 
In the female reproductive system angiogenesis is required for the development of the 
corpus luteum in the ovary, the endometrium during the menstrual cycle and in the 
placenta throughout gestation (Reynolds et al., 1992). Revascularisation of tissue in a 
wound bed following injury is essential for the delivery of nutrients and immune cells 
and removal of debris and is accomplished by angiogenesis (Arbiser, 1996). 
Angiogenesis is also required for development and healing of bones (Winet, 1996). 
Under these circumstances angiogenesis is briefly turned on and then completely shut 
down. Aberrant angiogenesis can occur in a number of pathological states other than 
tumour growth. In rheumatoid arthritis, new capillary blood vessels invade the joint and 
destroy cartilage (Koch, 1998). Ocular neovascularisation, including diabetic 
retinopathy, is the most common cause of blindness and dominates approximately 20 
eye diseases (Folkman and Shing, 1992). Psoriasis is a chronic inflammatory disease 
that involves proliferation of the epidermis with nutritional support from increased 
angiogenesis in the dermis (Malhotra et al., 1989). Ischemic heart disease and
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peripheral vascular diseases occur when there are insufficient blood vessels to feed the 
heart (Battegay, 1995).
1.7 Steps in angiogenesis
Angiogenesis is a complex multi-step process and although it is a continuous process it 
has been divided into six steps:
1) the release of angiogenic factors
2) activation of endothelial cells
3) release of proteolytic enzymes
4) endothelial cell migration and morphogenesis
5) endothelial cell proliferation
6) microvessel differentiation
A simplified version of the process is illustrated in figure 1.1. The angiogenic cascade 
begins in response to the release of angiogenic factors. Tumour cells and host cells can 
secrete a large number of factors that are capable of inducing angiogenesis. Table 1.1 
provides a list of the most common endogenous protein angiogenic factors. In addition 
to these factors there are a variety of carbohydrates (lactic acid, hyaluronan fragments), 
lipids (prostaglandins) and other compounds (copper, nicotinamide) (comprehensively 
reviewed by Bouck et al., 1996). The precise role of each of these factors is still unclear 
as yet because of the wide range of mechanisms through which they can act. Some 
factors act nearly exclusively on endothelial cells, such as vascular endothelial growth 
factor (VEGF) (Jakeman et al., 1992), while other factors may act on a variety of 
different cells like basic fibroblast growth factor (bFGF), which may act on fibroblast, 
endothelial cells and smooth muscle cells (Gospodarowicz, 1990). Factors such as 
transforming growth factor p-1 (TGFp-1) and tumour necrosis factor a  (TNF-a) may 
inhibit the proliferation of endothelial cells but can still promote angiogenesis indirectly 
by involvement with other elements of the angiogenic cascade, such as the 
differentiation of endothelial cells (Pepper et al., 1993; Frater-Schroder et al., 1987). 
Angiogenic factors, bFGF in particular, are also found bound to the extracellular matrix 
and are activated when released by proteases (Baird and Ling, 1987). Angiogenic 
factors also act with varying degrees of potency with factors such as VEGF and bFGF 
being the most potent. The effects of multiple angiogenic factors may be synergistic 
such as seen with bFGF and VEGF (Goto et al., 1993), and bFGF with TGFfM
(Gajdusek et al., 1993). This was demonstrated in in vitro experiments where the effect 
of both factors together was greater than the sum effect of each factor alone. Because of 
the large number of angiogenic factors and the interplay between them and other factors 
the exact response from release of angiogenic factors may be hard to predict.
The target vessels for angiogenic factors are the post capillary venules and small 
terminal venules (Guvakova and Surmacz, 1997). These vessels are comprised of 
endothelial cells that lie upon a basal lamina surrounded by a discontinuous layer of 
pericytes and smooth muscle cells embedded in the extracellular matrix. The 
morphology of the endothelial cells is altered in response to angiogenic factors. There 
is an increase in the amount of endoplasmic reticulum, Golgi apparatus and 
mitochondria and the endothelial cells form protrusions on the abluminal side (Fox et 
al., 1996).
In order to accommodate new capillaries and allow their formation the basement 
membrane and extracellular matrix must be degraded. This is achieved by the 
production of a variety of proteolytic enzymes including plasminogen activators (uPA 
and tPA) and metalloproteinases (MMPs), secreted by endothelial cells (Bacharach et 
al., 1992; Hiraoka et al., 1998). The urokinase plasminogen activator generates plasmin, 
which is a broad spectrum protease that is capable of degrading most matrix 
components (Fox et al., 1996) while the membrane type 1-MMP (mt-1 MMP) degrades 
fibrin and can also effectively degrade matrix in plasmin deficient mice (Hiraoka et al., 
1998). Inhibition of urokinase activity inhibited angiogenesis and tumour growth of 
B16 cells in syngeneic mice (Brock et al., 1991). Protease inhibitors are also produced 
(Pepper and Montesano, 1990; Bacharach et al., 1992) so that a co-ordinated process of 
degradation and migration can be achieved. The angiogenic factor VEGF increases the 
number of uPA receptors (uPAR) on endothelial cells and this is believed to be 
important in co-ordinate regulation of matrix degradation and migration of endothelial 
cells (Mandriota et al., 1995). The matrix remodelling is a carefully controlled process 
balanced by the signals promoting and inhibiting proteolysis (Pepper and Montesano, 
1990).
The breakdown of the basement membrane and extracellular matrix allows 
endothelial cells from post capillary venules to migrate and form sprouts. Projections 
form and as the gap between endothelial cells grows neighbouring cells follow from the 
parental vessel. The endothelium initially forms as a solid cord but eventually inter- and
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intra-cellular spaces appear to form lumina (Folkman and Haudenschild, 1980). Very 
little is known about regulation of migration though VEGF is chemotactic for 
endothelial cells (Yoshida et al., 1996). Several cytokines have been reported that 
modulate migration but the signalling mechanism is only partly understood (Fox et al.,
1996). Expression of various cell adhesion molecules including integrin a vP3, E- 
selectin, sialyl Lewis-X and sialyl Lewis-A are essential for capillary morphogenesis 
(Brooks et al., 1994b; Nguyen et al., 1993).
As the endothelial sprout forms cells at the base proliferate to supply the 
elongating vessel. New capillaries therefore grow from the base and not from the tip 
(Fox et al., 1996). Endothelial cells are normally quiescent and divide very rarely, every 
7-10 years or so, while tumour endothelium divides much more rapidly. Endothelial 
cells in a tumour environment have been found to proliferate approximately 40 times 
faster than in normal tissue (Vartanian and Weidner, 1994). Remodelling of 
surrounding tissue also leads to an increase in endothelial cell numbers within the 
tumour tissue (Fox et al., 1993).
Developing buds anastomose with other developing buds or pre-existing vessels 
to form capillary loops that facilitate transport of blood and tissue perfusion (Polverini,
1995). In normal tissue new vessels stabilise and persist for as long as they are required. 
In a tumour environment, however, the endothelium of the new capillaries have wide 
cell junctions, numerous trans-endothelial channels and a discontinuous lining (Fox et 
al., 1996). The vessels are often lined with tumour cells. An irregular basement 
membrane often forms which is composed of varying amounts of fibronectin, laminin, 
and collagen. Cells such as smooth muscle cells, fibroblasts, pericytes also contribute to 
the formation of the matrix (Paku and Paweletz, 1991). VEGF cause hyper­
permeability of blood vessels (Senger et al., 1983). Because of both the structure of 
these new vessels and the action of VEGF on permeability these vessels are usually very 
leaky. Even after all these events have taken place there is a constant remodelling of 
formed vessels as well as the recruitment of new vessels so that the tumour vasculature 
is highly unstable (Fox et al., 1996). Endothelial cells are highly heterogeneous 
(McCarthy et al., 1991) and the morphology of the tumour vasculature is highly variable 
between tumours of different sites (Roberts et al., 1998).
Angiogenic factors
t
In situ tumour
Endothelial cells
Angiogenic factor receptors
B.
> •
Fig 1.1: Steps in angiogenesis
Tumour cells release angiogenic factors which bind to receptors on endothelial cells 
(A). Endothelial cells release proteases to degrade the extracellular matrix and migrate 
along a chemotactic gradient (B). Capillaries mature and a functional lumen allows 
transport of oxygen and nutrients to the tumour (C).
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Factor Endothelial cell 
(EC) mitogen
Reference
Acidic fibroblast growth factor 
(aFGF)
Positive (Thomas et al., 1985)
Basic fibroblast growth factor 
(bFGF)
Positive (Gospodarowicz, 1990)
Angiogemn no effect (Kurachi et al., 1985)
Transforming growth factor-a 
(TGFa)
Positive (Schreiber et al., 1986)
Transforming growth factor-(3 
(TGF(3)
Inhibitor (Roberts et al., 1986)
Tumour necrosis factor-a (TNF-a) Inhibitor (Fràter-Schroder et al., 1987)
Vascular endothelial growth factor 
(VEGF)
Positive (Connolly et al., 1989)
Platelet-denved endothelial cell 
growth factor (PD-ECGF)
Positive (Ishikawa et al., 1989)
Colony stimulating factor (CSF) Positive (Bussolino et al., 1991)
Insulin-like growth factor I 
(IGF-1)
n/a (Grant et al., 1993)
Platelet-denved growth factor 
(PDGF)
Positive (Risau et al., 1992)
Epidermal growth factor (EGF) Positive (Stewart et al., 1989)
Interleukm-8 (IL-8) Positive (Stneter et al., 1992)
Table 1.1: Endogenous protein angiogenic factors, n/a = not assessed
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1.8 Switch to the angiogenic phenotype
Tumour progression is known to occur in a multi-step manner in which cells become 
increasingly deregulated and proceed through a number of stages from a hyperplastic 
lesion to a metastasising neoplasm. The acquisition of an angiogenic phenotype is 
believed to be a critical event in the progression of the tumour. Most malignancies of 
epithelial origin have a pre-neoplastic stage that may last for several years and these pre­
neoplastic lesions are avascular compared with the highly angiogenic neoplasms. 
Studies of mice expressing oncogenes in the P-cells of pancreatic islets show that these 
cells readily become hyperplastic but only a few islets become angiogenic and this 
angiogenic activity is necessary for, and precedes, tumour formation (Folkman et al., 
1989). In another mouse model, basal keratinocytes were transformed into a squamous 
cell carcinoma by the human papillomavirus type 16 oncogene and tumour progression 
was only seen after sudden onset of angiogenesis that had been quiescent until that point 
(Coussens et al., 1996). Examination of sections from cervical smears has demonstrated 
that angiogenesis precedes late stage disease but is absent in the earlier stages of this 
cancer (Guidi et al., 1995). This demonstrates that increased tumour cell proliferation is 
not sufficient for the development of angiogenesis but that another key step, the 
acquisition of an angiogenic phenotype is also required. This has led to the 
development of the concept that tumours must activate an angiogenic ‘switch’ before 
tumour growth can progress to the formation of a clinically relevant tumour (Hanahan 
and Folkman, 1996).
Under normal physiological conditions angiogenesis is regulated by the release 
of anti-angiogenic factors which counter the effect of angiogenic factors. For example, 
studies of physiological angiogenesis have demonstrated that it occurs in highly 
regulated fashion and can be effectively and completely shut down when not required. 
Table 1.2 lists some of the more common endogenous inhibitors of angiogenesis that 
have been identified. These anti-angiogenic molecules function to inhibit angiogenesis 
when it is actively taking place or to suppress angiogenesis under normal circumstances 
(Quinn et al., 1993).
Cells must have some mechanism whereby they can integrate the pro- and anti- 
angiogenic signals and determine whether they should proceed to an angiogenic 
phenotype. The switch to the angiogenic phenotype is controlled by the overall balance 
of angiogenic promotors and inhibitors (Hanahan and Folkman, 1996).
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Thrombospondin, which inhibits angiogenesis, is produced constitutively by a normal 
hamster kidney fibroblast cell line but is downregulated during tumourigenesis 
(Rastinejad et al., 1989). By the time the tumour has become angiogenic these cells are 
only producing approximately 4% of the thrombospondin that their normal precursors 
produced (Rastinejad et al., 1989). This switch has been described in the progression of 
tumourigenesis by human fibroblasts cultured from Li Fraumeni patients (Volpert et al.,
1997). Initially these cells produce abundant thrombospondin that overrides VEGF also 
produced and the cells have no net angiogenic activity. Loss of both p53 alleles and 
transformation by activated ras allowed the cells to become angiogenic in a stepwise 
fashion. Thrombospondin production was decreased and there was a large increase in 
VEGF production (Volpert et al., 1997).
Expression of many angiogenic and anti-angiogenic factors is under the 
control of oncogenes and tumour suppressor genes. Some oncogenes code for 
angiogenic factors such as bFGF which is coded by the FGF-2 oncogene (Rodgelj et al., 
1988) and PDGF-B coded by the sis oncogene (Waterfield et al., 1983). Other 
oncogenes can stimulate production of angiogenic factors. The oncogenes v-H-ras, v- 
raf, and v-src stimulate the production of VEGF by NIH3T3, human glioblastoma- 
astrocytoma cells and human fetal kidney cells, respectively (Grugel et al., 1995; 
Mukhopadhyay et al., 1995). Other angiogenic factors are also increased by oncogenes, 
for example, v-erbh  increases PDGF-A expression by glial cells (Iglesias et al., 1995) 
and N-ras increases TNF-a production by human melanoma cells (Castelli et al., 1994). 
Various oncogenes can also aid angiogenesis indirectly, by increasing levels of the 
enzymes that assist angiogenesis, such as K-ras and N-nzs that increase urokinase by 
human fibrosarcoma cells (Jankun et al., 1991). Activated oncogenes may decrease 
levels of angiogenesis inhibitors, such as w-ras that decreases levels of thrombospondin 
in bronchial epithelial cells (Zabrenetzky et al., 1994). Human mammary epithelial 
cells are not normally angiogenic but following transfection with the int-2 gene, which 
codes for FGF-3, these cells are capable of eliciting an angiogenic response (Costa et 
al., 1994). Tumour suppressor genes may also function to alter the levels of these 
agents. Loss of p53 decreases the levels of thrombospondin in fibroblasts (Dameron et 
al., 1994). VEGF is down-regulated by wild type (wt) p53 in a human foetal kidney cell 
line (Mukhopadhyay et al., 1995) while mutant (mt) p53 increases VEGF expression by 
NIH3T3 (Kieser et al., 1994). It would appear that the development of an angiogenic
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phenotype is driven by the same processes of oncogene activation and tumour 
suppressor gene loss, that also results in the initiation of unregulated proliferation.
1.9 Tumour vascularity
The extent of angiogenesis may be measured by staining tumour sections for endothelial 
cell specific markers Endothelial cell specific markers that have been widely used to 
date include factor VUI-related antigen, platelet-endothelial cell adhesion molecule 
(PECAM or CD31) and the CD34 antigen (Weidner et al., 1991; Horak et al., 1992, 
Heimann et al., 1996). Microvessel density (MVD) can then be assessed by the extent 
and intensity of staining. Breast tumours have been shown to have significantly higher 
vascularisation than normal breast tissue and than benign tumours (Horak et al., 1992; 
Goede et al., 1998) Vessel count has been positively associated with vanous clinical 
outcomes. Horak et al (1992) found that the number of vessels in primary breast 
tumours was associated with nodal status, the size of primary tumour and the degree of 
differentiation of the tumour. Microvessel density has also been associated with 
metastatic disease (Weidner et al., 1991). Recent analysis of 531 breast cancer patients 
with a follow-up of greater than 6 years has found MVD to be a significant prognostic 
indicator for relapse-free survival and overall survival in a multivariate model 
(Gaspanni et al., 1998). Clinical use of MVD as a prognostic factor may be delayed 
however because of variability of the methods used. Several papers have demonstrated 
that counts may be highly variable and of no prognostic significance (Gouldmg et al., 
1995; Costello et a l , 1995). Improvements m technology, such as automated image 
analysis systems, may overcome these difficulties as demonstrated by Simpson et al 
who found that such a system measuring overall endothelial area withm a section to be 
more useful than manual vessel counts (Simpson et al., 1996)
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IInhibitor Antitumour
Activity
Reference
Angiostatm Yes (Quinn et a l , 1993)
Endostatin Yes (O'Reilly et al., 1997)
Angiostatic steroids Yes (Ingber et al., 1986)
Interferon-a Yes (Sidky and Borden, 1987)
Interferon-P Yes (Sidky and Borden, 1987)
Interferon-y Yes (Nonoka et al., 1994)
IFN-y - inducible 
protein 10
n/a (Stneter et al., 1995)
Interleukin-1 Yes (Cozzolino et al., 1990)
Interleukin-12 Yes (Voest et al., 1995)
Platelet Factor 4 Yes (Maione et al., 1990)
Thrombospondm Yes (Rastinejad et al., 1989)
Table 1.2: Endogenous inhibitors of angiogenesis. n/a = not assessed.
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1.10 Vascular endothelial growth factor
VEGF, also known as vascular permeability factor (VPF) and vasculotrophin, was 
originally isolated as a factor regulating vascular permeability in guinea pigs with 
implanted hepatocellular carcinomas (Senger et al., 1983). It was independently 
discovered in the conditioned medium of bovine pituitary folliculostellate cells as a 
factor that specifically increased the growth of adrenal endothelial cells (Ferrara and 
Henzel, 1989). Subsequent analysis showed that they were the same protein (Connolly 
et al., 1989). It is a basic, heparin-binding, homodimeric glycoprotein of 32-45kDa 
(Connolly et al., 1989). VEGF is inactivated by reducing agents but is heat and acid 
stable (Ferrara, 1995).
Analysis of VEGF clones shows that there are 5 different isoforms of 121, 145, 
165, 189 and 206 amino acids generated by alternative splicing of 8 different exons 
(Figure 1.2)(Tischer et al., 1991; Poltorak et a l, 1997). All isoforms contain a 26 amino 
acid signal sequence that is cleaved upon secretion. All iso forms contain the 115 amino 
acid amino-terminal exons 1-5 and the 6 amino acid carboxyl-terminal exon 8. There 
are 8 cysteine residues required for dimer formation and are all contained in exons 1-5. 
VEGF206 contains an additional 17 amino acid stretch termed 6’ which is derived from a 
contiguous downstream sequence of exon 6 and is due to the shift of the exon 6 splice 
donor further downstream into the intron and is not an independent exon.
These isoforms have different properties due the presence of the different exons. 
VEGF121 has no heparin binding activity and is freely secreted by the cell (Houck et al.,
1992). VEGF189 and VEGF206 contain exon 6 which is highly basic and readily binds 
heparin. These isoforms are secreted but are almost entirely bound to the cell surface or 
to the extracellular matrix. Addition of heparin, heparan sulphate and heparinase 
induces the release of VEGF189 into the cell culture medium suggesting heparin- 
containing proteoglycans as likely binding sites for VEGF189 (Houck et al., 1992). 
VEGF165, which contains exon 7 that is basic and has weak heparin binding activity, 
displays an intermediate behaviour with some being freely secreted and some apparently 
bound also to the cell surface (Houck et al., 1992). Although VEGF145 contains the 
heparin binding exon 6 it is also freely secreted but does remain bound to the 
extracellular matrix (Poltorak et al., 1997). VEGF206 has, to date, only been detected in 
embryonal liver tissue (Houck et al., 1991). As yet, there is little information on which 
isoforms are expressed within tumours. Most studies have either measured total VEGF
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mRNA or VEGF165 protein. One recent study has demonstrated that mRNA for the 121, 
165 and 189 isoforms were detectable in breast tumours but only the protein for 
VEGF165 was detected (Scott et al., 1999).
VEGF 121 iia
VEGF145
v e g f 165
v e g f 189
VEGF206
Exon 1-5
i i
6 6’
Figure 1.2 VEGF isoforms
1 6
1.11 VEGF family
VEGF is now understood to be just one member of a growing family of 
endothelial growth factors. The other members of the family are placenta growth factor 
(P1GF), platelet-derived growth factors (PDGF-A and PDGF-B), VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, (Maglione et al., 1991; Olofsson et al., 1996b; Joukov et al., 1996; 
Yamada et al., 1997; Ogawa et al., 1998). All factors are secreted as dimers, have 8 
conserved cysteine residues involved in inter- and intra-molecular disulphide bonds 
between the two subunits and share 20-45% homology. P1GF is alternatively spliced to 
give 2 isoforms and both isoforms are ligands for vascular endothelial growth factor 
receptor-1 (VEGFR-1 or flt-1) only (Park et al., 1998). P1GF is most highly expressed 
in the placenta and most likely regulates placental vasculature during gestation 
(Maglione et al., 1991). Although members of this family of growth factors tend to be 
homodimers, heterodimers of P1GF with VEGF have been identified and are capable of 
binding VEGFR-2 though there is diminution of response compared with binding of 
VEGF homodimers (Cao et al., 1996). PDGF is produced as two chains, PDGF-A and 
PDGF-B which dimerise to form a combination of PDGF-AA, -AB, -BB which have 
similar potencies (Hannink and Donoghue, 1989). VEGF-B is the most related member 
to VEGF, sharing approximately 45% homology to VEGF, and forms two isoforms but 
receptors for it have not yet been discovered (Olofsson et al., 1996a). It is expressed in 
a variety of human tumours including melanomas, sarcomas, head and neck tumours 
and breast tumours (Salven et al., 1998). VEGF-C binds to the VEGFR-2 and VEGFR- 
3 receptors (Joukov et al., 1997). VEGFR-3 is only expressed on lymphatic endothelial 
cells and overexpression of VEGF-C is associated with proliferation of lymphatic 
endothelial cells which suggests that VEGF-C is a regulator of lymph vessels (Jeltsch et 
al., 1997). VEGF-D is also a ligand for VEGFR-2 (flk-1) and VEGFR-3 (flt-4) and is 
most closely related to VEGF-C with both containing a cysteine rich C-terminus distinct 
from other members (Achen et al., 1998). VEGF-D is highly expressed in normal lung 
tissue, an organ containing a highly developed vascular system, and may be involved in 
the regulation of vasculature in this organ (Yamada et al., 1997). VEGF-E was 
originally identified as an open reading frame in the genome of the Orf virus NZ-7 
strain (Ogawa et al., 1998). This virus causes contagious skin lesions that are highly 
vascular in nature (Ogawa et al., 1998). VEGF-E is a ligand for VEGFR-2 but has not 
yet been discovered in humans
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1.12 Role for VEGF in angiogenesis
The essential role of VEGF m blood vessel formation can be seen even in the early 
stages of embryonic development. The formation of blood vessels was abnormal m 
mice embryos that had a heterozygous deficiency for the VEGF gene (VEGF +/-) 
(Carmeliet et a l , 1996). In mice embryos that had a homozygous VEGF deficiency 
(VEGF -/-) there was even greater impairment of vascular development and embryos 
died mid-gestation (Carmeliet et al., 1996). Mice that had a homozygous deficiency for 
the VEGF receptors flt-1 and flk-1 (VEGFR-1 and VEGFR-2) also died in utero after 
approximately 9 days (Fong et al., 1995; Shalaby et al., 1995). There were no organised 
blood vessels within the embryo or yolk sac at any stage of development VEGF 
expression has been associated with, spatially and temporally, the physiological 
angiogenesis that occurs m the ovary (Ravindranath et al., 1992) and m healing wounds 
(Nissen et al., 1998) VEGF expression has also been associated with pathological 
angiogenesis associated with diabetic retinopathy and other ocular disorders (Miller et 
al., 1994) and the angiogenesis occurring during rheumatoid arthritis (Koch et a l , 
1994). Many tumours express abundant VEGF (Berse et al., 1992). Direct evidence for 
a role of VEGF in tumour angiogenesis has also been described. Mouse embryonic 
stem cells with homozygous deficiencies for VEGF have a dramatically reduced ability 
to form tumours m nude mice compared to normal stem cells and the tumours have a 
significantly reduced number of blood vessels (Ferrara et a l , 1996). Administration of a 
monoclonal antibody against VEGF was found to inhibit the growth of a variety 
experimental tumours in mice including human rhabdomyosarcoma, glioblastoma and 
fibrosarcoma (Kim et a l , 1993; Asano et al., 1995; Borgstrom et a l , 1996) C6 glioma 
cells, transfected with a eukaryotic expression vector bearing an anti-sense VEGF 
cDNA, injected into nude mice were found to be significantly growth inhibited 
compared to control cells (Saleh et al., 1996). These tumours also had fewer blood 
vessels and a larger area of necrosis. The role of a VEGF-receptor system m tumour 
growth has been highlighted by experiments whereby tumour growth was inhibited by 
mterfenng with the signalling of the VEGF receptor VEGFR-2 using dominant-negative 
mutants (Millauer et al., 1994)
18
1.13 VEGF receptor system
The intracellular effects of VEGF are mediated by binding to one of two VEGF 
receptors. The receptors are/ms-like tryrosme kmase (fit-1) and fetal liver kmase 1 (flk- 
1) otherwise known as kinase insert-domain containing receptor (KDR) (De Vnes et al., 
1992; Terman et al., 1992). Because of the confusion regarding the nomenclature of an 
increasing number of endothelial cell-specific tyrosine kmase receptors these receptors 
have recently been given the respective names VEGFR-1 (flt-1) and VEGFR-2 (flk-1) 
There is a third receptor, flt-4 (VEGFR-3), which is restricted to endothelial cells of 
lymphatic ongm (Kaipainen et al., 1995) and is a ligand for VEGF-C (Joukov et al.,
1996). Neither VEGF121 nor VEGF165 bind to VEGFR-3 (Wilting et al., 1996). 
VEGFR-1 and VEGFR-2 are predominately expressed on endothelial cells (Peters et al., 
1993; Quinn et al., 1993) and are highly homologous to other tyrosine kmase receptors 
such as c-fms (receptor for colony stimulating factor 1 (CSF-1) and PDGF-Ra and 
PDGF-Rp (receptors for PDGF) (Shibuya et al., 1990). Both VEGFR-1 and VEGFR-2 
are type III receptor tyrosine kmases (Terman et al., 1992) Each receptor contains 7 
immunoglobulin-like domains, a transmembrane domain and a long kmase insert in the 
kmase domain (Terman et al., 1992).
VEGFR-1 has a higher affinity for VEGF than VEGFR-2, Kd of 10-20 pM (« 30 
-  60 pg/ml) and 100-125 pM (» 300 -  375 pg/ml), respectively (Terman et al., 1992) 
and the receptors are reported to have different signal transduction properties 
(Waltenberger et al., 1994; Seetharam et al., 1995). When both receptors were stably 
expressed in porcine aortic endothelial cells that lack endogenous VEGF receptors a 
different pattern of responses was observed between the two receptors. Cells expressing 
VEGFR-2 showed changes in morphology, actin reorganisation, membrane ruffling, 
chemotaxis and mitogemcity whereas the cells expressing VEGFR-1 showed none of 
these responses (Waltenberger et a l , 1994). A similar experiment m the same 
endothelial cells demonstrated that binding of VEGF m VEGFR-2 expressing cells 
induced DNA synthesis and migration of cells but m VEGFR-1 expressing cells these 
responses did not exist (Landgren et al., 1998). In the VEGFR-1 cells, however, 
urokinase plasminogen activator (uPA) expression was induced which did not occur in 
the VEGFR-2 expressing cells (Landgren et al., 1998). NIH3T3 cells stably transfected 
with VEGFR-1 did not show an increase m proliferation upon binding VEGF 
(Seetharam et al., 1995). Monocytes express VEGFR-1 and binding of VEGF does
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induce a chemotactic response in these cells (Clauss et al., 1996). Mutational analysis 
of both receptors show that mutations in VEGFR-2 disrupts VEGF stimulated 
proliferation of transfected Chinese hamster ovary (CHO) cells while mutations in 
VEGFR-1 had no effect (Keyt et al., 1996). The same study shows that both receptors 
bind different parts of VEGF165 (Keyt et al., 1996).
Upon binding VEGF both receptors are autophosphorylated (Waltenberger et al., 
1994). VEGF binding to bovine aortic endothelial (BAE) cells promotes the tyrosine 
phosphorylation of at least 11 proteins (Guo et al., 1995). VEGF promoted the tyrosine 
phosphorylation of several proteins that contain SH2 domains, including phospholipase 
C-y (PLC-y), ras GTPase activating protein (GAP) and phosphatidylinositol 3-kinase 
(PI-3 kinase) in bovine aortic endothelial cells (Guo et al., 1995). NIH3T3 cells 
transfected with VEGFR-1 phosphorylate PLCy, GAP and mitogen activated protein 
kinase (MAPK) following ligand binding without increasing proliferation (Seetharam et 
al., 1995). The same cells transfected with VEGFR-2 also activate the same signal 
molecules but with a mitotic response (Takahashi and Shibuya, 1997). Activation of 
MAPK appears to be essential for the response of endothelial cells and the 
antiangiogenic mechanism of a 16 kDa fragment of prolactin appears to be by blocking 
MAPK activation (D'Angelo et al., 1995). The end molecules of VEGF induced 
transduction and the gene elements involved are as yet unknown. In general, it has been 
accepted that VEGFR-2 plays a greater role in tumour biology as it is responsible for the 
mitogenic and chemotactic responses of endothelial cells to VEGF and that the role of 
VEGFR-1 may be in development alone (Zachary, 1998).
The heparin binding capacity of VEGF appears to be important for binding. Cell 
surface-associated heparin-like molecules have been shown to be essential for the 
binding of bFGF to its high affinity receptors (Yayon et al., 1991). Although VEGF has 
a lower affinity for heparin than bFGF the interactions of VEGF with heparin are 
important for binding to its receptors. Cross-linking experiments have demonstrated 
that when the concentration of heparin-like molecules on the cell surface of BAE cells 
are reduced by heparinase, VEGF165 no longer binds to its putative receptors (Gitay- 
Goren et al., 1992). Exogenous heparin restores binding. Low concentrations of 
exogenous heparin (0.1-1 ng/ml) have been shown to enhance the binding of VEGF165 
to both receptors in BAE cells and to endogenous receptors in NIH3T3 cells (Gitay- 
Goren et al., 1992; Tessler et al., 1994). Heparin however, at the same concentrations,
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was found to inhibit binding and autophosphorylation of VEGF to a chimeric receptor 
containing the extracellular domain of VEGFR-2 fused to the transmembrane and 
intracellular domain of c-fms transfected into NIH3T3 cells (Tessler et al., 1994). 
Terman et al demonstrated that heparin had a stimulatory effect on VEGF binding to 
VEGFR-2 expressing BAE and CMT3 cell lines but had a inhibitory effect on VEGF 
binding on VEGFR-1 expressing SK-MEL-37 cells (Terman et al., 1994). This would 
indicate that the specific characteristics of the receptor as well as the heparin binding 
activity of VEGF itself is important in binding. One mechanism through which heparin 
seems to regulate the binding of VEGF to its receptors is by increasing or decreasing the 
number of receptors on the cell surface (Gitay-Goren et al., 1992; Terman et al., 1994). 
Heparin was also found to potentiate the binding of VEGF165 to a soluble fusion protein 
containing the extracellular domain of VEGFR-2 fused to alkaline phosphatase, 
VEGFR-2/SEAP (Tessler et al., 1994). This experiment was conducted in a cell free 
environment and therefore excludes the effects of heparin sulphate proteoglycans 
already on the cell surface. Heparin sulphate had the same effect. Interestingly the 
degree of sulphation was found to be important as desulphated heparin had no effect and 
oversulphated heparin had a greater effect on VEGF binding than normally sulphated 
heparin (Tessler et al., 1994). This experiment demonstrated that heparin can also 
directly modulate the binding of VEGF165 to VEGFR-2/SEAP, and that this modulation 
is probably due to the interaction of heparin with VEGF since heparin did not bind to 
the fusion protein (Tessler et al., 1994).
Hypoxia is known to increase VEGF expression but also increased VEGFR-2 
expression in a cerebral slice culture system (Kremer et al., 1997). In addition, 
exogenously added VEGF increased VEGFR-2 expression in the same system (Kremer 
et al., 1997) and this effect was lost by the addition of anti-VEGF antibodies. The 
VEGF signal may also be regulated by the production of a soluble VEGFR-1 (Kendall 
and Thomas, 1993). This soluble receptor is coded from alternative splicing of the full 
VEGFR-1 and binds VEGF with high affinity (Kendall and Thomas, 1993). 
Transfection of soluble VEGFR-1 into human fibrosarcoma cells inhibited tumour 
growth, metastasis and mortality when implanted into nude mice (Goldman et al.,
1998). These indicate possible mechanisms whereby VEGF receptor expression 
regulates angiogenesis.
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1.14 Macrophages in breast tumours
Breast tumours are composed of a heterogeneous population of both host and tumour 
cells. In addition to endothelial cells there are other host cells present that include 
fibroblasts and a variety of immune cells. Macrophages form a major component of the 
immune infiltrate into many solid tumours and may account for up to 50% of breast 
tumour mass (O'Sullivan and Lewis, 1994). Macrophages are multifunctional cells 
capable of performing a number of functions including angiogenesis (Sunderkotter et 
al., 1994). Macrophages may mediate tumour cytotoxicity but many tumour cells can 
escape this immune surveillance by suppressing macrophage immune function by 
releasing suppressing factors such as TGF[M, interleukm-10 (IL-10) and prostaglandin 
E2 (PGE2) (Elgert et al., 1998). Macrophages can induce angiogenesis in wounds 
(Knighton et al., 1983) Conditioned medium from tumour associated macrophages 
isolated from experimental fibrosarcomas induced endothelial cell proliferation in vitro 
and angiogenesis in vivo (Polvermi and Leibovich, 1984). Experimental munne 
fibrosarcomas were less vasculansed when their hosts were depleted of monocytes 
(Sunderkotter et al., 1994). There is a significant positive correlation between breast 
tumour vascularity and macrophage content and increased macrophage content was 
associated with reduced relapse free survival and overall survival (Leek et al., 1996). 
Macrophages are capable of releasing a number of angiogenic factors including EGF, 
TNF-oc, TGFp, bFGF, 1L-8 and VEGF (O'Sullivan et al., 1993, Leibovich et al., 1997; 
Lewis et al., 1995; Koch et a l , 1998; Harmey et al., 1998). In addition to release of 
angiogenic factors, macrophages are also capable of releasing proteases to degrade the 
extracellular matrix such as plasminogen activators (Nathan, 1987) and can be involved 
in remodelling the matrix (Sunderkotter et al., 1994). Macrophages do, however, also 
produce metalloelastase which cleaves plasminogen to the angiogenesis inhibitor, 
angiostatin (Dong et al., 1997).
1.15 Anti-angiogenic therapy
Since angiogenesis is essential for tumour growth, the inhibition of angiogenesis offers 
a very attractive target for treating cancer. Since angiogenesis is a multi-step process, 
interruption of any of these processes may decrease tumour growth. Angiogenesis 
could be inhibited by decreasing or abrogating the effects of angiogenic factors, by 
increasing levels of angiogenesis inhibitors, inhibiting the activity of degradative
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enzymes or by inhibiting endothelial cell proliferation, migration or tube formation. 
The huge advantage m altering angiogenesis alone is that side effects should be minimal 
since angiogenesis is normally quiescent throughout the body. A wide variety of 
experimental mechanisms have been employed to inhibit angiogenesis. Amongst these 
are the administration of anti-VEGF antibodies (Asano et al., 1995; Kondo et al., 1993) 
and antisense VEGF (Saleh et al., 1996). A fusion protein of YEGF with the diphtheria 
toxm injected into animals retarded the growth of Kaposi’s sarcoma (Arora et al., 1999). 
Antibodies to a v(33 mtegrin inhibited angiogenesis in the CAM assay by inducing 
apoptosis of proliferating endothelial cells (Brooks et al., 1994a). While these 
experiments are informative they are not practical as therapeutic options. Greater than 
200 compounds have been reported as having anti-angiogemc activity (Holmgren and 
Bicknell, 1997). These compounds act in a wide variety of ways to inhibit various steps 
necessary for angiogenesis. Table 1.3 lists some of the more relevant compounds that 
are currently undergoing clinical trials for the inhibition of angiogenesis. Amongst the 
most promising of these drugs are angiostatm and endostatin. Both are endogenous 
inhibitors of angiogenesis (O'Reilly et al., 1994; O'Reilly et al., 1997; O'Reilly et al.,
1997) that increase apoptosis of endothelial cells (Claesson-Welsh et al., 1998; Stneter 
et a l , 1995). Results m mice have shown that these compounds greatly reduce tumour 
growth. However, all these compounds are still undergoing clinical trials to determine 
their safety and efficacy and will not be available for clinical use for several years. In 
the meantime the extended use of well characterised drugs as anti-angiogemc agents 
would be of huge benefit. One such drug is the anti-oestrogen tamoxifen.
Tamoxifen is used as the primary hormonal therapy for women with breast 
cancer It is primarily used as adjuvant therapy following surgical removal of a tumour. 
Tamoxifen reduces mortality, recurrence of disease and the incidence of contralateral 
breast cancer (Early Breast Cancer Tnahst's Collaborative Group, 1992). Recently, 
prophylactic tamoxifen therapy has been shown to decrease the incidence of invasive 
breast cancer by 49% m women with an increased risk (Fisher et al., 1998). One 
mechanism through which tamoxifen may exert its effects is by reducing angiogenesis. 
Tamoxifen has been shown to inhibit angiogenesis in an in vivo model (Gagliardi and 
Collms, 1993). The major advantage of such a drug is that it is well characterised and 
has been used by millions of women over the last 20 years. Though there is an 
increased nsk of endometnal cancer, thrombosis and visual disturbances the benefits are
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believed to outweigh the risks (Assikis and Jordan, 1997) Tamoxifen is a well tolerated 
drug and m clinical trials less than 5% of patients discontinued treatment due to adverse 
side effects (Nolvadex, prescribing information, Zeneca Pharmaceuticals, Wilmington, 
USA) Being such a well characterised and well tolerated drug, adaptation of its uses to 
include prescription as an anti-angiogemc agent could be earned out with relative ease 
Exploration of its use as an anti-angiogemc agent may generate huge benefits m patients 
suffenng from vanous angiogenic pathologies dunng the time that other more potent 
anti-angiogemc agents are undergoing developmental work and clinical trials
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Drug Mode of action Trial Reference
Manmastat Inhibits MMPs Phase
II
(Pluda and Parkinson, 
1996)
Thalidomide Unknown Phase
II
(D’Amato et a l , 1994)
Carboxyammoimidazole
(CAI)
Blocks Ca++ involvement 
m EC organisation
Phase
I
(Alessandro et a l , 
1994)
Interleukin 12 
(11-12)
Induction of interferon 
mducible protein (IP-10)
Phase
I
(Voest et a l , 1995)
Interferon-a 2a Downregulation of bFGF Phase
III*
(Folkman, 1989)
TNP470
(formerly AGM-1470)
Inhibits EC proliferation 
and migration
Phase
III
(Ingber et a l , 1990)
Angiostatm Induces EC apoptosis Phase
I
(O'Reilly et a l , 1994)
Endostatm Induces EC apoptosis Phase
I
(O'Reilly et a l , 1997)
Table 1.3: Compounds undergoing clinical trials for use as anti-angiogenic therapy *, 
for infantile haemangiomas
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1.16 Aim
Angiogenesis is essential for tumour growth and for the development of métastasés 
VEGF is the most potent angiogenic factor identified to date but the degree of 
expression of VEGF and the regulation of expression are not fully descnbed for breast 
cancer Altering the expression of VEGF, or disrupting any aspect of the angiogenic 
cascade, offers potential therapeutic benefits The aims of this thesis were, therefore, as 
follows
• Determination of the expression levels of VEGF in breast cancer by examining 
expression of VEGF by breast cancer cell lines, examination of levels of VEGF 
withm breast tumours and determination of the levels of VEGF within the serum of 
breast cancer patients
• Identification of regulators of VEGF that are relevant m a breast tumour 
environment
• Determination of any anti-angiogemc effects of tamoxifen that may or may not be 
mediated through VEGF
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C H A P T E R  2
M A T E R IA L S  A N D  M E T H O D S
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2.1 Preparation and handling of reagents
All chemicals and reagents were stored according to the manufacturers instructions. 
General purchase chemicals were of analytical grade (Sigma Chemical Compay, St. 
Louis, MO, USA and BDH Chemicals Ltd., Poole, UK, unless otherwise stated). Solid 
chemicals were weighed using a Sartorius AC1215 electronic balance (Gottingen, 
Germany) and were prepared in distilled water with a conductivity of greater than 
18mQ. The pH of solutions was measured using a Radiometer PHM82 pH Meter 
(Copenhagen , Denmark). Solutions were autoclaved within a few hours of preparation. 
Liquid transfer for volumes of less than and including 1ml were carried out using Gilson 
pipettes and for volumes greater than 1 ml an electronic pipette aid (Drummond, 
Broomall, PA, USA) and disposable plastic pipettes were used.
2.2 Tissue culture
All tissue culture work was carried out in an aseptic manner within a laminar air flow 
cabinet (Holten LaminAir HB2436, Allerad, Denmark). The cabinet was switched on at 
least 20 min prior to use. The cabinet was thoroughly sanitised using 70% (v/v) 
isopropyl alcohol (IPA). All equipment and reagents were also sanitised before being 
brought into the cabinet. Disposable gloves and a clean lab coat with elasticated cuffs 
were worn at all times. The cabinet was cleaned again after completion of work and air 
was allowed to circulate for at least 20 min.
2.2.1 Breast Cancer Cell lines
Two human breast cancer cell lines were used for the duration of this project. BT474 
(ATCC HTB20) cells, derived from a primary breast tumour, were received from the 
ATCC and MDA-MB-231 (ECACC92020424) cells, isolated from a pleural effusion, 
were received from the EC ACC. BT474 cells were maintained in Roswell Park 
Memorial Institute medium (RPMI) 1640 supplemented with 10% (v/v) foetal calf 
serum (FCS) and 10 fj.g/ml bovine insulin in 25 cm2 or 75 cm2 filter lid flasks at 37°C in 
a humidified atmosphere of 5 % C 02 (Forma Scientific 3193 Water Jacket Incubator, 
Ohio, USA). MDA-MB-231 cells were maintained in Leibovitch L I5 supplemented 
with 10% (v/v) FCS at 37°C. L15 is used independent of C 02 and so sealed flasks
were used with this medium. FCS was heat inactivated for 10 min at 56°C and stored in 
50 ml aliquots at -20° C. Antibiotics were not used for routine culture of cells. For 
experiments, both cell lines were cultured in Dulbelco's Modification Eagle’s Medium
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(DMEM) with no loss of viability or obvious morphological changes. RPMI, LI 5, 
DMEM and FCS were from Gibco-BRL (Paisley, Scotland). Tissue culture flasks were 
from Sarsedt (Wicklow, Ireland).
2.2.2 Cell subculture
Cells were checked daily using an inverted phase contrast microscope (Nikon TMS, 
Tokyo, Japan) and were sub-cultured when they reached 80 - 90% confluency. Both 
cell lines grew as anchorage dependent monolayers and were detached by trypsin 
treatment for sub-culturing. For trypsinisation, the growth medium was decanted and 
cells were rinsed twice with 5 mis of 0.01 M phosphate buffered saline (13.8 mM NaCl,
2.7 mM KC1, pH 7.4) (PBS) to remove residual FCS, 1 - 1.5 ml of trypsin- 
ethylenediamine tetracetic acid (EDTA) (0.05% (w/v) trypsin, 0.02% (w/v) EDTA) 
(Gibco-BRL, Paisley, Scotland) was added to the flasks and placed at 37°C for several 
minutes until the cells had clearly detached from the flask surface. 5 ml of complete 
medium (medium containing 10% FCS) was added and cells were transferred to a sterile 
centrifuge tube and pelleted by centrifugation (MSE Instruments Mistral 2000, London, 
UK) at 300 x g for 5 min. The supernatant was discarded and the cell pellet was 
resuspended in 5 ml of full medium and used to seed fresh flasks at a ratio of between 
1:3 to 1:6 for BT474 cells and between 1:6 to 1: 12 for MDA-MB-231 cells. 
Approximately 5 ml and 12 ml of full medium were added to cells in 25 cm2 and 75 cm2 
flasks, respectively. Cells were maintained as described (2.2.1).
2.2.3 Preparation of frozen cell culture stocks
Cell stocks were stored under liquid nitrogen in a cyrofreezer (L’air Liquide RCB40A, 
Champigny, France). Frozen stocks were prepared from cells in log phase growth at 
less than 80 % confluency. Cells were washed twice with PBS and trypsinised as above 
(2.2.2). Trypsinised cells were recovered and pelleted through a 2 - 3 ml cushion of 
FCS by centrifugation at 300 x g for 5 min. FCS containing cell debris was discarded 
and the cell pellet was resuspended, with FCS, at a concentration of 1 x 106 cells / ml. 
An equal volume of 10% (v/v) dimethyl sulfoxide (DMSO) in FCS was added dropwise 
to the cell suspension with gentle mixing between additions. 1 ml aliquots of the cell 
suspension were added to cryovials and placed in a styrofoam rack at - 80°C for 24 hr 
before being transferred to the liquid nitrogen tank for long term storage.
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2.2.4 Revival of stored cells
Cryovials were removed from the liquid nitrogen and rapidly thawed at 37°C Cells 
were transferred to a centrifuge tube, 10 ml of full medium was added and the cells were 
pelleted by centrifugation at 300 x g for 5 mm The supernatant was discarded and the 
cell pellet was resuspended in 5 ml of full medium and added to a 25 cm2 flask Cells 
were incubated at 37°C for 16 - 24 hr Following incubation the medium was replaced 
with fresh medium Cells were then cultured and passaged as before (2 2 2)
2.2.5 Human microvascular endothelial cells
Primary cultures of human dermal microvascular endothelial cells (HMECs) were 
obtained from Bio Whittaker (Niederlassung, Germany) The manufacturer supplied 
Endothelial Cell Growth Medium (EGM) containing the following supplements 
hydrocortisone, hFGF-B, R3-IGF, ascorbic acid, hepann, VEGF, hEGF, GA-100 and 
5% (v/v) FBS Medium was changed every 2 days HMEC cell cultures are irreversibly 
contact inhibited and therefore were subcultured before they reached 85% confluency 
For trypsmisation cells were rinsed twice with Hanks Balanced Salt Solution (HBSS) 
and trypsmised as before Once cells were detached trypsm was inactivated by the 
addition of an equal volume of a trypsm neutralising solution HBSS, trypsm/EDTA 
and trypsm neutralising solution were also supplied with the cells These cells have a 
very limited life span and usually reached senescence within 5 passages
2.2.6 Cell Counting
Cell suspensions were counted using an Improved Neubauer haemocytometer slide 
Trypan blue dye exclusion was used to determine cell viability 20 p.1 of cell suspension 
was added to 180 ja.1 of trypan blue, mixed, and allowed to stand for 2 mm A sample of 
this mixture was added to the counting chamber and the cells visualised and counted 
under a light microscope Viable cells only were included The four comer squares of 
the gird, each containing a volume of 1 mm2, were counted and the number of cells 
calculated using the following equation
cells / ml -  count x * >000 x 10 (dilution factor)
4
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2.2.7 Mycoplasma testing of cell cultures
On arrival into the laboratory all cell cultures were tested for mycoplasma 
contamination Routine testing of cell cultures was also earned out every 6 months 
thereafter Mycoplasma testing was earned out using a commercial PCR ELISA 
(Boehnnger Mannheim, Mannheim, Germany) Mycoplasma testing was earned out 
according to the manufacturers instructions except that the ELISA step was omitted 
since it was unnecessary for simply confirming the presence or absence of mycoplasma, 
which could be easily confirmed by gel analysis alone In bnef, a 1ml sample of 
medium from cells neanng confluency was taken Cell debns was removed by 
centnfiigation at 200 x g for 10 mm Supernatant was removed and mycoplasma were 
pelleted by centnfiigation at 13,000 x g for 10 mm The supernatant was decanted and 
the pellet resuspended m 10 pi of stenle distilled water (SDW) and 10 p.1 of lysis 
reagent and incubated for 1 h at 37°C A positive control, supplied with the kit, and a 
negative control with SDW and lysis buffer alone were also included Following this 
incubation 30 jul of neutralisation buffer was added 10 jal of sample was mixed with 25 
pi of a PCR ready-to-go solution and 10 pi of SDW m a thermo-tube The tubes were 
placed m a PCR thermal cycler machine (PTC 2000 Peltier Thermal Cycler, MJ 
Research, MA, USA) and product was amplified using the following program 5 mm at 
95°C, 40 cycles of 95°C for 30 sec, 62°C for 30 sec, 72°C for 1 mm and a final 
extension of 10 mm at 72°C The resulting PCR product was visualised by ethidium 
bromide staining following electrophoresis (2 4 3)
2.2.8 Isolation of monocytes
Approximately 30 ml of blood from human volunteers was collect by venopuncture into 
hepanmsed tubes (Sarsedt, Wicklow, Ireland) A discontinuous gradient of 10 ml of 
Histopaque 1119, overlaid with Histopaque 1077 (Sigma, St Louis, MO, USA) was 
prepared and the 30 ml of blood layered onto this The gradient was centnfuged at 400 
x g for 30 mm at room temperature Following centnfiigation the cells layered as seen 
m Figure 2 1 The plasma layer was recovered and filtered through a 0 2 pm synnge 
filter (Gelman, Ann Arbor, MI, USA) The lymphocyte/monocyte layer was collected 
and cells were washed twice m DMEM and pelleted by centnfiigation at 220 x g for 10
mm. After washing the pellet was resuspended and cells were counted and viability
/
assessed (2 2 6) Monocyte content of recovered cells was established using flow 
cytometry staining for CD14/CD45 (2 2 10) The cells were resuspended at a
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concentration of 1 x 10& monocytes / ml in DMEM containing 20% (v/v) autologous 
plasma. The cells were seeded into tissue culture plates and monocytes allowed to 
adhere by incubating at 37°C for 2 h. Following this incubation the non-adherent 
lymphocytes were removed by washing twice with PBS. Fresh DMEM containing 20% 
(v/v) autologous plasma was added to the monocytes.
Pre-centrifugation Post-centrifugation
-Blood
Histopaque 1077
Histopaque 1119
^ P la sm a
Lymphocytes 
* and
Monocyte
4—  Granulocytes
Erythrocytes
Fig. 2.1: Layers formed before and after centrifugation of whole blood through a
Histopaque density gradient.
2.2.9 Preparation of monocyte derived macrophages
Monocytes isolated according to 2.2.8 were matured for 5 days in 96-well plates in 
DMEM containing 20% autologus plasma (AP). Over this period cells visibly increased 
in size. Following maturation monocytes were washed twice with PBS and activated 
for 24 hr by the addition of 100 ng recombinant human interferon y (rh-IFNy (103 units) 
(Gibco-BRL, Paisley, Scotland) in DMEM with 10% (v/v) FCS. Following activation 
the monocytes assume a macrophage like morphology.
2.2.10 CD14/45 Flow cytometry
Percentage monocytes present was assessed by determining the percentage of cells that 
expressed CD 14 and CD45. CD45 is present on nearly all leukocytes while CD 14 is 
specific for monocytes. A 100 ^1 aliquot of cells was incubated with 10 fa.1 of CD 14 and 
CD45 labeled monoclonal antibodies (Becton Dickinson, San Jose, CA, USA). The 
sample was mixed and incubated at 4°C for 30 min protected from the light. Cells were 
washed with 2 ml of cold PBS and centrifuged at 300 x g for 5 min. Cells were
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resuspended with FACS fluid and analyzed (FACScan, Becton Dickinson, San Jose, 
CA, USA). Percentage of CD 14 positive leukocytes was calculated. A sample dot plot 
and histogram for CD14/CD45 flow cytometric analysis can be seen in appendix 2.
2.2.11 Proliferation assay
For proliferation assays 200 pi of cells at a concentration of 1 x 105 cells/ml were 
seeded into 96-well plates in DMEM with 10% (v/v) FCS and incubated for 16 - 24 hr. 
Tamoxifen or 4-hydroxytamoxifen (Sigma, St.Louis, MO, USA) was added at various 
doses in 200 [4.1 of DMEM with 10% (v/v) FCS and incubated for 72 hr. These drugs 
are very insoluble in aqueous solutions and must be initially solubilised in ethanol. An 
ethanol control containing 0.5% (v/v) ethanol in DMEM (equivalent to the volume of 
ethanol in the highest doses of tamoxifen) was also included. Cell proliferation was 
assessed using a CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega, 
Madison, WI, USA) and was used in accordance with the manufacturers instructions. In 
brief, cells are incubated for 4 hr with 15 pi of a tetrazolium dye and living cells 
metabolise the tetrazolium to a formazan product. 100 (0.1 of solubilisation solution 
was added and incubated at 37°C for 16 hr to solubilise the formazan product. 
Absorbance was measured at 570 nm in a plate reader. The absorbance reading is 
directly proportional to the number of cells present in each well. The proliferation of 
control cells which received no treatments was expressed as 100%) and proliferation in 
other experimental cells was expressed as % of controls.
2.2.12 Human microvascular endothelial cell migration (HMEC)
Endothelial cell migration was assessed using Transwells® (Costar, Cambridge, MA, 
USA). These are sterile, disposable, 24-well plate inserts that form two different 
compartments within a well separated by membrane containing 8 pm pores (Figure 2.2). 
Cells on the upper surface of the membrane can migrate through the 8 pm pores onto 
the lower surface of the membrane. Migration of cells can be assessed by counting the 
number of cells that have migrated in response to a chemoattractant added to the bottom 
compartment. Endothelial cells were collected from tissue culture flasks and 105 cells in 
250 pi of EGM added onto the top compartment of a Transwell® with 500 pi of EGM 
alone in the bottom compartment. Cells were allowed to recover overnight. 
Chemoattractant (20 ng/ml VEGF in EGM) was added to the bottom compartment and 
tamoxifen at various dose (0, 0.625, 1.25, 2.5, 5 pg/ml and a 0.5% (v/v) ethanol control)
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was added to both compartments Cells were incubated for 48 hr Following incubation 
the inserts were removed and cells on the top surface of the porous membrane were 
removed by wiping the membrane with a wet cotton swab Cells on the lower surface of 
the membrane were fixed by incubating with 0 4% (v/v) formaldehyde for 30 mm and 
stained with haemotoxyhn for 1 mm Membranes were then removed from the insert 
housing using a scalpel and mounted on slides in DPX mounting medium Migrated 
cells on each membrane were counted using a light microscope under 400 x 
magnification
Upper compartment
8 p.m porous membrane 
Lower compartment
Fig. 2.2: Illustration of a Transwells®
2.2.13 Transendothelial migration of monocytes
Transendothehal migration of monocytes was assessed using collagen coated 
Transwells® (Costar, Cambndge, MA, USA) with a 3 (im pore membrane m 12-well 
plates HMEC were removed from culture with trypsm (2 2 5) and 5 x 10s cells in 0 5 
ml of EGM was added to the top chamber and 1 ml of EGM to the bottom chamber 
Cells were allowed to recover overnight and were examined the following day to ensure 
that a confluent monolayer of endothelial cells had formed that left no parts of the 
porous membrane exposed Monocytes were isolated as described (2 2 8) and 5 x 105 
monocytes added to the top compartment in 0 5 ml of EGM Tamoxifen (0, 2 5 (ig/ml 
and a solvent control containing 0 5% (v/v) ethanol) was added to both the upper and 
lower reservoirs VEGF at a concentration of 20 ng/ml was added to the lower 
compartment to act as a chemoattractant for monocytes Cells were incubated for 5 hr 
and cells from the top compartment removed Cells in the lower compartment were 
collected by removing the medium and by gently washing the well and the underside of
Cells
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the Transwell membrane in 0.0025% (w/v) trypsin, 0.01% (w/v) EDTA in PBS. 
Monocytes were counted using an a haemocytometer (2.2.6).
2.2.14 Preparation of cells
Cells required for an experiment were harvested by trypsinisation and counted. When 
looking at VEGF or TGF(3-1 protein, 200 jul of cells were seeded onto 96-well plates at 
a density Of 100,000 cells/ml. For reverse transcription polymerase chain reaction (RT- 
PCR) 1 ml of cells at 100,000 cells/ml were seeded onto 12-well plates. Cells were 
allowed to recover for approximately 16 hr in DMEM with 10%) (v/v) FCS. 
Experiments were usually carried out using DMEM containing 0.5% (w/v) tissue 
culture grade BSA (Sigma, St.Louis, MO, USA). Treatment with cytokines and 
tamoxifen was carried out by preparing these agents in DMEM and adding to the wells 
for the stated incubation period. Following incubation the conditioned medium was 
removed and stored at -20°C. Plates were also stored at -20°C for protein assay as 
described in section 2.7.3.
Hypoxic conditions were simulated by placing plates into a sealed chamber and 
sparging with 5% C 02/95% N2 for several minutes to expel air. This resulted in an 
aqueous 0 2 concentration of approximately 2% as measured using a probe for dissolved
o2.
2.3 RNA Extraction
2.3.1 General Precautions
Since RNA is readily degraded by ubiquitous RNase enzymes a number of precautions 
were always taken when working with RNA. Gloves and a clean lab coat with 
elasticated sleeves were worn at all times.
All buffers were autoclaved or sterile filtered. Diethylpyro-carbonate (DEPC) 
inactivates RNases and DEPC-treated water was prepared by adding DEPC at 0.01 % 
(v/v) for 16 hr. DEPC was then inactivated by autoclaving. Disposable plastics were 
used when possible. When using glassware it was soaked in 0.5 M NaOH for 2 hr, 
rinsed in DEPC-treated water, autoclaved and dried for 3 - 4 hr at 120°C. Non­
disposable plasticware such as gel boxes and accessories were soaked in 0.5 M NaOH 
and rinsed in DEPC water. RNase free filter tips were used for pipetting. Solid 
chemicals were never weighed using a spatula but rather tipped out. All solutions were 
stored in aliquots.
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2.3.2 Isolation of total RNA from cultured cell monolayers
RNA was isolated from cell cultures growing m 12 well plates or 25 cm2 flasks Cells 
were washed twice with PBS at 4°C 600 jul of TRIzol® LS (Gibco-BRL, Paisley,
Scotland) was added to a single well of a 12 well plate and 2 ml of Tnzol to a 25 cm2 
flask TRIzol® LS was incubated for 5 mm at room temperature and removed to a clean 
microfuge tube 300 (il of chloroform was added per 600 |_il of TRIzol® LS, vigorously 
shaken and allowed to stand at room temperature for 2 - 15 mm Phases were separated 
by centrifugation at 12,000 x g for 15 mm (Eppendorf Centnfuge 5417, Hamburg, 
Germany) Approximately 300 fxl of the aqueous phase was removed and the RNA 
precipitated with 1 ml of isopropyl alcohol (IP A) for 10 mm at room temperature RNA 
was pelleted by centrifugation at 12,000 x g for 10 mm The supernatant was aspirated 
and the pellet washed m 1 ml of 70% (v/v) ethanol RNA was pelleted by centrifugation 
at 7,500 x g for 5 mm, ethanol was carefully aspirated and the pellet was air dried over 2 
- 4 mm Pellets were resuspended m a suitable volume of DEPC water and immediately 
placed on ice The concentration and punty of RNA was assessed 
spectrophotometncally as outlined in 2 3 3 Integrity of RNA was also analysed by gel 
electrophoresis (2 3 4)
2.3.3 Quantification of RNA
RNA was assessed spectrophotometncally using a Genequant (Pharmacia, Cambndge, 
UK) by measunng the absorbance at 260 nm, the wavelength at which nucleic acids 
absorb maximally (Xmax) A 40 \xg!m\ sample of RNA has an absorbance value of 1 at
260nm The punty of RNA was determined by reading the absorbance at 260 nm, the 
X-max of nucleic acids, and at 280 nm, the A,max for proteins and obtaimng the ratio of 
these absorbances Pure RNA has an A,„/A,s. ratio of 1 6 - 1 8 Lower ratios often260 2o0
indicate presence of protein and higher ratios the presence of organic reagents 
Absorbance was measured m a quartz cuvette with a suitable dilution of RNA sample
2.3.4 Qualitative gel electrophoresis of RNA
The integnty of RNA was evaluated by electrophoresis The presence of two discrete 
strong bands, representing the 28 S and 18 S nbosomal RNA subunits, signified intact 
RNA RNA was electrophoresed m a similar manner as that descnbed m section 2 4 3 
except that 5 jul of RNA sample was mixed with 15 jul of sample buffer (50 % (v/v)
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formamide, 8 3 % (v/v) formaldehyde, 0 027 M MOPS, 6 7 mM sodium acetate, 0 67 
mM EDTA) and 3 fil of loading buffer (50 % glycerol (v/v), 1 mM EDTA, 0 4 % (w/v) 
bromophenol blue, 1 (J.g/ml ethidium bromide) RNA was denatured by heating to 70°C 
for 10 mm (Techne Dn-Block DB-1M, Cambridge, UK) and electrophoresed as for 
DNA electrophoresis
2.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
RT-PCR was used to detect and compare mRNA levels of VEGF in cells (3-actm, a 
constitutively expressed gene, was also amplified and acts as an internal control for 
quantity of starting material and gel loading differences The ratio of VEGF to (3-actm 
allows semi-quantitative comparison between samples The conditions used for 
amplification of VEGF and P-actin have been previously demonstrated to allow semi- 
quantitative analysis (Harmey et al 1998) Qualitative RT-PCR was also earned out to 
detect the iso forms of VEGF produced but was not quantitative
2.4.1 Reverse Transcription
1 |ig of total RNA was used for the RT reaction DNase I treatment was earned out to 
remove contaminating DNA 1 |xl of DNase I (Gibco-BRL, Paisley, Scotland) (1 U) 
was added to 1 ng of total RNA m 10 jo.1 of 1 x DNase buffer in DEPC water and 
incubated at room temperature for 15 mm DNase I was inactivated by adding 1 |xl of 
25 mM EDTA and heating at 70°C for 10 mm 1 jul random pnmer (Promega, Madison, 
WI, USA)(500 |ig/ml) was added to DNase treated RNA and incubated at 70°C for 10 
mm and then placed on ice The following RT reaction components were prepared as a 
mastermix and added to each reaction sample 0 5 (al DEPC water; 0 5 ]_il RNasin 
(Promega, Madison, WI, USA) (19 U), 1 |ul 5 mM dNTPs (1 1 1 1  dATP, dCTP, dGTP, 
cTTP)(Promega, Madison, WI, USA), 4 ja.1 5X RT buffer (supplied by the 
manufacturers with Superscnpt II™ reverse transenptase), 2 (il 0 1 M DTT, 1 ^1 
Superscnpt II™ Reverse Transenptase (200 U)(Gibco-BRL, Paisley, Scotland) cDNA 
synthesis was earned out for 3 hr at 37°C and the cDNA either used immediately for 
PCR or stored at -20°C for a maximum of 48 hr
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2.4.2 Polymerase Chain Reaction
The PCR reaction components were prepared as a mastermix and added to 1 5 (4,1 of 
cDNA Each 50 |xl reaction contained the following 5 (il 10 x buffer (supplied by the 
manufacturers with Taq polymerase enzyme), 2 jo.1 25 mM MgCl2, 2 (j.1 5 mM dNTPs,
1 (xl of forward and reverse primers (50 pmol)(Genosys, Cambridge, UK), 0 5 (4.1 Taq 
DNA polymerase (2 5 U) (Promega, Madison, WI, USA) and DEPC water to a final 
volume of 48 5 jjlI  Samples were placed m the PCR machine (PTC 2000 Peltier 
Thermal Cycler, MJ Research, MA, USA) and amplification earned out using the 
appropnate cycle The cycle used for amplification of VEGF was 30 cycles of 94°C for 
1 mmute, 55°C for 2 minutes, and 72°C for 1 5 minutes using the following pnmers, 
which amplify all VEGF isoforms, as desenbed previously (Berse et al 1992) 
forward 5 ’-CGC AAG CTT AGG AGT ACC CTG ATG AG-3 ’ 
reverse 5’-CCG TCT AGA ACA TTT GTT GTG CTG T-3’
These pnmers amplify a 204 bp fragment The cycle used for amplification of p-actm 
was 32 cycles of 94°C for 45 seconds, 60°C for 45 seconds, and 72°C for 1 5 minutes 
using a commercial actm pnmer mix (Stratagene, La Jolla, CA, USA) which amplifies a 
661 bp fragment Specific iso forms were amplified by using pnmers that hybndise to 
opposite ends of the VEGF gene so that each PCR product will be of a different size 
depending on the number of exons present m each isoform Isoforms of VEGF were 
amplified using 30 cycles of 94°C for 1 mm, 58°C for 1 5 mm and 72°C for 2 mm The 
reaction conditions were same as for total VEGF reaction except the mastermix was 
compnsed of 3 (al of 25 mM MgCl2 for each 50 jal reaction and Taq was added just pnor 
to the beginning of the cycle when the samples were at 94°C The following pnmers 
were used (Figure 2 3)
forward 5 ’-GGA GGG CAG AAT CAT CAC-3 ’ 
reverse 5 ’ -CCG CCT CGG CTT GTC ACA-3 ’
Isoform specific pnmers were designed using Oligo 4 (Molecular Biology Insights, 
Cascade, CO, USA) and specificity was checked by companng the pnmer sequence 
against the Genbank database to ensure that pnmers were specific to the VEGF gene 
All pnmers used span an mtron so that if genomic DNA was amplified it would be of a 
far greater size than a product from cDNA PCR was visualised by electrophoresis on a 
1 5 % agarose gel as desenbed in 2 4  3 or for isoform specific PCR after southern 
blotting (2 6)
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Amplicon size
VEGF121 , , 4„ , 363 bp
VEGFl45 435 bp
VEGF165 —►_____________________________________ 495 bp
VEGF189 | 567 bp
VEGF206 t | | 618 bp
Exon 1-5 6 6’ 7 8
Forward primer  w Reverse primer ^_
Fig. 2.3: Primers used for iso form specific PCR amplification Primers anneal to 
opposite ends of the VEGF transcript so that the size of the PCR product will be 
dependent on the number of exons in the transcript and therefore on the isoform present
2.4.3 Agarose gel electrophoresis of DNA
An agarose gel was prepared by boiling an appropnate amount of agarose in 50 ml of 1 
x TAE buffer (40 mM Tns, 20mM acetic acid, 1 mM EDTA, pH 8 0) A 1 5 % (w/v) 
gel was the most commonly used The solution was allowed to cool to approximately 
60°C (warm to the hand) and poured into a level gel mold of an Easi-E-Cast Gel System 
(Hybaid, Middlesex, UK) Bubbles were removed, the combs were put m place and the 
gel allowed to set Once the gel had set it was placed m the electrophoresis tank filled 
with 1 x TAE A suitable volume of 6 x loading buffer (30% (v/v) glycerol, 0 01% 
(w/v) bromophenol blue) was added to samples to give a final concentration of 1 x The 
gel was run at a constant voltage of 80 V (E-C Apparatus Corporation EC105, FL, 
USA) until the bromophenol blue m the loading buffer approached the end of the gel 
Bands were visualised on a UV transilluminator (Syngene, Cambridge, UK)
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2.5 Densitometry
Blots and gel images were recorded using a Syngene UV transilluminator and white box 
in a Syngene darkroom with camera. The software used was GeneSnap version 2.6 by 
Syngene. Densitometric analysis was performed using GeneTools version 2.1.
2.6 Southern Blotting
2.6.1 Preparation of competent cells
Cells used for transformation were E. coli DH10B. Cells were streaked onto LB agar 
plates (0.005% (w/v) yeast extract, 0.01% (w/v) tryptone (both Bacto Laboratories, 
Liverpool, UK), 0.25 M NaCl, 0.015% (w/v) agar (Bacto Laboratories); pH 7.0) and 
incubated overnight at 37°C. Single colonies were selected the following day and 
cultured for 2 hr at 37°C with vigorous shaking at 200 rpm in an orbital shaker 
(Gallenkamp, Loughborough, UK). Contents were transferred to 75 ml LB broth 
(0.005%) (w/v) yeast extract, 0.01% (w/v) tryptone, 0.25 M NaCl; pH 7.0) in a 250 ml 
flask and returned to the incubator. The absorbance at A550 was monitored until it 
reached 0.5 and the cells were placed on ice. Cells were collected by centrifugation at 1 
500 x g for 5 min at 4°C. The cell pellet was resuspended in 30 ml of transformation 
buffer I (30 mM K-acetate, 50 mM MnCl2, 100 mM KC1, 10 mM CaCl2, 15% (w/v) 
glycerol, final pH 5.8) and left on ice for 10 min. Cells were pelleted by centrifugation 
and resuspended in 3 ml transformation buffer II (10 mM Na-MOPS, 75 mM CaCl2, 10 
mM KC1, 15%) (w/v) glycerol, final pH 7.0). Competent cells were aliquoted and flash 
frozen in liquid nitrogen and stored at -80°C.
2.6.2 Transformation of competent cells
pGEM3Z-hVEGF was a gift from Dr Larry Brown (Berse et al. 1992) and contains a 
204 bp fragment of the VEGF gene cloned into a HindlW and ¿scoRI site of the multiple 
cloning site (Figure 2.4). An aliquot of competent cells was thawed on ice and 100 fj.1 
of cells incubated for 20 min on ice with 10 ng of plasmid in 1 |ul. Cells were heat 
shocked for 90 sec at 42°C. 900 fo.1 of LB broth was added and cells incubated for 1 hr 
at 37°C. 100 |al of transformed cells was spread on LB agar plates containing 50 fig/ml 
ampicillin and incubated overnight at 37°C. Transformed colonies were picked the 
following day and cultured in 10 ml o f LB broth, containing 50 ng/ml ampicillin, for 16 
hr at 37°C with vigorous mixing. Cells were then either frozen at -80°C or collected for
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a miniprep of the VEGF plasmid. Transformation efficiency was approximately 1 x 107 
colony forming units (cfu) /(ig DNA.
Fig 2.4: Plasmid map of pGEM3Z-hVEGF. A 204 bp fragment of the VEGF gene was 
cloned into the multiple cloning site between Hindlll and EcoRl restriction sites. 
Interruption of the lacZ allows detection of positive clones since the ability to degrade 
X-gal is lost.
2.6.3 Preparation of probe
A single colony of transformed cells were cultured overnight in 10 ml of LB broth
containing 50 |J.g/ml of ampicillin. Plasmids were isolated the following day using
Wizard DNA Minipreps (Promega, Madison, WI, USA) according to the manufacturers
instructions. In brief, 2 ml of cells were pelleted by centrifugation at 21,000 x g for 10
min. The pellet was resuspended in 200 fj.1 of Cell Resuspension Solution. Cells were
lysed by the addition of 200 fa.1 of Lysis Solution. 200 |^ 1 of Neutralisation Solution was
added and cellular debris was pelleted by centrifugation at 21,000 x g for 5 min.
Cleared supernatant was aspirated and placed in a fresh tube. 1 ml of Wizard™
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Miniprep DNA Purification Resin was added to the supernatant and the contents mixed. 
The Resin/DNA mix was added to a Wizard™ Minicolumn using a 5 ml syringe. The 
column was washed with 2 ml of Washing Solution and the Wash solution was 
completely removed by centrifugation in a micro fuge tube at 21,000 x g for 2 min. The 
column was transferred to a fresh micro fuge tube and 50 jal of SDW added. DNA was 
eluted by centrifugation at 21,000 x g for 20 sec. DNA was checked by electrophoresis 
and quantified by spectrophotometry. The VEGF insert was released by digesting 7.5 
fig of DNA with 5 (0.1 of EcoRi (50 U) and 10 pi of Hindlll (100 U) (both enzymes from 
Gibco-BRL, Paisley, Scotland) with 25 pi of 10 x React 2 buffer in a total volume of 
250 pi for 1.5 hr at 37°C. DNA was precipitated by adding 25pl of 3 M Na-acetate, pH
5.5 and 550 pi of 95% (v/v) ethanol and leaving at -20°C overnight. DNA was pelleted 
by centrifugation at 12,000 x g for 20 min and resuspended in 20 pi of TE (10 mM Tris, 
1 mM EDTA, pH 7.4). Digested DNA was electrophoresed through a low melting point 
agarose gel (Gibco-BRL, Paisley, Scotland). The insert band was excised using a 
scalpel. Insert was then purified using Wizard PCR Preps (Promega, Madison, WI, 
USA) according to the manufacturers instructions. Briefly, the excised band was melted 
by heating to 70°C for 5 min. 1 ml of Wizard™ PCR Prep Resin was added and the 
contents gently mixed. The Resin/DNA mix was added to a Wizard™ Minicolumn using 
a 5 ml syringe. The column was washed with 2 ml of 80% (v/v) isopropanol and 
isopropanol was completely removed by centrifugation in a micro fuge tube at 12,000 x 
g for 20 sec. The column was allowed to air dry for 2 min, transferred to a fresh 
microfuge tube and 50 pi of SDW added. DNA was eluted by centrifugation at 12,000 
x g for 20 sec. Purified plasmid was examined by electrophoresis.
2.6.4 Southern blotting
DNA samples were electrophoresed on an appropriate agarose gel. The gel was 
photographed with a ruler placed along the side of the gel. DNA was denatured by 
washing the gel twice for 30 min each in 1.5 M NaCl, 0.5 M NaOH. The gel was rinsed 
briefly with de-ionised water and washed twice for 30 min each with neutralisation 
buffer (1 M Tris-HCl, ph 7.4, 1.5 M NaCl). To transfer the DNA, 0.45 pm nylon 
transfer membrane (Hybond, Amersham, Uppsala, Sweden) was cut to an appropriate 
size, pre-wetted in SDW and placed onto the gel. These were then placed in the 
sandwich depicted below (Figure 2.5). All items of the sandwich were carefully layered 
so as to ensure that there were no bubbles between any of the layers. The membrane
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was marked with the orientation of the gel and the gel was surrounded with clingfilm to 
prevent the separate filter paper layers from contacting as the gel is reduced in size. The 
buffer reservoir was filled with 10 x SSC and DNA allowed to transfer by capillary 
diffusion for 16 hr. After transfer the membrane was removed and washed in 5 x SSC. 
DNA was fixed by baking at 80°C for 2 hr.
Glass plate
Filter Paper 
Gel
10 x SSC
.Weight
Paper towels
«— Nitrocellulose membrane 
ilter Paper
Fig. 2.5: Preparation of southern blot sandwich for transfer of DNA onto nitrocellulose
2.6.5 Probe labeling
Probe labeling was carried out using Prime-A-Gene system (Promega, Madison, WI, 
USA) according to the manufacturers instructions. 25 ng of gel purified VEGF insert in 
10 jul of SDW was denatured for 5 min at 95°C and placed on ice. In a second screw 
cap centrifuge tube the following components were added in the order shown: 10 (j.1 5 x 
labeling buffer, 2 jal dNTPs, 10 ¡j.1 of denatured DNA, 2 |al of BSA, 5 [j.132P-dATP (50 
HCi) (Amersham, Uppsala, Sweden), 20 |il SDW, 1 j_il (5 U) Klenow fragment DNA 
polymerase I (Gibco-BRL, Paisley, Scotland). Probe labeling was carried out for 1 hr at 
room temperature. 2 |il of 0.5 M EDTA was added and the reaction heated to 95°C for 2 
min to terminate the reaction. The labeling reaction was then placed on ice and the
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probe purified by Nick® Columns Sephadex G-50 (Pharmacia, Cambridge, UK) 
according to the manufacturers instructions. In brief, excess liquid was poured off and 
the column rinsed once with TE (10 mM Tris-HCl, ph7.8; 1 mM EDTA). 3 ml TE 
buffer was added to the top of the column and allowed to run through. Labeled probe 
was then added to the column and 400 (j.1 of TE added and allowed to run through. 
Probe was eluted with a further 400 (j.1 TE buffer and collected. 100 pi of 10 mg/ml 
salmon sperm DNA, 80 pi SDW and 150 pi 1M NaOH was added to 400 pi of probe. 
Probe was then denatured at 95°C for 5 min and placed on ice. 150 jlxI IM HC1 and 800 
pi 1M potassium phosphate, pH 6.5 were added, mixed and the probe added to 
hybridisation fluid.
2.6.6 Hybridisation
The membrane was prehybridised for 3 hr at 65°C in 20 ml of Rapid-Hyb buffer 
(Amersham, Uppsala, Sweden). Denatured probe was added to the hybridisation buffer 
and allowed to hybridise overnight. Hybridisation fluid was removed and the 
membrane was rinsed twice in 2 x SSC, 0.1% (w/v) SDS, washed twice for 15 min each 
in 2 x SSC, 0.1 % (w/v) SDS at room temperature and then washed twice for 30 min 
each in 0.5 x SSC, 0.1% (w/v) SDS at 65°C. Membranes were sealed in plastic and 
exposed to X-ray film.
2.7 Protein electrophoresis
2.7.1 Protein isolation from cell cultures
Cell monolayers were washed twice with ice cold PBS. Cells were lysed in 1 X TNE (5 
mM Tris-HCl, pH 7.5, 0.15 M NaCl, 5mM EDTA) containing 0.5% (w/v) SDS, 0.5% 
(v/v) Triton X-100, 0.005%) (w/v) deoxycholic acid and 1 mM phenylmethylsulfonyl 
fluoride (PMSF). Minimum volumes of lysis buffer were used to ensure maximum 
concentration of protein, typically 0.5 ml for a 75 cm2 flask. The culture vessel 
containing the lysis buffer was placed on ice for 15 - 30 min. The lysate was passed 
through a 20 gauge needle several times to shear the genomic DNA and then boiled for 
10 min. Debris was pelleted by centrifugation at 15,000 g for 10 min. The cleared 
lysate was stored at -20°C in aliquots. If the recovered protein extract was very dilute it 
was concentrated by precipitation overnight at -20°C in at least 4 volumes of methanol. 
Protein was recovered by centrifugation at 15,000 x g for 10 min and resuspended in 1 x 
TNE buffer.
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2.7.2 Protein isolation from tissue samples
VEGF and TGF(3-1 were measured m normal and malignant breast tissue Tissue 
samples were removed from mastectomy samples by a pathologist Normal tissue was 
that which looked macroscopically normal and was sufficiently distant from the tumour 
margins as to be considered free of tumour Tissue samples were divided into separate 
cryotubes and flash frozen in liquid nitrogen withm approximately half an hour of 
resection They were then stored at -80°C until they were required On the day samples 
were required they were ground to a fine powder using a mortar and pestle with liquid 
nitrogen The powder was resuspended m tns buffered saline (TBS) (25 mM Tns-HCl, 
pH 7 6, 150 m M NaCl) and homogenised using a Dounce homogemser The 
homogenate was centrifuged at 15,000 g for 10 mm and the supernatant removed to a 
fresh tube and assayed for VEGF and TGFp-1 using a commercial ELISA (R&D 
Systems, Abingdon, UK and Genzyme, Cambridge, MA, USA, respectively) Protein 
levels were determined (2 7 3) and the levels of each factor expressed as pg VEGF/mg 
protein and ng TGFp-l/mg protein
2.7.3 Protein Determination
The bichinoic acid (BCA) protein microassay (Pierce, Rockford, IL, USA) was used for 
the determination of total protein In this assay Cu++ reacts with the protein under 
alkaline conditions to give Cu+ which reacts with the BCA to give a coloured product 
The commercially available assay is provided as two reagents, A, an alkaline 
bicarbonate solution and B, a copper sulphate solution, which are mixed together at a 
50 1 ratio prior to use 200 fj.1 of working reagent was added to 10 jal of sample or 
standard in a 96-well plate and incubated at 37°C for at least 30 mm The absorbance of 
each well was read at 570 nm (Bio-Tek Microplate Autoreader EL311, VT,USA) The 
protein concentration was determined from a standard curve of known concentrations of 
BSA between 0 and 1000 ng/ml
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2.7.4 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE)
PAGE was carried m the presence of SDS and 2-mercaptoethanol to denature proteins 
A 12% (w/v) gel was generally used for Western blot analysis A 7 5% (w/v) gel was 
used for Western blots analysis of the KDR protein Separating gel was prepared by 
mixing the following solutions
Separating 7 5 % 12%
acrylamide bisacrylamide (37 5 1) 5 5 ml 9 2 ml
1 875 M Tns-HCl, pH 8 8 4 5 ml 4 5 ml
Distilled water 12 ml 8 3 ml
10 % (w/v) SDS 220 jil 220 (a.1
10 % (w/v) ammonium persulphate 150 \i\ 150 |j.l
N,N,N’,N ’-tetramethyl-ethylenediamine (TEMED) 10 ^1 10 nl
The solutions were mixed and cast m vertical gel plates (Atto Corporation AE-6450 
mim-slabs, Tokyo, Japan) A small volume of IPA was added to the gel to aid 
polymerisation by excluding oxygen, removing bubbles and keeping the top of the gel 
level Once the gel had set the IPA was poured off and the gel was nnsed m distilled 
water The stacking gel was prepared and added onto the resolving gel and combs 
inserted
Stacking Gel 1 7 ml_acrylamide bisacrylamide (37 5 1), 2 ml 0 6 Tns-HCl, pH 6 8, 6 
ml distilled water, 100 (¿1 10 % (w/v) SDS, 150 jal 10 % (w/v) ammonium persulphate, 
10 nl TEMED
An equal volume of 2 x Llaemmh buffer (2 ml 0 6 M Tns-HCl, pH 6 8, 5 ml 10 % 
(w/v) SDS, 1 ml 2-mercaptoethanol, 2 ml glycerol and 0 01% (w/v) of bromophenol 
blue) was added to sample or protein markers and denatured by boiling for 10 min The 
samples were added to the wells and electrophoresed at 20 raA /gel in electrode buffer 
(50 mM Tns base, 384 mM glycine and 0 1 % (w/v) SDS) until the dye front 
approached the bottom of the gel
2.7.5 Staining with Coomassie Brilliant Blue
Gels were stained for protein by immersion m Coomaisse bnlliant blue (50% (v/v) 
methanol, 10% (v/v) acetic acid, 0 25% (w/v) Coomaisse bnlliant blue G250) for 30 
mm Gels were destamed with 5% (v/v) methanol with 7 5% (v/v) acetic acid until 
bands were visible
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2.8 Western Blotting
Following electrophoresis the gel was overlaid with 0 2 (im nitrocellulose membrane 
and 3 layers of Whatman blotting paper stacked over the gel with no bubbles between 
any of the layers A wet transfer was earned out m transfer buffer (0 15 M glycme, 20 
mM Tns, 0 01 % (w/v) SDS, 20 % (v/v) methanol) at 70 mA overnight or 400 mA for 3 
hr m a Bio-Rad Trans Blotter (Hercules, CA, USA) Dunng transfer temperature was 
maintained at 4°C using a cooling apparatus (Medmgen KK5E, Bonn, Germany) 
Following transfer the membrane was blocked for at least 1 hr with 5 % (w/v) dned 
milk (Marvel) m TBST (25 mM Tns-HCl, pH 7 6, 150 m M NaCl, 0 05 % (v/v) Tween 
20) and the pnmary antibody (VEGFR-2 from Santa Cruz, CA, USA) was added at a 
suitable dilution (1 100) in blocking buffer for 2 hr Following incubation with pnmary 
antibody the membrane was washed 3 times for 10 mm each m TBST The appropnate 
secondary antibody was diluted in TBST (1 750 for anti-rabbit IgG alkaline phosphatase 
(AP) conjugate (Promega, Madison, WT, USA) and 1 2,000 for anti-rabbit IgG 
horseradish peroxidase (HRP) conjugate (Dako, Cambndge, UK)) and added to the 
membrane for a 2 hr incubation with gentle agitation The membrane was washed for 
10 mm each m TBST For alkaline phosphatase (AP) conjugated antibodies the bound 
antibody was detected using a colonmetnc substrate (0 335 mg/ml BCIP, 0 67 mg/ml 
NBT (Promega, Madison, WI, USA) m substrate buffer of 100 mM Tns-HCl, pH 9 5, 
100 mM NaCl, 5 mM MgCl2) The reaction was stopped, when bands were visible, by
pouring off substrate solution and adding water For horseradish peroxidase (HRP) 
conjugated antibodies a chemilummescent substrate system was used (Pierce, Rockford, 
IL, USA) The reagents are provided as two solutions which are mixed equally just 
before development and added to the blot for 5 mm Following this incubation the 
membrane was sealed m plastic and exposed to an X-ray film m a dark room and 
developed Exposure times vaned between a few seconds and several minutes 
depending on the amount of starting protein
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2.9 Serum processing
Preoperative blood was collected from patients and also from healthy controls. Blood 
was collected by venopuncture into serum blood tubes (Sarstedt, Wexford, Ireland). 
Blood was centrifuged at 1,100 x g for 30 minutes. Serum was collected and filtered 
through a 0.2 |om Acrodisc (Gelman Sciences, Ann Arbor, MI, USA) and stored in 
aliquots at -80°C. Ascites fluid, freshly drained, was processed in the same way.
2.10 VEGF ELISA
VEGF protein levels were determined using an ELISA. For cell culture supernatants a 
sandwich ELISA using two antibodies was developed. Plates were prepared by adding 
100 |ol of the coating antibody (R&D Systems Anti-human VEGF neutralising antibody) 
at a concentration of 0.7 (og/ml in PBS and incubating overnight at room temperature in 
sealed plates. The following day the plates were washed, 4 times, with wash buffer 
(0.05% (v/v) Tween-20 in PBS, pH 7.4) and blocked by incubating with blocking buffer 
(1%> (w/v) BSA and 5% (w/v) sucrose in PBS) for 1 hr at room temperature. Following 
blocking, plates were washed again and at this stage could be used directly or could be 
stored by drying completely and storing sealed, with desiccant, at 4 - 8°C for a few 
months. Samples or standards were prepared in diluent (0.1% (w/v) BSA, 0.05% (v/v) 
Tween-20 in TBS, pH 7.3) and 1 OOjj.1 added to the wells for 2 hr at room temperature. 
The plates were washed 4 times with wash buffer and 1 OOjj.1 of biotinylated detection 
antibody (R&D Systems Biotinylated Anti-human VEGF antibody) at a concentration 
of 500 ng/ml in dilution buffer was added for a 2 hr incubation at room temperature. 
The plate was washed again 4 times with wash buffer and lOOfxl of streptavidin HRP 
(Zymed Laboratories, San Francisco, CA, USA) added for 30 min at room temperature. 
The plate was washed 4 times with wash buffer and 100 [il of substrate was added (0.1 
mg tetramethylbenzidine (TMB), 10%) (v/v) DMSO, 0.045 M phosphate-citrate buffer, 
0.006 % (v/v) hydrogen peroxide, pH 5.0) for 40 min at room temperature in the dark. 
The reaction was stopped by the addition of 50 |ol of 0.5 M H2S04. Absorbance was 
read at 450 nm with a correction wavelength of 570 nm. VEGF levels in samples were 
determined from a standard curve constructed from known standards (Appendix 1 A)
The VEGF ELISA used for cell culture supernatants was found to be unsuitable 
for measurements of VEGF in serum or tumour homogenates and a commercial ELISA 
was used instead (R&D Systems, Abington, UK). This was used in accordance with the 
manufacturers instructions. In brief, 100 |ol of assay diluent and 100 (0.1 of sample or
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standard was added to each well and incubated for 2 hr at room temperature. The 
contents were aspirated and the wells washed 4 times by filling each well with 400 |_il of 
wash buffer. 200 \il of an antibody conjugate was added for a 2 hr incubation at room 
temperature. The wells were washed 4 times with 400 jal of wash buffer and 200 |o.l of 
substrate added for 25 min. The reaction was stopped by the addition of 50 |_il of stop 
solution and the absorbance for each well read at 450 ran with a 570 nm correction. 
VEGF levels in samples were determined from a standard curve constructed from 
known standards (Appendix IB).
2.11 TGFp-1 ELISA
TGFp-1 levels were measured in culture supernatants, serum and tumour homogenates 
using a commercial ELISA (Genzyme, Cambridge, MA, USA). The assay was 
performed in accordance with the manufacturers instructions. In brief, TGFP-1 was 
activated by acidification. For serum samples 450 jal of assay diluent was added to 10 
|al of serum sample and 20 (ol of 1M HC1 for 1 hr at 4°C. For cell culture samples 200 
|j,l of sample was mixed with 200 jal of sample diluent and 20 (J.1 of 1M HC1 for 1 hr at 
4°C. The acid was neutralised by the addition of 20 |il of 1M NaOH for the serum 
samples and 15 )nl of 1M NaOH for cell culture samples. 100p.l of activated sample was 
added to a 96-well plate for 1 hr at 37°C. Sample was removed and the wells were 
washed 5 times by filling the wells with 400|j,l of 1 x wash buffer. 100 |nl of an anti- 
TGFp-1 HRP-conjugate was added to each well for lhr at 37°C. Conjugate was 
aspirated and the wells washed again, 5 times, by the addition of 400 p.1 of 1 x wash 
buffer. 100 (il of a substrate reagent was added for 20 min at room temperature. 
Substrate reaction was stopped by the addition of 100 jil of stop solution and the 
absorbance at 450 nm was measured in each well. TGFP-1 levels were calculated 
following the construction of a standard curve for TGFp-1 of known concentration 
(Appendix 1C).
2.12 Statistical Analysis
Data is graphically presented as mean ± standard error of mean (SEM). Normal probability 
plots were prepared to determine whether the data was normally distributed. For normally 
distributed data statistical significance was determined using students t-test and ANOVA 
for samples with more than 2 groups. A Scheffe post-hoc test was carried with the 
ANOVA to determine differences between groups. Data that was not normally distributed
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was analyzed using Wilcoxon signed rank m place of paired t-test and a Mann-Whitney U 
for a students t-test Correlation coefficients were determined using Pearson Product 
Moment (normally distributed data) or Spearman Rank (abnormally distributed data) Data 
was taken to be significant where p < 0 05 Data was analysed using DataDesk 4 1 for a 
Macintosh computer (Data Description Inc , Ithaca, NY, USA)
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CHAPTER 3
VEGF EXPRESSION IN BREAST CANCER
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3.1 Introduction
Solid tumours, such as breast tumours, cannot grow beyond 2mm3 without new vessel 
formation Angiogenesis occurs when the net balance of angiogenic promotors is 
greater than that of the angiogenesis inhibitors Constitutive expression of VEGF by 
breast cancer cells and a consequent increase of VEGF withm the tumour tissue would 
be indicative of a shift m the balance of angiogenic promotors and suggest a role for 
VEGF m breast tumour mediated angiogenesis VEGF was first identified m the ascites 
fluid of guinea pig bearing syngeneic hepatocellular tumours (Senger et a l , 1983) 
VEGF has since been shown to be overexpressed m many different cancers including 
bram tumours (Hatva et a l , 1995), colon cancer (Takahashi et a l , 1995), kidney and 
bladder cancer (Brown et a l , 1993), hepatocellular cancers (Suzuki et a l , 1996), ovarian 
cancers (Mesiano et a l , 1998) hemangioblastomas (Wizigmann-Voos et a l , 1995) and 
breast tumours (Toi et a l , 1995, Anan et a l , 1996, Yoshiji et a l , 1996) Many different 
cancer cell lines have also been found to express VEGF (Senger et a l , 1993) These cell 
lines are grown under normal cell culture conditions and as such have abundant 
nutnents and oxygen available It is likely therefore that the overexpression of VEGF 
by these cell lines may be due to mutations, such as mutations to p53, resulting m 
deregulated production of VEGF Northern blot analysis showed that VEGF mRNA 
levels were increased m breast tumour tissue relative to adjacent normal breast tissue 
(Yoshiji et a l , 1996) In situ hybridisation demonstrated that malignant epithelium 
stained strongly for VEGF mRNA while only weak staining was found m normal 
epithelium of the breast (Brown et a l , 1995)
The VEGF gene is alternatively spliced as described earlier to give 5 different 
isoforms (Figure 1 2) The isoforms are named according to the number of ammo acids 
they contain (VEGFI21, VEGF145 VEGF165, VEGF189 and VEGF206) (Tischer et a l , 1991, 
Plouet et a l , 1997) All isoforms contain a signal sequence which direct it for secretion 
from the cell VEGF121 is the only isoform that is freely available VEGF165 contains 
exon 7 that is slightly basic and has some heparin binding activity and this isoform is 
loosely bound to the cell membrane Exon 6 which is present m VEGF145, VEGF189 and 
VEGF206 is highly basic and maintains these lsoforms tightly bound to the cell 
membrane (Houck et a l , 1992) The isoforms that a tumour cell produces determine its
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bxoavailabihty (Houck et a l , 1992) Clearly synthesis of soluble iso forms would result 
m an immediate angiogenic response but synthesis of the larger isoforms may result m 
delayed angiogenesis
Receptors for VEGF were originally identified on endothelial cells (Jakeman et 
a l , 1992) and were initially thought to be exclusive to these cells VEGF receptors, 
however, have been found on other cell types The VEGFR-1 receptor has been found 
on monocytes and is involved m the chemotactic response of monocytes to VEGF (Shen 
et a l , 1993) VEGF also binds to cultured osteoblasts and induces differentiation of 
these cells (Macaulay et a l , 1995) Both the VEGFR-1 and VEGFR-2 receptors are 
expressed on uterine smooth muscle cells (Brown et a l , 1997) Binding expenements 
with I25I-VEGF have demonstrated that human melanoma cells but not normal 
melanoctyes bind VEGF (Gitay-Goren et a l , 1993) though it is not yet known whether 
VEGF acts as an autoenne growth factor m these cells VEGF is an autoenne mitogemc 
growth factor for human retinal pigment epithelial cells (Guemn et a l , 1995)
The aim of this chapter was to establish VEGF expression levels in breast cancer 
cell lines and determine which lsoforms BT474 and MDA-MB-231 cells produced In 
order to do this a VEGF ELISA and a method for determining the isoforms present was 
required Since the VEGFR-2 receptor is considered to play a greater role m tumour 
development (Waltenberger et a l , 1994), expression of this receptor by breast cancer 
cell lines was examined VEGF protein levels m breast tumour tissue and matched 
normal breast tissue were measured Circulating levels of VEGF m breast cancer 
patients were also measured to determine whether there is an elevation of VEGF m the 
serum of patients with breast cancer and the relationship between the stage of the 
disease and the level of serum VEGF
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3.2 Results
3.2.1 BT474 and MDA-MB-231 cell lines
Figure 1A and IB are representative photographs of cultured BT474 and MDA-MB-231 
cell lines, respectively The BT474 cell line is a cell line is derived from a ductal 
carcinoma BT474 cells grow slowly outward from islands of cells, a typical 
morphological feature of breast cancer cell lines (Leibovitz, 1994) MDA-MB-231 cell 
were derived from a malignant pleural effusion m a woman with primary breast cancer 
and are considered to be representative of metastatic breast cancer cells These cells 
grew rapidly m an epithelial like manner Both cell lines are ER negative
3.2.2 Mycoplasma testing of BT474 and MDA-MB-231 cell cultures
Mycoplasma is a common contaminant of cultured cell lines All cell lines were 
routinely tested for mycoplasma contamination as described (2 2 7) Cell lines coming 
into the laboratory were tested upon arrival and cell lines positive for mycoplasma were 
discarded Culture supernatants were centrifuged to pellet any mycoplasma present 
Resuspended pellet was treated with lysis buffer and mycoplasma DNA was amplified 
by PCR Figure 3 2 is representative of an agarose gel of PCR products following 
amplification for mycoplasma-specific DNA Lane 1 shows molecular weight markers, 
<j)X174 digested with Haelll A negative control (no added template) and a positive 
control (mycoplasma DNA) were included with the samples for PCR There is no 
amplified product m the negative control (lane 2) demonstrating that no contamination 
of the samples occurred A 660 bp PCR product was amplified from the positive 
control (lane 3) Smearing of this sample indicates some degradation of template 
probably as a result of repeated freezing and thawing Mycoplasma specific PCR 
reactions from BT474, MDA-MB-231 and HMEC cells are shown m lanes 4, 5 and 6 
Absence of PCR product indicates that these cell lines are free from mycoplasma 
contamination PCR products from a mycoplasma positive cell line are shown m lane 7
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Fig. 3.1: Monolayer cultures of BT474 (A) and MDA-MB-231 cells (B).
bp Markers 2 3 4 5 6 7
Fig. 3.2: Mycoplasma specific PCR reaction The PCR products were resolved on a 
1 5% (w/v) agarose gel and photographed under UV light Markers are 4>X174 DNA 
digested with HaelW Lanes 2 and 3 contain a negative and positive control, 
respectively Lanes 4, 5 and 6 contain samples from BT474, MDA-MB-231 and HMEC 
cells, respectively Lane 7 contains a sample for a cell line found to be contaminated 
with mycoplasma Positions of primers and mycoplasma specific band (660 bp) are 
indicated
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3.2.3 Development of an ELISA to measure VEGF
In order to measure VEGF produced by cell lines a sandwich ELISA using two anti- 
VEGF polyclonal antibodies was developed The final protocol developed that was 
used for VEGF measurements is described (2 10) The principle of the assay, m brief, is 
a sandwich ELISA m which a 96-well plate is coated with an anti-VEGF polyclonal 
antibody (R&D Systems AF-293-NA) The samples to be assayed are added to the well 
and are bound by the antibody Following this incubation a second biotmylated anti- 
VEGF antibody is added (R&D Systems BAF293) and also binds VEGF A 
streptavidm molecule conjugated to horseradish peroxidase (HRP) binds to biotm and 
HRP converts a substrate (tetramethylbenzidine -  TMB) to a coloured product, the 
intensity of which is dependent on the quantity of VEGF present The optimum 
concentration of each element was determined empirically by repeatedly performing the 
assay with different concentrations of each component Table 3 1 represents some data 
from several assays, performed m duplicate, where the concentration of each component 
was varied A regression coefficient (r2) of greater than 0 95 was required for the assay 
to be considered linear withm the concentration range used (0 - 1000 pg/ml) The mtra- 
assay precision was calculated by performing the assay 8 times with the same sample on 
one plate and the inter-assay precision was calculated by performing the assay with the 
same sample on four different plates m duplicate The intra-assay coefficient of 
variance (CV) was 5 7%, while the inter-assay CV was 9 7% A CV of less than 10% is 
usually sufficiently precise for an ELISA Samples were suitably diluted so that they 
were typically at a concentration roughly equivalent to the mid-pomt of the 
concentration standards A representative standard curve for the assay is illustrated m 
appendix 1A Unfortunately, this assay did not accurately measure VEGF levels m 
serum samples as determined by measuring serum containing known levels of VEGF 
Other factors were also found to be essential for the accurate performance of the assay 
and they included, 1) incubation of plates on a shaker during binding steps and 2) filter 
tips, such as those used for DNA work could not be used with TMB substrate as they 
caused an immediate reaction with this substrate VEGF levels were reported as pg/ (a,g 
total cellular protein m conditioned medium, pg/ |ig protein m tissue and as pg/ml serum 
for serum samples
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Primary 
(Coating) Ab 
(fig/ml)
Biotinylated 
Secondary Ab 
(|ig/ml)
Streptavidin -
HRP
(dilution)
Absorbance
Range
Regression
Coefficient
(r2)
0 4 02 20 000 0 281 0 914
0 4 02 8 000 0 240 0 975
0 4 02 4 000 0 492 0 992
0 4 02 2 000 0 579 0 995
0 4 02 1 000 0 32 0 679
05 02 2000 0 643 0 988
06 02 2000 0 791 0 986
07 0 2 2000 0 870 0 993
1 02 2000 0 132 0 85
07 03 2000 921 0 985
07 04 2000 1 002 0 987
0.7 0.5 2000 1.132 0.995
Table 3.1 Optimisation of ELISA protocol The assay was performed m duplicate with 
different concentrations of each component The absorbance range and correlation 
coefficient were calculated for each assay and the optimum concentration of each 
component was empirically assessed The optimum concentrations are shown m bold
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3.2.4 Breast cancer cell line expression of VEGF protein
VEGF protein production by BT474 and MDA-MB-231 cell lines was examined Both 
cell lines were found to produce VEGF protein (Fig 3 3) These experiments were 
performed m serum-free medium so as to avoid induction of VEGF by agents m serum, 
indicating that this represents constitutive expression by these cells VEGF protein 
produced was measured in the conditioned medium of the cells over 24 hr Without the 
presence of other earner proteins m the medium VEGF may degrade over time, and 
0 5% (w/v) BSA was therefore added to the medium to stabilise VEGF protein Levels 
of VEGF were expressed as pg VEGF/|ag of total cellular protein The metastatic 
MDA-MB-231 cells produced almost 3 fold more (p = 0 001) VEGF protein (12 1 ± 2 4 
pg/(j.g protein) than did the pnmary cell line BT474 (4 09 ± 0 69 pg/|J,g protein)
3.2.5 VEGF mRNA in BT474 and MDA-MB-231 cell lines
Semi-quantitative PCR was earned out to establish VEGF mRNA levels m cells lines 
(Fig 3 4) Conditions used have previously been shown to result m semi-quantitative 
amplification of VEGF (Harmey et a l , 1998) The PCR pnmer pair used amplifies a 
204 bp fragment from all VEGF isoforms As a control, constitutively expressed P- 
actm mRNA was also amplified by RT-PCR, resulting m a 661 bp product Pnmers 
used m both cases span mtromc sequences, allowing differentiation from PCR products 
arising from amplification of genomic DNA PCR products were quantified by 
densitometry and the VEGF product normalised against P-actin and expressed as the 
ratio of VEGF/p-actm Cells were cultured m medium without FCS so that there would 
be no interference from agents m the FCS MDA-MB-231 (lane 1) cells appeared to 
produce more VEGF mRNA than the BT474 cell line (lane 2) (0 96 vs 0 29 
densitometnc units) This represents a 3 3 fold increase m VEGF mRNA m MDA-MB- 
231 cells compared to BT474 cells Figure 3 4B shows the VEGF/p-actm ratio for 3 
independent expenments MDA-MB-231 cells produce significantly higher levels of 
VEGF mRNA than the BT474 cells
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Fig 3.3: VEGF protein production by BT474 and MDA-MB-231 cells over 24 hr Data 
represents 3 independent expenments earned out m tnplicate and are expressed as mean 
± SEM Statistical analysis was by unpaired students t-test *, p = 0 001 MDA-MB- 
231 vs BT474
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Fig 3.4A: 1 5% (w/v) agarose gel electrophoresis of VEGF and P-actm PCR products 
generated by RT-PCR of RNA from MDA-MB-231 (lane 1) and BT474 (lane 2) cells 
Cells were cultured for 24 hr m fresh medium and RNA isolated and amplified by semi- 
quantitative RT-PCR Position of molecular weight markers, <|)X174 digested with 
HaeIII, are shown (bp) Position of VEGF product and pnmers and P-actm product are 
indicated
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Fig 3.4B: Relative VEGF/p-actm mRNA levels in BT474 and MDA-MB-231 cells as 
assessed semi-quantitatively by densitometry Data is expressed as relative VEGF/p- 
actm with the BT474 cells arbitrarily taken as 1 0 and is from 3 independent 
experiments Statistical analysis was by students t-test *, p < 0 005 vs BT474 cells
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3.2.6 VEGF isoform expression by BT474 and MDA-MB-231 cells
VEGF lsoform expression in BT474 and MDA-MB-231 cells was examined by RT- 
PCR (2 4) followed by hybridisation with a VEGF probe (2 6) This combination of 
techniques was used because of problems with weak signal following the PCR step To 
prevent non-specific amplification a reduced number of PCR cycles (25) combined with 
a hot start (heating template to 94°C for 10 mm before adding Taq polymerase) was 
earned out The increased specificity resulted m weak amplification of PCR products 
Thus, to visualise PCR products southern blotting using a hVEGF probe was earned 
out The probe used for southern blotting was a 204 bp fragment of the VEGF gene 
released by EcoRI and Hindlll digestion of the pGEM3Z-hVEGF plasmid (Figure 
3 5 A) Lanes 1-4 show plasmid DNA following digest and a 204 bp fragment that was 
released This fragment was punfied, labelled with P32 and used as a probe m southern 
blot analysis of isoform specific PCR products The VEGF isoforms produced by both 
cell lines is shown m figure 3 5B The hVEGF probe bound to two bands of the BT474 
PCR products at 363 and 495 bp, which correspond to the VEGF12I and VEGF165 
isoforms The hVEGF probe bound to two bands of the PCR products of MDA-MB- 
231 cells at 495 bp and 567 bp which correspond to the VEGF165 and the VEGF189 
isoforms
3.2.7 Western blot analysis of VEGFR-2 expression by BT474 and MDA-MB-231 
cells
The BT474 and MDA-MB-231 cell lines were examined for the presence of VEGFR-2 
(KDR) to determine whether there was a possibility that VEGF may act as an autoenne 
growth factor for breast tumour cells Western blots were performed on both cell lines 
using an antibody directed against VEGFR-2 Figure 3 6 shows the results of a western 
blot analysis for VEGFR-2 protein Coomaisse staining of polyacrylamide gel was used 
to determine the mtegnty of the protein, which was satisfactory A positive control, the 
carboxyl terminus of VEGFR-2 (lane 1) was detected at 47 and 42 kDa The VEGFR-2 
receptor is highly glycosylated and the two different bands in the positive control lane is 
most likely due to alternative glycosylation VEGFR-2 expression was not detected m 
cell lysates of either BT474 (lane 2) or MDA-MB-231 (lane 3) cells
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Fig. 3.5 : Southern blot analysis of iso form specific RT-PCR (A) shows a 1 5% 
agarose gel of plasmid pGEM3Z-hVEGF digested with 50U EcoRl and 100U of Hindlll 
for 3 hr Position of molecular weight markers (MW), (j)X174 digested with Haelll, are 
shown (bp) Lanes 1-4 show digested plasmid (2745 bp) and released VEGF insert (204 
bp) (B) Southern blot analysis of VEGF isoform cDNA generated by RT-PCR PCR 
product was resolved on a 1 5% agarose gel, transferred to nylon membrane and 
hybridised with P32 labelled hVEGF probe Lanes 1 and 2 show a sample from BT474 
and MDA-MB-231 cells, respectively Molecular weight markers (MW) and VEGF 
isoforms present are indicated The figure is of two autoradiographs aligned along side 
each other
64
bp
175
83
62
47.5
32.5
Positive control
Positive control
Fig 3.6: Western blot analysis of VEGFR-2 protein expression in BT474 and MDA- 
MB-231 cell lysates Cell lysates were fractionated on a 7 5% (w/v) SDS-PAGE, 
transferred to nitrocellulose membrane and incubated with an anti-VEGFR-2 antibody 
Bound antibody was detected by enhanced chemilummescence Lane 1 shows antibody 
bound to a positive control, the carboxyl terminus of the VEGFR-2 protein Anti 
VEGFR-2 antibody did not bind to VEGFR-2 m lysates of BT474 and MDA-MB-231 
cells, respectively (Lanes 2 and 3, respectively)
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3.2.8 VEGF protein expression in breast tumour tissue as compared to matched 
normal tissue
As cultured breast cancer cells produced large quantities of VEGF, VEGF levels m 
tumour tissue were measured and compared to the levels found m a matched 
histologically normal piece of tissue (Fig 3 7A) Both normal and tumour tissue, with 
the exception of 1 normal sample, contained detectable levels of VEGF In every case 
there were greater levels of VEGF protein found in the tumour tissue as compared to the 
normal tissue The mean VEGF protein level in tumour tissue (321 3 ± 390 8 pg VEGF/ 
mg protein range 132 - 1212 pg/mg protein) was significantly greater than the mean 
VEGF level m normal tissue (1801 ± 196 pg VEGF/ mg protein range 0 0 - 65 9 
pg/mg protein) (Figure 3 7B) The mean increase m VEGF levels in tumour tissue was 
a 21 4 fold increase (range 1 3 - 64 8 fold increase)
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Fig. 3.7A: VEGF protein levels m tumour tissue (H) and matched normal tissue (□) m 
9 patients with malignant breast disease (A) Tissue was homogenised and VEGF 
measured by ELISA Total cell protein was measured by BCA assay and VEGF levels 
expressed per mg protein
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Fig. 3.7B: VEGF protein levels in tumour tissue and matched normal tissue in 9 patients 
with malignant breast disease Tissue was homogenised and VEGF measured by 
ELISA Total cell protein was measured by BCA assay and VEGF levels expressed per 
mg protein Data is expressed as mean VEGF levels ± SEM Statistical analysis was by 
Wilcoxon Signed Rank *, p < 0 005
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3.2.9 VEGF is elevated in the serum of breast cancer patients
VEGF was measured in the serum of patients with malignant breast disease (n = 44) and 
from patients with benign fibroadenoma (n = 21). VEGF was also measured in a group 
of healthy controls (n = 15) who were age matched with the malignant group. 
Malignancy was later confirmed histologically. The patient series with malignant 
disease was comprised of 37 ductal, 6 lobular and 1 mucinous carcinoma. Tumours 
were staged according to the size definitions of the TNM staging system (TNM Atlas, 
1992). Three of the patients had carcinoma in situ (Tis) and the remaining patients were 
as follows: T l, n = 13; T2, n = 18; T3, n = 5; T4, n = 5. Nodal status was also examined 
though there were sampling difficulties depending on the type of surgery performed. 
The nodal status for 16 patients was unknown, 13 patients were node positive and the 
remaining were node negative. Patient data is summarised in Table 3.1. The mean ages 
for the three groups was 59.1 ± 11.8 years, 36.5 ± 5.09 years and 50.33 ± 7.3 years for 
the malignant, benign and control groups respectively. There was no significant 
difference between the mean age of the malignant and control patients (p > 0.05) though 
both were significantly older than patients with benign breast disease 
(ANOVA, p < 0.05). Serum VEGF levels were significantly elevated (p < 0.05) in 
patients with malignant breast disease compared to both patients with benign 
fibroadenoma and age-matched controls as assessed by ANOVA (Fig. 3.8). The mean 
serum level in the malignant group was 393.07 ± 278.59 pg/ml, in the benign group
233.7 ± 184.21 pg/ml and in the control group was 230 ± 127.18 pg/ml. Serum VEGF 
levels in patients with malignant disease was also examined according to tumour stage 
(Fig 3.9). The levels of VEGF in patients with different stage of disease was Tis = 
370.92 ± 127.93, Tl = 292.66 ± 159.78, T2 = 363.98 ± 212.51, T3 = 533.81 ± 490.59, 
T4 = 631.41 ± 384.07 pg/ml. Although there was no statistical significance in the serum 
VEGF levels between the different stages there is a very clear trend for increased serum 
VEGF with advancing stage. This is possibly due to the fact that there were a small 
number of T3 and T4 patients. It is unusual for patients to present with disease at these 
stages. Three patients who presented with known clinical metastatic disease had serum 
VEGF of greater than 1000 pg/ml (mean -  1157.26 ± 151.42). There was no significant 
difference in serum VEGF levels between patients who were node positive (295.07 ± 
155.56 pg/ml) and node negative (358.51 ± 254.75 pg/ml)(Mann-Whitney U > 0.05).
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There was also no significant difference between VEGF levels m patients who were ER 
positive (390 58 ± 348 8 pg/ml) and ER negative (336 65 ± 197 34 pg/ml)(Mann- 
Whitney U > 0 05)
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Number Stage Age Nodal status ER Status VEGF (pg/ml)
1 T2 74 n/a pos 784.71
2 T2 66 neg neg 498.27
3 T2 51 neg n/a 417.67
4 T1 58 neg n/a 489.17
5 T3 68 neg pos 1092.48
6 T1 50 neg pos 173.28
7 T2 44 pos pos 43.40
8 T2 79 pos neg 416.28
9 T2 74 n/a pos 463.09
10 T2 43 pos neg 249.92
11 T2 49 n/a neg 768.59
12 T1 47 neg neg 440.88
13 T4 58 pos pos 277.38
14 T1 47 n/a pos 88.31
15 Tis 44 pos n/a 390.00
16 T2 62 neg n/a 432.00
17 T2 43 neg neg 46.00
18 T3 50 pos neg 172.00
19 T1 32 neg neg 360.00
20 T1 68 pos pos 546.00
21 T3 60 n/a n/a 1049.00
22 T2 75 pos pos 252.84
23 T1 63 neg pos 179.63
24 Tis 44 pos n/a 234.52
25 T1 85 n/a pos 245.94
26 Tis 51 n/a n/a 488.23
27 T1 60 neg pos 199.27
28 T3 54 pos pos 197.53
29 T2 60 pos neg 109.79
30 T2 65 neg neg 313.93
31 T1 59 neg neg 465.95
32 T1 76 neg neg 219.25
33 T2 59 n/a pos 318.28
34 T2 65 n/a pos 364.30
35 T2 61 pos neg 401.70
36 T3 74 n/a neg 158.03
37 T4 53 n/a pos 1330.29
38 T2 64 n/a pos 126.36
39 T4 70 n/a n/a 316.22
40 T1 59 neg neg 49.81
41 T1 50 n/a pos 347.27
42 T4 57 n/a neg 508.18
43 T4 79 n/a n/a 725.00
44 T2 52 pos neg 544.55
Table 3.1 Patient characteristics, pos = positive, neg = negative, n/a = not available.
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Fig. 3.8: Serum levels of VEGF m patients with malignant breast disease (n = 44), 
patients with benign fibroadenoma (n = 21) and healthy age-matched controls (n = 15) 
Data is expressed as the mean ± SEM Statistical analysis was by ANOVA with Scheffe 
post hoc correction *, p = 0 03, malignant vs benign and controls
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Fig. 3.9 : Seram levels of VEGF according to stage in patients with breast cancer 
VEGF levels were measured preoperatively m the serum and tumour stage was assessed 
from the histology reports Tis, n = 3, T l, n = 13, T2, n = 18, T3, n = 5, T4, n = 5 Data 
is expressed as the mean ± SEM Statistical analysis was by ANOVA with Scheffe post 
hoc correction p = ns
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3.3 Discussion
An ELISA method was developed to measure the amount of VEGF protein in cell 
culture supernatant. Cultured breast cancer cells produce high levels of VEGF protein 
and mRNA. MDA-MB-231 cells, which are metastatic in origin, produced significantly 
higher levels of both VEGF mRNA and protein than the primary BT474 cells. Isoform 
specific RT-PCR followed by southern blotting showed that the BT474 cell line 
produced the VEGFm and VEGF165 iso forms while the MDA-MB-231 cells produced 
the VEGF165 and VEGF189 isoforms. The antibody used for measuring the levels of 
VEGF protein was raised against VEGF165 and no information is available about its 
cross-reactivity with the other iso forms. If it does cross-react with the other isoforms 
then it is possible that the levels detected for MDA-MB-231 cells may be an under 
representation of total VEGF since this cell line produces the VEGF189 that is not 
released into the conditioned medium. However, these cell lines are independently 
derived from different people so direct comparison of expression of VEGF and the 
origin of the cells is not possible. However, it has been shown that metastatic colon 
carcinoma cells produced more VEGF than did their primary counterparts (Takahashi et 
al., 1995). We also found higher levels of serum VEGF in patients with metastatic 
disease. Expression of VEGF has been shown to correlate with the level of metastases 
in colon carcinomas and in experimental melanomas (Takahashi et al., 1995; Claffey et 
al., 1996). VEGF causes hyperpermeability of blood vessels which may allow tumour 
cells to migrate through blood vessels and into the circulation. VEGF also increases 
expression of proteases, which are required for metastasis, including interstitial 
collagenase, gelatinase A, urokinase-like and tissue plasminogen activators and 
(Unemori et al., 1992) (Lamoreaux et al., 1998; Pepper et al., 1991).
There are currently no methods available to distinguish between the different 
isoforms so an RT-PCR method was developed to examine the isoform species that each 
cell line produced. RT-PCR analysis of mRNA using primers to exon 1 and exon 8 that 
span splice junctions and that yield different sized products depending on the isoform 
mRNA. This showed that the BT474 cell line produced the more highly diffusible 
VEGF121 and the VEGF165 isoforms while the MDA-MB-231 cell line produced the 
VEGF165 and VEGF189 isoforms. Although the BT474 cells appear to produce the more
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immediately soluble isoforms, the VEGF189 isoform that the MDA-MB-231 cells 
produce has a greater angiogenic potential once it is cleaved from the cell membrane 
(Keyt et al., 1996b). Breast tumours have been shown to produce a number of different 
proteases including urokinase, which has also been shown to be capable of cleaving 
VEGF189 from the cell membrane (Plouet et al., 1997). Once released from the cell 
membrane VEGF189 is capable of inducing a greater angiogenic response since it also 
has the ability to release bFGF, another angiogenic factor, from the extracellular matrix 
(Jonca et al., 1997). Production of the VEGF165 and VEGF189 isoforms could lead to a 
more co-ordinated angiogenic response. Release of VEGF165 increases expression of 
proteases which can then release cell bound VEGF189 so that the overall levels of VEGF 
are sustained, which may be important for mitogenesis and chemotaxis. The fact that the 
MDA-MB-231 cells produce more VEGF and also produces isoforms that are capable 
or eliciting a greater angiogenic response is in keeping with the more aggressive nature 
of these metastatic cells. The VEGFR-2 receptor was not detected on either the MDA- 
MB-23 1 or BT474 cell line, which indicates that VEGF is unlikely to act on these cells 
in an autocrine manner.
Examination of clinical material showed that malignant tumour tissue contained 
elevated levels of VEGF compared to the normal breast tissue from the same patient. 
Previous studies have shown that breast tumour tissue had increased levels of VEGF 
mRNA (Yoshiji et al., 1996) but our study showed that this was also true at the protein 
levels. We only looked at VEGF-A levels but both VEGF-B and VEGF-C have also 
been found to be expressed in tumours (Salven et al., 1998) and it is likely that the 
expression of these proteins is also increased in tumours. Together with evidence that 
breast cancer cell lines constitutively produce VEGF, the results presented here suggest 
that VEGF has a central role in breast cancer. There were also, in all but one case, 
detectable levels of VEGF within the normal tissue. Previous studies have shown 
VEGF mRNA expression in a variety of normal tissue (Berse et al., 1992) and VEGF 
mRNA was also found, at low levels, in normal breast (Brown et al., 1995). VEGF 
mRNA is regulated at several different stages and may not necessarily correlate with 
protein levels. However, in this study protein levels were measured. VEGF has been 
shown to bind to the extracellular matrix (Park et al., 1993) and small amounts of VEGF 
may be stored there for immediate use following injury, such as occurs with bFGF.
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Small amounts of VEGF may also be required for the maintenance of normal 
vasculature (Alon et a l , 1995)
The elevated VEGF found m tumour tissue was also reflected m serum 
measurements of breast cancer patients Patients with malignant breast disease had 
significantly higher levels of serum VEGF than did patients with benign fibroadenomas 
and also a group of healthy age-matched controls Serum VEGF levels m mice are 
significantly increased from undetectable levels by subcutaneous transplantation with 
solid tumour (Kondo et a l , 1994) Other authors have found elevated VEGF m the sera 
of patients with various types of neoplasia including small cell lung carcinoma, ovarian 
and gastrointestinal carcinoma (Kraft et a l , 1999, Salven et a l , 1997) An elevation in 
the serum levels of VEGF was associated with poor outcome m urothelial cancer and m 
small-cell lung cancer (Miyake et a l , 1999, Salven et a l , 1998) We did not show that 
there was a statistically significant increase in serum VEGF with stage, however, there 
was a very clear trend indicating that VEGF levels increased with advancing stage 
Most patients present m the clinic with T1 or T2 tumours, relatively few present with 
advanced T3 or T4 disease Since there were smaller numbers of T3 and T4 tumours 
compared to lower stage tumours the variance is considerably greater and may account 
for the lack of significance One study, with over 500 patients, has shown that serum 
VEGF measurements are of high prognostic value m node negative breast cancer 
(Lmderholm et a l , 1998) Patients above the median value for serum VEGF 
measurements had a significantly shorter survival time Patients with metastatic lung 
cancer who had high levels of serum VEGF (greater than 500 pg/ml) had a poorer 
response to treatment than patients who had lower serum VEGF levels (Salven et a l , 
1998) This may be because metastases have already been established Preoperative 
serum levels of VEGF were significantly associated with tumour stage m colorectal 
cancer m that a high stage of disease was associated with higher levels of serum VEGF 
(Kumar et a l , 1998) In colorectal cancer, patients with the highest tumour doubling 
time also had higher serum VEGF and bFGF levels than other patients (Dinx et a l ,
1996) In this study, patients with clinically confirmed metastatic disease had the 
highest levels of serum VEGF Together with the data m MDA-MB-231 and BT474 
cells, showing that the metastatic MDA-MB-231 cells produced more VEGF than the
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primary BT474 cells, this may suggest that VEGF with associated with presence of 
metastatic disease
VEGF was also detected m the serum of patients with benign fibroadenoma and 
m the age-matched controls In addition to its role m angiogenesis VEGF is also 
thought to play a role m maintaining the integrity of large blood vessels (Tsurumi et a l ,
1997) which would explain the presence of low levels of VEGF m people without 
evidence of cancer or other angiogenesis related disease pathologies This study was 
initiated prior to publication of data showing that platelets contain and release VEGF 
(Verheul et a l , 1997) Degranulation of platelets, which may occur during serum 
preparation, would release VEGF into the serum The levels of serum VEGF measured 
may have a contribution from platelet release but the relative levels of VEGF between 
malignant patients and benign patients and controls would still exist as would the 
relative VEGF levels between different stages of cancer In future studies plasma 
preparation would be a better measure of VEGF withm the circulation However, it is 
important to note that hepanmsed tubes should not be used since VEGF is a heparin 
binding growth factor and heparm m the tubes would deplete plasma VEGF
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CHAPTER 4
REGULATION OF VEGF
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4.1 Introduction
As VEGF plays a central role m tumour growth by promoting angiogenesis, factors 
regulating VEGF production are critical m control of angiogenesis One mechanism 
through which VEGF may be regulated is by hypoxia (low oxygen tension) Hypoxia 
within a tumour is a common feature of a number of malignancies including breast 
cancer (Vaupel et a l , 1991) The obvious response to a hypoxic stress m any tissue is to 
increase the vascular supply to satisfy the metabolic needs of the tissue This response 
has been seen m the development of new capillaries m ischaemic tissue that would 
otherwise be quiescent for angiogenesis and with the angiogenesis associated with the 
healing of hypoxic wounds (Knighton e ta l 1983) We had previously shown that 
hypoxia increased VEGF expression by macrophages (Harmey et al 1998) 
Glioblastoma cells cultured in vitro showed increased VEGF mRNA levels when 
exposed to hypoxia and levels returned to normal following a return to normal oxygen 
levels (Shweiki et a l , 1992) VEGF expression m glioblastoma tumours was increased 
beside necrotic regions which are presumed to have insufficient oxygen supply (Shweiki 
et al 1992) VEGF mRNA is more highly expressed withm the inner regions of 
tumour spheroids which are presumed to be the areas with the lowest oxygen tension 
than m the outer regions which have easier access to oxygen (Shweiki et a l , 1995) 
When these tumour spheroids were exposed to 95% oxygen for 16 hr, which would 
presumably allow oxygen to reach the inner core of the spheroid, the VEGF mRNA 
levels, withm the inner regions, were reduced (Shweiki et al 1995) Hypoxia increase 
VEGF by increasing the levels of a transcription factor, hypoxia inducible factor-1 
(HIF-1) that binds to a hypoxia response element (HRE) m the VEGF gene and initiates 
transcription (Forsythe et a l , 1996) HIF-1 is constitutively produced but is rapidly 
broken down by ubiquitin-proteosomes in the presence of oxygen (Shih and Claffrey, 
1998) Hypoxia inhibits this breakdown thereby increasing HIF-1 levels and binding to 
DNA The oxygen sensing mechanism of HIF-1 is believed to be controlled by a heme- 
protien (Jiang et a l , 1996) In addition to a transcriptional increase, hypoxia may also 
increase VEGF mRNA levels by stabilising VEGF mRNA (Shima et a l , 1995)
Insulin-like growth factor-I (IGF-I) is a single chain polypeptide that is a 
member of a large family of peptides that are structurally related to insulin It exerts its
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cellular action by binding with high affinity to a heterotetramenc transmembrane 
tyrosine kinase receptor (IGF-1R) IGF-1 also binds with high affinity to a family of 6 
soluble IGF-1 binding proteins (IGFBPs) that regulate IGF-1 bioavailabihty by binding 
to IGF-1 and thereby making it of incapable of binding to target cells (Ullnch et a l , 
1986) There is some significant evidence that IGF-1 promotes breast cancer In vitro 
IGF-1 is mitogenic for breast cancer cell lines, IGF-1R is present on cultured breast 
cancer cell lines and primary breast tumours and anti-IGF-1 antibodies inhibit breast 
tumour growth (Huynh et a l , 1993) There is a positive association between circulating 
levels of IGF-1 and risk of breast cancer m premenopausal women (Hankinson et a l ,
1998) In a study of 44 patients with breast cancer, plasma levels of IGF-1 were 
significantly elevated in patients with breast cancer compared with healthy controls 
(Peyrat et a l , 1993) Breast cancer patients show altered serum profiles of IGFBPs 
which may reflect IGF-1 bioavailabihty (Ng et a l , 1998) A large number of cell lines 
express IGF-1 and IGF-1 mRNA has been detected m breast cancer cell lines which 
may indicate a possible autocrine loop (Qumn et a l , 1996) In addition to the direct 
effects on epithelial cells IGF-1 promoted angiogenesis in the rabbit cornea assay (Grant 
et al 1993, Nicosia et a l , 1994) IGF-1 increases VEGF mRNA and protein 
production m a number of colorectal carcinoma cell lines (Warren et a l , 1996)
Another important molecule believed to be indirectly involved m angiogenesis is 
transforming growth factor (5-1 (TGFP-1) TGF(3-1 is one member of a family of 
growth factors that also include activm/mhibm, bone morphogenetic protein (BMP), 
Mullerian inhibiting substance and glial cell line-derived neurotrophic factor (Oft et a l ,
1996) There are 5 different forms of TGFp which are TGFP-1, 2, 3, 4, 5, though only 
P-l, P-2 and P-3 are expressed m mammals The three mammalian forms of TGFp are 
coded by unique genes but share about 70 - 80% homology (Roberts et a l , 1988) 
TGFP is highly conserved amongst species suggesting an important biological role 
(Roberts et al 1988) TGFp is synthesised as a precursor, the C-termmus is then 
cleaved and the molecule dimenses to give the mature 25 kDa protein TGFp family 
members are secreted m an inactive form bound to 2 other proteins, non-covalently to a 
75 kDa glycoprotein termed the latency associated protein (LAP) and covalently to the 
135 kDa modulator/binding protein (Miyazono et a l , 1988) This latent form is unable 
to bind to TGFp receptors and can be activated enzymatically (plasmm, cathepsin),
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thermally or by acid treatment (Miyazono et al. 1988). Hypoxia, which may be present 
in a tumour environment, activates TGFp (Behzadian et al., 1998). The plasminogen 
activator system is also upregulated in a tumour environment and also activates TGFp 
which can then further upregulate urokinase plasminogen activator (uPA) which is 
suggestive of autocrine activation of TGFp (Amoletti et al., 1995). TGFp exerts its 
effects through the formation of heterotetrameric complexes between its 2 membrane 
serine-threonine kinases receptors TGFpRI and TGFpRII (Muñoz-Antonia et al., 1996). 
TGFP binds to TGFpRII which then recruits TGFpRI. TGFpRII is constitutively 
phosphorylated and transphosphorylates TGFpRI to mediate cellular signal (Yamashita 
et al., 1994). TGFP is involved in a great number of cellular activities including 
proliferation, differentiation, immune response, wound healing and tissue remodelling, 
embryogenesis and carcinogenesis (Roberts et al. 1988).
TGFp-1 is recognised as one of the most potent inhibitors of epithelial cell 
proliferation (Satterwhite and Moses, 1995). It reversibly arrests cell cycle progression 
in late Gl. In the early stages of breast cancer development TGFP-1 has a tumour 
inhibiting effect by inhibiting proliferation of tumour cells (Reiss and Barcellos-Hoff,
1997). As a tumour progresses it produces increasing amounts of TGFP-1 and it has 
been hypothesised that in advanced breast cancer TGFP-1 may promote tumour 
development (Reiss and Barcellos-Hoff, 1997). Tumour cells can become resistant to 
the inhibitory effects of TGFP-1 (Geiser et al., 1992). Absence of or mutations in the 
TGFpRII has been noted in cancer cells including breast cancer cell lines (Sun et al., 
1994). Mutations in TGFp receptors can result in loss of responsiveness to the growth 
inhibitory effects of TGFp-1 while still regulating the expression of TGFp-1 regulated 
genes, such as the induction of fibronectin expression (Geiser et al. 1992). A tumour 
promoting role for TGFP-1 may be seen by the fact that it can act as an angiogenic 
factor (Roberts et al. 1986). Chinese hamster ovary (CHO) cells transfected with 
TGFp-1 showed increased growth in nude mice with an associated increase in blood 
vessel formation (Ueki et al., 1992). Both of these effects were inhibited by the 
introduction of anti-TGFp-1 antibodies (Ueki et al. 1992). There is a positive 
correlation between the plasma levels of TGFP-1 and vascularity in patients with 
hepatocellular carcinoma (Ito et al., 1995). The manner in which TGFp-1 stimulates 
angiogenesis would appear to be indirect since TGFP-1 inhibits endothelial cell
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proliferation, invasion and lumen formation (Pepper et al 1993) This indirect 
angiogenic response may be achieved by the induction of other growth factors such as 
VEGF TGFp-1 has been shown to increase VEGF production by mouse embryo 
fibroblasts, a lung adenocarcinoma cell line, vascular smooth muscle cells, glial cells 
and macrophages (Pertovaara et a l , 1994, Harmey et al 1998, Brogi et a l , 1994)
The aim of this chapter was to establish factors that regulate VEGF expression 
m breast cancer cells A rational approach that involved the examination of factors that 
are known to be present m the breast tumour microenvironment and that have strong 
influences on VEGF expression and breast tumour growth was chosen The factors 
chosen therefore were hypoxia, IGF-1 and TGFp-1 Also, the two latter factors, IGF-1 
and TGFp-1, may play a role m response of breast tumour cells to tamoxifen (Huynh et 
al 1993) and therefore had additional interest because of other work with tamoxifen 
(Butta et a l , 1992)
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4.2 Results
4.2.1 Effect of hypoxia on VEGF protein production by BT474 and MDA-MB-231 
cells
The effect of exposure to hypoxia on VEGF production by BT474 and MDA-MB-231 
cells was examined Cells were exposed to a hypoxic environment (approximately 2% 
0 2 as measured using a dissolved oxygen probe) for 24 hr and the VEGF levels m the 
conditioned medium examined This is similar to the oxygen levels found within
regions of solid tumour including breast tumours (Vaupel et al 1991) There was no
/
FCS m the medium to avoid interference by agents m the FCS but VEGF produced was 
stabilised by the addition of 0 5% (w/v) BSA Hypoxia significantly (p < 0 01) 
increased VEGF expression by both the BT474 and MDA-MB-231 cell lines as 
measured by ELISA, figures 4 1A and 4 IB, respectively In the BT474 cells this was 
an increase from 3 18 ± 1 14 under normoxic conditions to 15 77 ± 3 16 pg/^g protein 
under hypoxic conditions This represents a 5-fold increase m VEGF protein 
production In the MDA-MB-231 cells the increase was from 15 54 ± 2 8 under 
normoxia to 5217 ± 5 7  pg/|ag protein under hypoxia, and is a 3 4 fold increase m 
VEGF production
4.2.2 Effect of IGF-1 on VEGF protein production by BT474 and MDA-MB-231 
cells
As IGF-1 is associated with breast cancer progression and can promote angiogenesis, 
the effect of IGF-1 on VEGF protein production by BT474 and MDA-MB-231 cells was 
examined Cells were treated with IGF-1 (0, 100, 200, 300, 400, 500 ng/ml) m FCS free 
medium for 24 hr These were the same doses that have previously been shown to 
increase VEGF production by colorectal carcinoma cell lines (Warren et al 1996) 
VEGF produced was stabilised by the addition of 0 5% (w/v) BSA to the medium and 
was measured by ELISA Conditioned medium following 24 hr exposure to IGF-1 was 
examined for the levels of VEGF produced IGF-1 had no significant effect on VEGF 
production by either the BT474 (Fig 4 2A) or MDA-MB-231 cell line (Fig 4 2B)
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Fig. 4.1: Effect of exposure to hypoxia for 24 hr on VEGF production by BT474 (A) 
and MDA-MB-231 (B) cell lines. Data is representative of 3 experiments carried out in 
triplicate and is expressed as the mean ± SEM. Statistical analysis was by students t- 
test. * ,p<0.05 .
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Fig. 4.2: Effect of IGF-1 on production of VEGF protein over 24 hr by BT474 (A) and 
MDA-MB-231 (B) cells Data is representative of 3 independent experiments earned 
out in tnplicate and is expressed as mean + SEM Statistical analysis was by ANOVA 
with Scheffe post hoc correction, p = non-significant
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4.2.3 Correlation between serum and tumour VEGF and TGFP-1
Having identified high levels of VEGF m breast cancer patients, levels of TGFp-1, 
which has been shown to regulate VEGF in some cells types, were measured m a subset 
of breast cancer patients Measurements were made in both the serum and tumour tissue 
of these patients There was a moderate but statistically significant (p < 0 05) positive 
correlation (Pearson Product Moment Correlation coefficient = 0 57) between levels of 
TGFp-1 and VEGF m the serum of breast cancer patients (n = 33) (Figure 4 3A) Table 
4 1 outlines the patient characteristics The mean TGFP-1 levels m the serum was 58 5 
± 26 9 ng/nl (range 30 68 -  110 07 ng/ml)
Tumour tissue was homogenised and the levels of both factors measured and 
expressed per mg of protein Tumour tissue from 9 patients was examined and there 
was a significant (p < 0 05) positive correlation between the levels of TGFP-1 and 
VEGF (Pearson Product Moment Correlation coefficient = 0 69) (Figure 4 3B) The 
mean TGFP-1 levels m tumour tissue was 358 7 ± 285 7 ng/mg protein (range 99 24 -  
682 68 ng/mg protein)
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No. Stage Age Nodal
status
ER Status Type TGFß-1
(ng/ml)
VEGF
(pg/ml)
1 T2 66 neg neg ductal 65 6 498 3
2 T2 51 neg n/a ductal 84 6 417 7
3 T1 58 neg n/a ductal 108 6 489 2
4 T3 68 neg pos ductal 182 2 1092 5
5 T2 74 n/a pos ductal 81 58 463 1
6 T2 43 pos neg ductal 110 1 249 9
7 T1 47 neg neg ductal 78 5 440 9
8 T4 58 pos pos ductal 30 7 277 4
9 Tis 44 pos n/a ductal 51 6 390 0
10 T2 43 neg neg ductal 61 0 46 0
11 T3 50 pos neg lobular 45 2 172 0
12 T1 32 neg neg ductal 63 1 360 0
13 T1 68 pos pos ductal 32 9 546 0
14 T1 76 neg neg ductal 31 6 208 1
15 n/a 69 n/a n/a n/a 36 7 297 4
16 T1 60 neg pos ductal 55 3 199 3
17 T3 54 pos pos lobular 40 3 197 5
18 T2 60 pos neg ductal 36 0 109 8
19 T2 65 neg neg ductal 42 9 313 9
20 T1 59 neg neg ductal 60 6 465 9
21 T1 76 neg neg ductal 59 8 219 2
22 T2 59 n/a pos ductal 44 3 318 3
23 T3 74 n/a neg ductal 72 3 158 0
24 n/a 63 n/a n/a n/a 40 9 124 5
25 T2 64 n/a pos ductal 46 7 126 4
26 T4 70 n/a n/a ductal 42 5 3162
27 n/a 66 n/a neg ductal 48 6 68 3
28 T1 59 neg neg ductal 49 8 49 8
29 n/a 54 n/a n/a n/a 44 3 81 4
30 T1 50 n/a pos ductal 51 2 347 3
31 T4 57 n/a neg ductal 40 7 508 2
32 T4 79 n/a n/a ductal 45 7 725 0
33 T2 52 pos neg ductal 48 5 544 5
Table 4.1 Patient characteristics for correlation of serum TGF(3-1 with VEGF pos = 
positive, neg = negative, n/a = not available
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Fig 4.3 : Association between serum (A) and tumour (B) TGFp-1 and VEGF levels 
Statistical analysis was by Pearson Product Moment Correlation Correlation 
coefficient = 0 57, serum and 0 69, tumour tissue, p < 0 05
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4.2.4 Effect of TGFP-1 on VEGF protein production by BT474 and MDA-MB-231 
cells
Having found a positive correlation between the serum and tumour levels of TGFf3-l 
and VEGF m breast cancer patients, the effect of TGFp-1 on VEGF production by 
cultured breast cancer cells was examined BT474 and MDA-MB-231 cells were 
exposed to TGFP-1 (0, 2 5, 5, 7 5 10 ng/ml) for a 24 hr period and VEGF levels m the 
conditioned medium measured by ELISA The medium did not contain FCS so that 
there would be no interference from agents m the FCS and 0 5% (w/v) BSA was 
included to stabilise secreted VEGF The BT474 cell line produced significantly (p = 
0 03) more VEGF protein following 5 ng/ml TGFP-1 compared to controls (6 04 ± 0 68 
vs 4 09 ± 0 69 pg/(ag protein) (Figure 4 4A) The MDA-MB-231 cell line showed a 
concentration dependent increase m VEGF production following TGFP-1 exposure 
(Figure 4 4B) This was statistically significant at 7 5 and 10 ng/ml TGFp-1 compared 
to untreated controls (21 24 ± 2 26 and 25 25 ± 5 5 v s l 2 1 ± 2 4  pg/(ig protein, p = 
0 03) The correlation between TGFp-1 and VEGF m the serum and tumour tissue only 
shows there is an association between these two factors but gives no information of the 
effect of each factor on the other A reciprocal experiment, examining the effect of 
VEGF on TGFP-1 expression by BT474 and MDA-MB-231 cells was also performed 
The BT474 cells did not produce any TGFp-1 as measured by ELISA The MDA-MB- 
231 cell line produced very low levels of TGFp-1 (3 39 ± 2 58 pg/ml in untreated 
controls), that were at the limits of detection of the ELISA used, but VEGF (0, 1, 5, 10, 
20, 100 ng/ml) did not significantly alter (p > 0 05) TGFp-1 protein production over 24 
hr (Figure 4 5)
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Fig. 4.4A: Effect of TGFp-1 on VEGF production by BT474 cells Cells were exposed 
to TGFp-1 for 24 hr and VEGF m conditioned medium examined by ELISA Data is 
representative of 3 independent expenments and is expressed as mean ± SD Statistical 
analysis is by ANOVA with Scheffe post hoc correction *, p < 0 05 vs 0 ng/ml TGFP- 
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Fig. 4.4B: Effect of TGFp-1 on VEGF production by MDA-MB-231 cells Cells were 
exposed to TGFp-1 for 24 hr and VEGF m conditioned medium examined by ELISA 
Data is representative of 3 independent experiments and is expressed as mean ± SD 
Statistical analysis is by ANOVA with Scheffe post hoc correction *, p < 0 05 vs 0 
ng/ml TGFP-1
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Fig. 4.5: Effect of VEGF on TGFp-1 production by MDA-MB-231 cells Cells were 
exposed to VEGF for 24 hr and TGFp-1 m the conditioned medium was examined by 
ELISA Data is representative of 3 independent experiments and is expressed as mean ± 
SEM Statistics is by ANOVA with Scheffe post hoc correction p = ns
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4.2.5 Effect of TGFp-1 on VEGF mRNA in BT474 and MDA-MB-231 cells
Having found that TGF(3-1 increased VEGF protein production by BT474 and MDA- 
MB-231 cells the effect of TGFp-1 on VEGF mRNA levels m these cells was 
examined Cell lines were treated with TGFp-1 (0, 2 5, 5, 7 5, 10 ng/ml) for 12 hr m 
FCS free medium Total RNA was isolated, reverse transcribed and VEGF mRNA 
amplified by PCR The mRNA for P-actm, a constitutively expressed gene, was also 
amplified and the ratio of VEGF/p-actin intensity m an agarose gel was assessed by 
densitometry Figure 4 6A shows a representative agarose gel of PCR products 
amplified from the BT474 cells Figure 4 6B represents the relative VEGF/p-actm ratio 
from 3 independent experiments A representative photograph of VEGF and P-actin 
PCR products m the MDA-MB-231 cell line following exposure to TGFp-1 is shown in 
figure 4 7A and the VEGF/p-actm ratio from 3 experiments can be seen in figure 4 7B 
For the graphs m both figures the ratio of VEGF/p-actin in the control sample is taken 
as 1 and the other samples are graphed relative to the control Though it was not 
significant, TGFp-1 at 2 5,5 and 7 5 ng/ml appears to increase VEGF mRNA levels in 
BT474 cells while TGFP-1 at 7 5 and 10 ng/ml increases VEGF mRNA levels m MDA- 
MB-231 cells
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Fig. 4.6: Effect of TGFp-1 on BT474 VEGF mRNA over 12 hr (A) shows a 1 5% 
agarose gel of VEGF and P-actin PCR products generated by RT-PCR from total RNA 
Position of molecular weight markers (MW), (|)X174 digested with Haelll, are shown 
(bp) (Lane 1) Lanes 2 - 5 are samples treated with 0, 2 5, 5, 7 5 and 10 ng/ml TGFP-1, 
respectively Position of VEGF and P-actin PCR products is indicated (B) 
Densitometnc analysis of the relative ratio of VEGF/p-actin Data is expressed as mean 
VEGF/p-actin relative to the untreated sample ± SEM and is from 3 independent 
experiments Control value is taken as 1
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Fig. 4.7: Effect of TGFp-1 on MDA-MB-231 VEGF mRNA over 12 hr (A) shows a 
1 5% agarose gel of VEGF and P-actm PCR products generated by RT-PCR from total 
RNA Position of molecular weight markers (MW), (|)X174 digested with Haelll, are 
shown (bp) (Lane 1) Lanes 2 - 5 are samples treated with 0, 2 5, 5, 7 5 and 10 ng/ml 
TGFp-1, respectively Position of VEGF and P-actm PCR products is indicated (B) 
Densitometnc analysis of the relative ratio of VEGF/p-actm Data is expressed as mean 
VEGF/p-actm relative to the untreated sample ± SEM and is from 3 independent 
experiments Control value is taken as 1
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4.2.6 Time course of TGF(3-1 induction of VEGF protein production by BT474 
and MDA-MB-231 cells
As TGFp-1 increased breast cancer cell line production of VEGF, a time course of 
TGFp-1 induction of VEGF was earned out The BT474 and MDA-MB-231 cell lines 
were treated for vanous time penods (2, 4, 8, 12, 16, 24 and 48 hr) with TGFP-1 at the 
dose previously shown to result m maximal induction of VEGF (5 ng/ml for BT474 
cells and 10 ng/ml for MDA-MB-231 cells, Fig 4 4A and Fig 4 4B respectively) As 
before, the medium did not contain FCS so that there would be no interference from 
agents m FCS and VEGF produced was stabilised by the addition of 0 5% (w/v) BSA 
In order to account for VEGF that would have accumulated under basal conditions the 
same expenment was earned out without the addition of TGFp-1 and subtracted from 
TGFp-1 stimulated production The BT474 cell line showed increased VEGF 
production from 4 - 48 hr (Figure 4 8A) This induction was maximal at 16 hr (1 98 
pg/fo.g protein increase over untreated cells) The MDA-MB-231 cell line showed 
increased VEGF production from 8 - 48 hr (Figure 4 8B) The maximal induction for 
MDA-MB-231 cells was at 24 hr (15 13 pg/(ig protein increase over untreated cells)
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Fig. 4.8: Effect of TGFp-1 over time on VEGF production by BT474 (A) and MDA- 
MB-231 cells (B). Data is representative of 3 independent experiments and is expressed 
as the increase in VEGF compared to untreated cells at the same time period ± SEM. 
Statistical analysis was by ANOVA with Scheffe post hoc correction. *, p 0.05 vs 2 hr.
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4.3 Discussion
Hypoxia upregulated VEGF production by the breast cancer cell lines, BT474 and 
MDA-MB-231 In the BT474 cell line there was a 5 fold increase while in the MDA- 
MB-231 cells there was a 3 4 fold increase This is a similar to the increase found by 
another group that showed an increase of 1 4 to 6 9 fold m VEGF expression levels m a 
panel of different breast cancer cell lines (Scott et a l , 1998) Other authors have found 
VEGF levels to be highest near necrotic regions of breast tumours, which are believed 
to be the most hypoxic regions of a tumour (Wnght et a l , 1997) The exact mechanism 
through which hypoxia regulated VEGF was not examined but other studies have 
highlighted a number of mechanisms that may be employed by these cells Hypoxia 
increases VEGF mRNA transcription rate m C6 glioma cells (Levy et a l , 1995) A 
post-transcnptional mechanism whereby hypoxia stabilises VEGF mRNA has also been 
descnbed m pheochromocytoma cell line and in C6 glioma cells (Levy et a l , 1996, 
Levy et al 1995) Increasing the half life of mRNA means that there is increased 
translation of transcripts and therefore more protein produced Hypoxia increased the 
half life of VEGF mRNA by 43 mins to 106 mm by a mechanism that involved the 
binding of a hypoxia-inducible factor to the 3’- untranslated region (UTR) of the VEGF 
gene (Levy et al 1996) The inclusion of a binding site for hypoxia-mducible factor 1 
(HIF-1) m the promotor region of the VEGF gene and the requirement for the 3’- 
regulatory region, that conforms under certain conditions to stabilise VEGF mRNA, 
further supports the hypothesis that hypoxic induction is by a combination of 
transcription and post-transcnptional mechanisms (Damert et a l , 1997) The mRNA 
levels of VEGFR-1 (flt-1) were upregulated threefold m the liver of rats exposed to low 
oxygen levels or injection with cobalt, which mimics the effects of hypoxia (Sandner et 
a l , 1997) The levels of the other VEGF receptors remained unchanged Endothelial 
cells do not normally express VEGF but exposure to hypoxia allows both human 
umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells 
(HMEC) to express VEGF (Namiki et a l , 1995) It would seem that the extreme stress 
of hypoxia may allow VEGF to act on endothelial cells m an autocrine manner 
Hypoxia did not upregulate the expression of VEGF-B or VEGF-C m human fibroblasts 
(Enholm et a l , 1997) and downregulated P1GF expression m a trophoblast
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choriocarcinoma cell line (Khaliq et a l , 1999) which demonstrates that the response to 
hypoxia is not conserved amongst the VEGF family members
IGF-1 did not increase BT474 or MDA-MB-231 cell line production of VEGF 
protein Concomitant research within the lab had previously demonstrated that these 
cell lines do express the IGF-1 receptor, however, activation of the IGF-1 receptor 
results m the stimulation of diverse intracellular pathways and it is possible that upon 
binding of IGF-1 the growth related genes are activated without activation of the VEGF 
gene (Rubm and Baserga, 1995) In colorectal carcinoma cell lines IGF-1, at the same 
doses, increased VEGF protein by both transcriptional and post-transcnptional 
mechanisms (Warren et al 1996) IGF-1 also increased VEGF expression by colon 
carcinoma cell lines by a transcriptional mechanism (Akagi et a l , 1998) In this case 
the increase of VEGF by IGF-1 occurred regardless of the presence of IGFBPs IGF-1 
also increased VEGF mRNA, in a concentration dependent manner m retinal epithelial 
cells (Punglia et a l , 1997) Interestingly, IGF-1 has been found to increase expression of 
target genes, the glucose transporters GLUT-1 and GLUT-3, by increasing HIF-1 levels 
(Zelzer et a l , 1998) The association of IGF-lwith the progression of breast cancer may 
be solely related to the mitogemc and anti-apoptotic effects of IGF-1 (Winder et a l,
1989)
A positive association was found between the levels of TGFP-1 and VEGF m 
the serum of patients with breast cancer and m the breast tumour tissue of breast cancer 
patients A high level of TGF(3-1 was associated with a high level of VEGF in both 
serum and tumour tissue The levels of TGFp-1 found m the serum (mean concentration 
approximately 60 ng/ml) are slightly higher than previously reported circulating levels 
in a study of 26 breast cancer patients (20 ng/ml) and considerably higher than the 
reported levels m normal healthy controls (4 3 ng/ml) (Kong et a l , 1995) In that study 
the levels of TGFp-1 were reduced after removal of the tumour indicating that elevated 
TGFP-1 was most probably produced by the tumour (Kong et al 1995) This is 
supported by the finding that TGFp-1 was elevated m the tumour tissue compared to the 
matched normal tissue of breast cancer patients (Toomey, 1998) Although we did not 
look at TGFp-1 levels m healthy controls or m normal tissue there does appear to be 
very high levels of TGFP-1 within the tumour tissue BT474 and MDA-MB-231 cells 
m this study produced negligible amounts of TGFP-1 which raise the question of which
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cells withm the tumour are producing TGFp-1 Previous studies have shown that breast 
tumour cells do produce TGF(3-1 (Zajchowski et a l , 1988) TGF(3-1 in tumours may 
also be produced by the stromal cells Northern blot analysis has demonstrated that 
fibroblasts from benign and malignant breast lesions produce TGFp-1 mRNA (Cullen et 
a l , 1991) TGFP-1 is chemotactic for macrophages which may also produce more 
TGFP-1 (Assoian et a l , 1987) VEGF upregulates endothelial cell expression of 
plasminogen activators (Pepper et al 1991) which may release matrix bound TGFP-1 
resulting m an increase m circulating and tumour levels of TGFP-1 TGFp-1 stimulates 
macrophage production of urokinase which can release more TGFP-1 and other matrix 
bound angiogenic factors such as bFGF and some VEGF isoforms (Falcone et a l , 
1993)
TGFP-1 increased VEGF protein production by BT474 and MDA-MB-231 
breast cancer cell lines In a reciprocal experiment both cell lines were treated with 
varying concentration of VEGF (0 -  100 pg/ml) Neither control nor TGFP-1 treated 
BT474 cells produced detectable TGFp-1 while the MDA-MB-231 cell line produced 
low levels of TGFP-1 that were at the limit of detection of the assay used and did not 
vary with exposure to VEGF Though it was not significant, TGFP-1 at 2 5,5 and 7 5 
ng/ml appears to increase VEGF mRNA levels m BT474 cells while TGFp-1 at 7 5 and 
10 ng/ml increases VEGF mRNA levels m MDA-MB-231 cells The response of BT474 
and MDA-MB-231 cell lines to TGFP-1 is slightly different The upregulation of 
VEGF m BT474 cells was somewhat irregular while the increase m MDA-MB-231 cells 
was clearly concentration dependent TGFP-1 induction of VEGF mRNA was at the 
same doses that increased VEGF protein production and suggest that the increase in 
VEGF protein is directly due to increased VEGF mRNA Induction of VEGF by TGFP- 
1 m the BT474 cells was more rapid than m the MDA-MB-231 cells, increasing withm 
4 hr m BT474 cells and 8 hr in MDA-MB-231 cells However, levels began to decrease 
earlier m the BT474 cells (within 16 hr) compared to in the MDA-MB-231 cells (withm 
24 hr) TGFP-1 does not universally upregulate VEGF production as it has been found 
to inhibit VEGF expression m both undifferentiated and differentiated colon cancer cells 
(Hsu et a l , 1995) TGFp-1 increases expression of VEGF-C, the VEGF species 
associated with lymphatic vessels, but did not upregulate expression of VEGF-B which 
shares the most homology to VEGF and can be expressed m tumours (Enholm et al
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1997). TGFp-1 downregulates levels of the VEGF receptor VEGFR-2 (Flk-1) and also 
decreases the binding of VEGF to this receptor (Mandriota et al., 1996). Flypoxia is 
known to activate TGFp-1 and hypoxia with TGFp-1 synergistically increases VEGF 
expression in breast cancer cells and macrophages (Berse et al., 1999; Harmey et al.
1998). In macrophages, TGFp-1 increased VEGF protein but not mRNA suggesting in 
addition to transcriptional mechanisms there is also post transcriptional mechanisms 
involved (Harmey et al. 1998).
The TGFp-1 levels used in vitro for this study are lower than the levels that were 
found in the tumour tissue but are similar to the levels that have previously been shown 
to increase VEGF expression within cells (Brogi et al. 1994). The effects of TGFP-1 
appear to be dependent on the concentration and probably also on the presence of other 
factors. Levels that increased VEGF expression in this study have been found to inhibit 
endothelial cell migration and capillary lumen formation (Pepper et al. 1993). Lower 
doses of TGFP-1 (0.2 - 0.5 ng/ml) potentiated the angiogenic effects of both bFGF and 
VEGF (Pepper et al. 1993) but at this concentration in this study did not effect VEGF 
production by BT474 or MDA-MB-231 cells. In a separate study, TGFP-1 at 0.5 ng/ml 
induced tube-like formation of microvascular endothelial cells in vitro (Merwin et al.,
1990) and at 1 ng/ml enhanced maturation and lumen formation of endothelial cells 
exposed to smooth muscle cell conditioned medium (Sakuda et al., 1992). TGFp-1 at 2 
ng/ml caused apoptosis of endothelial cells and development of capillary morphogenesis 
of microvascular endothelial cells (Choi and Ballermann, 1995). Transfection of cells 
with a mutant TGFRII inhibited this effect confirming the role of TGFp. Apoptosis of 
endothelial cells may be an important event in capillary morphogenesis since it allows 
for homeostasis of endothelial cells and allows these cells to align correctly and form 
functional endothelium. TGFp-1 also inhibits the formation of the anti-angiogenic 
molecule angiostatin by human pancreatic cancer cells (O'Mahony et al., 1998) which is 
yet another part in the complex role of this molecule with regard to angiogenesis.
The data presented in this chapter suggests a complex, self regulating association 
between TGFP-1 and VEGF and also with several other steps of the angiogenic cascade. 
The mechanism through which TGFP-1 aids tumour progression and angiogenesis is 
complex. We have confirmed that amongst other factors, TGFp-1 is a regulator of 
VEGF expression and with other evidence suggest that this molecule will play an
101
important role m breast cancer This data supports a recent hypothesis by Reiss et al 
(1997) which suggests that while TGFp-1 initially inhibits breast tumour growth it may 
begin to promote tumour growth as the disease advances
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CHAPTER 5
ANTI-ANGIOGENIC MECHANISMS OF TAMOXIFEN
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5.1 Introduction
Tamoxifen has been used as the primary hormonal therapy for breast cancer for almost 
30 years Structurally, tamoxifen is a nonsteroidal tnphenylethylene although it is 
capable of adopting a structure resembling that of steroids such as 17(3-oestradiol 
(Buckley and Goa, 1989) Tamoxifen was originally designed as an anti-oestrogen oral 
contraceptive m the late 1950s but it was found to increase ovulation Later it was 
found to have very complex pharmacological actions including those of a pure 
oestrogen agonist, a partial oestrogen agomst and an oestrogen antagonist depending on 
the tissue type and species In humans tamoxifen acts as an oestrogen antagonist m the 
breast and an agonist m the uterus (Boothe et a l , 1994) Tamoxifen has been widely 
used as an anti-oestrogen in breast cancer Oestrogen is mitogemc for epithelial cells of 
the breast and oestrogen receptors are expressed by approximately 60% of breast 
tumours (Lippman and Swam, 1992) Many tumours escape oestrogen dependency but 
it is believed that oestrogen is essential for tumour growth at the early stages of all 
breast tumours and remains the primary mitogemc signal m many tumours (King,
1991) The binding of oestradiol, the most soluble and freely available form of 
oestrogen, to the oestrogen receptor (ER) triggers a number of events Upon binding the 
ER is activated, dimenses, moves to the nucleus and binds to an oestrogen response 
element (ERE) m the promotor region of oestrogen responsive genes The oestrogen 
receptor then forms a transcription unit with RNA polymerase by binding various 
transcription activating factors and initiates transcription The exact anti-oestrogemc 
mechanisms of tamoxifen are unknown The probable mechanism, however, is that by 
competitively binding to the ER, tamoxifen blocks oestradiol binding and induction of 
gene expression and m turn only induces the expression of a limited number of genes 
(Jordan, 1994)
Traditionally, tamoxifen has been used as an oestrogen antagonist m the 
treatment of ER positive breast cancer as adjuvant therapy following surgical removal of 
tumour However, m recent years, there has been considerable interest m the potential 
benefits of tamoxifen therapy for ER negative breast cancer A report from the Early 
Breast Cancer Tnalist’s Collaborative Group, involving 75,000 women m 133 
randomised trials, showed that tamoxifen was of benefit m the treatment of some ER
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negative breast cancer Tamoxifen therapy significantly increased the recurrence-free 
survival by 13% in breast cancer patients of all ages with ER negative disease and by 
16% m those over 50 years Although this increase m recurrence free survival is less 
than m ER positive breast cancer patients (32% increase m recurrence-free survival) it 
indicates that tamoxifen has additional anti-tumour effects that are independent of the 
oestrogen receptor Overall survival was also improved m these patients, following 
tamoxifen therapy, by 11% m patients of all ages and by 16% m patients over 50 years 
(Early Breast Cancer Tnahst's Collaborative Group, 1992) There was no significant 
difference m the overall survival between ER negative and ER positive patients though 
the trend suggested better survival in ER positive patients (Early Breast Cancer Tnalist's 
Collaborative Group, 1992)
In addition to its use m the treatment of breast cancer, tamoxifen has been used 
m the treatment of some other malignancies Tamoxifen m conjunction with dacarbazme 
was found to be more effective than dacarbazme alone m the treatment of metastatic 
melanoma (Coccom et a l , 1992) In a separate study, tamoxifen reduced the size of 
metastatic melanoma lesions by approximately 50% m male patients (Hirota, 1997) 
The use of high dose tamoxifen treatment (100 mg/day) m patients with malignant 
gliomas resulted m a favourable response, reduction m tumour volume, in a mmonty 
(approximately a quarter) of these patients (Couldwell et a l , 1993) m a manner that is 
independent of the ER The results of the EBCTCG tnals and the benefit of tamoxifen 
therapy m the treatment of melanoma and gliomas suggests that while the pnncipal 
mode of action of tamoxifen is mediated through the ER it has other lesser but 
significant anti-tumour activities that do not depend on the ER
At a cellular level there is further evidence of ER independent actions of 
tamoxifen Inhibition of ER positive breast cancer cell growth by tamoxifen is not 
completely reversed by a large excess of oestradiol (Sutherland et a l , 1983), suggesting 
that tamoxifen may be acting at sites other than the oestrogen receptor Tamoxifen 
binds with low affinity to a high capacity microsomal protein termed the anti-oestrogen 
binding site (AEBS) (Sutherland et a l , 1980) though the relevance of this protein m 
breast cancer is still unknown Tamoxifen inhibits the action of protein kinase C (PKC) 
though it does not seem to do so through any interaction with the active site (O'Bnan et 
a l , 1985) Protein kmase C forms a part of the second messenger system for many
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growth factors and mutations m PKC have been shown to promote tumour growth 
(Guillem et a l , 1987) Calmodulin is an intracellular calcium receptor involved m the 
cell cycle and its inhibition with the specific antagonist calmidazohum blocks progress 
of MCF-7 cells through the cell cycle (Musgrove et a l , 1989) Calmodulin-dependent 
cAMP phosphodiesterase (CDP) is also inhibited by tamoxifen (Lam, 1984) 
Tamoxifen binds to and interferes with the action of calmodulin rather than the 
phosphodiesterase Tamoxifen retards glycosphingolipid metabolism m human cancer 
cells by inhibiting the glucosylceramide synthase (Cabot et a l , 1996)
Glycosphingolipids accumulate m multi-drug resistant (MDR) cancer cells (Lavie et a l ,
1996) and tamoxifen reverses MDR in an ER independent manner (Ramu et a l , 1984) 
Tamoxifen regulates the expression of a number of cytokines through an ER- 
mdependent mechanism Tamoxifen increased TGF(3-1 production by fibroblasts that 
were ER negative (Colletta et a l , 1990) Immunohistochemical analysis of breast tissue 
before and after 3 months of tamoxifen treatment demonstrated increased expression of 
TGFp-1, this increase was not associated with ER expression (Butta et al 1992) 
Interestingly, TGFP-1 staining was predominantly associated with stromal tissue rather 
than the tumour cells themselves Tamoxifen reduces the levels of the positive growth 
regulator insulin-like growth factors I in breast cancer patients (Poliak, 1990) Further 
work in rats led the authors to suggest that this may be through a mechanism 
independent of the interaction between tamoxifen and the ER since the effect was 
observed m variety of tissue types including those that would that have minimal levels 
ER expression (Huynh et al 1993)
There are a number of reports suggesting that tamoxifen is capable of inhibiting 
angiogenesis A sulphated polysaccharide peptidoglycan complex (SP-PG) isolated 
from Arthrobacter species inhibits angiogenesis induced by variety of breast cancer cell 
lines m female mice (Inoue et a l , 1988) Tamoxifen m combination with SP-PG 
suppressed the number of capillaries m MCF-7 and U-2 induced tumours m mice 
(Tanaka et a l , 1991) Tamoxifen treatment reduced blood vessel counts m MCF-7 
mammary tumours m Swiss mice by approximately 70% (Lmdner and Borden, 1993) 
In a separate study tamoxifen therapy reduced microvessel density of MCF-7 tumours 
implanted in mice by 50%, as measured by magnetic resonance imaging and 
histochemical staining (Furman Haran et a l , 1994) Tamoxifen inhibited angiogenesis
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in the chick egg chorioallantoic membrane assay (CAM)(Gagliardi and Collins, 1993) 
As this effect was not reversed by the addition of excess oestrogen it suggests that anti- 
angiogemc activity is by an ER independent mechanism One potential mechanism by 
which tamoxifen may reduce angiogenesis is by inhibiting the proliferation of 
endothelial cells and a number of studies have shown that this does occur Tamoxifen 
reduced H3-thymidme uptake by HUVECs by 70%, an effect that was potentiated by the 
addition of shark cartilage (McGuire et a l, 1994) Exposure of porcine pulmonary 
artery and human dermal microvascular endothelial cells to VEGF and bFGF, 
separately, increased the proliferation of these cells, but exposure with tamoxifen 
abolished this induction m proliferation (Gagliardi et a l , 1996) The effect was not 
reversed by an addition of excess 17p-oestradiol and provides further evidence that this 
effect is independent of the ER
The aim of this chapter was to examine potential anti-angiogemc effects of 
tamoxifen VEGF expression had already been found to be elevated m breast cancer and 
most likely plays a central role m the angiogenic response mounted by tumours Since 
tamoxifen has previously been shown to have anti-angiogemc activity and alters 
cytokine expression the effect of tamoxifen on VEGF levels in cancer patients was 
examined The effect of tamoxifen on breast cancer cell and macrophage production of 
VEGF was examined to determine the anti-angiogemc effect of tamoxifen on these 
cells Furthermore, the effect of tamoxifen on endothelial cell migration and the 
transendothehal migration of monocytes was assessed since these are important aspects 
in the development of angiogenesis
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5.2 Results
5.2.1 Tamoxifen decreases serum and ascites fluid levels of VEGF
The accumulation of ascites fluid is a frequent complication of advanced cancer and 
guinea pig ascites fluid contains high levels of VEGF (greater than approximately 400 
pg/ml)(Yeo et a l , 1993) Figure 5 1 shows the levels of VEGF m the serum and ascites 
fluid of a 67-year-old male patient with malignant ascites secondary to a gastric tumour 
during tamoxifen treatment (20 mg/day) Levels of VEGF m serum and ascites fluid, 
prior to tamoxifen therapy, were very high (732 29 and 1999 36 pg/ml, respectively) 
Following 2 weeks of tamoxifen treatment the levels of VEGF were notably reduced m 
both the serum and ascites fluid (408 24 and 361 35 pg/ml, respectively) This 
represents a reduction of 44% m the serum and 82% in the ascites fluid Continued 
tamoxifen treatment, for a further 2 weeks, maintained these reduced VEGF levels
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Fig. 5.1: Effect of tamoxifen treatment (20 mg/day) on both serum (—f —) and (—■—) 
ascites fluid levels of VEGF m a male patient with ascites associated with a gastric 
tumour
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5.2.2 Preoperative tamoxifen decreased serum VEGF levels in a subpopulation 
breast cancer patients
Patients presenting at the outpatients clinic with primary breast cancer were treated with 
20 mg of tamoxifen a day for 2 weeks prior to surgery Only patients with no previous 
history of cancer and who were not receiving chemotherapy or radiotherapy were 
recruited All patients were post-menopausal Approval from the Hospital Ethics Board 
had been sought and granted before patients were recruited A sample of serum was 
taken before (day 0) and after (day 14) tamoxifen treatment A 2 week treatment period 
was chosen since in a male patient treated with tamoxifen the maximum reduction m 
serum and ascites VEGF occurred withm 2 weeks In addition, treatment for 2 weeks 
did not delay surgery, which is usually scheduled 2 - 3  weeks after initial clinical visit 
Patient details are summarised m Table 5 1 Presence of tumour was confirmed from 
cytopathology or histology reports Tumour type, stage and presence of ER was 
determined from histology reports For some patients, who did not undergo curative 
surgery, this data was not available Tumours were staged using the size component of 
the TNM staging system (TNM Atlas, 1992) Tamoxifen treatment decreased serum 
levels of VEGF m 75% (15/20) of patients (Fig 5 2) Patient 8 had a massive increase 
m serum VEGF levels (318 3 to 1721 2 pg/ml) following tamoxifen treatment The 
basis of this atypical response is unknown The change m this patient skewed the mean 
so that there was an average increase m serum VEGF following tamoxifen therapy 
However, when patient 8 is excluded from analysis there was a significant (p < 0 01) 
decrease of 29 6% m the median serum VEGF levels following tamoxifen treatment 
(Figure 5 3) The median was plotted since the data was not normally distributed and a 
non-parametnc test was earned to examine statistical significance For the 15 patients 
who showed a decrease m serum VEGF levels the mean decrease was a 28 6% decrease 
Of the 15 patients that showed decreased serum VEGF levels 8 were ER negative, 4 
were ER positive, 1 of which was weakly positive, and for the remaining 3 the ER status 
was unknown This indicates that the decrease m serum VEGF is independent of the 
ER Of the patients that demonstrated a decrease m serum VEGF m response to 
tamoxifen therapy disease stages were as follows 3 wereTl, 4 were T2, 2 were T3, 4 
were T4 and the stage of remaining 2 tumours was unknown
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In the same patient cohort serum TGFP-1 was measured prior to and 14 days 
after tamoxifen treatment Serum TGFp-1 levels were decreased m 65% (13/20) of 
patients (Figure 5 4) There was a mean decrease of serum TGFP-1 of 9 98% though 
this did not prove to be statistically significant (Figure 5 5) The 13 patients that 
demonstrated a decrease m serum TGFp-1 following tamoxifen therapy had a mean 
decrease of 22 15% Of the 13 patients m whom tamoxifen therapy decreased TGFp-1, 
12 also showed a decrease m serum VEGF levels Patient 8 that demonstrated a very 
large atypical increase m serum VEGF following tamoxifen treatment had a slight 
decrease of 7 53% (44 35 to 41 01 ng/ml) There was a significant (p < 0 01) positive 
correlation between the change in serum VEGF and TGFp-1 levels (Spearman Rank 
Correlation coefficient = 0 75) (Figure 5 6)
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Fig. 5.2 : The effect of 2 weeks of tamoxifen treatment (20 mg/day) on the serum levels 
of VEGF m breast cancer patients Serum was obtained prior to, and 14 days after, 
tamoxifen treatment and the change in serum VEGF between the two samples plotted 
Bars below the x-axis are representative of a decrease m serum VEGF while the bars 
above the x-axis represent an increase m serum VEGF The y-axis is broken to order to 
graph patient no 8
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Fig. 5.3: Effect of 2 weeks tamoxifen treatment (20 mg/day) on serum VEGF levels m 
20 breast cancer patients Data is expressed as median ± SEM Statistical analysis is by 
Wilcoxon Signed Rank *, p < 0 01
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Fig. 5.4 : The effect of 2 weeks of tamoxifen treatment (20 mg/day) on the serum levels 
of TGFp-1 m breast cancer patients Serum was obtained prior to, and 14 days after, 
tamoxifen treatment and the change m serum TGFp-1 between the two samples plotted 
Bars below the x-axis are representative of a decrease m serum VEGF while the bars 
above the x-axis represent an increase in serum TGFp-1
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Fig. 5.5: Effect of 2 weeks tamoxifen treatment (20 mg/day) on serum TGF(3-1 levels 
m 20 breast cancer patients Data is expressed as median ± SEM Statistical analysis is 
by Wilcoxon Signed Rank, p = ns
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Fig. 5.6 : Correlation between the % change in serum TGF(3-1 with the % change m 
serum VEGF There is a significant (p < 0 05) positive correlation (Spearman Rank 
Correlation coefficient = 0 75) between % change TGF(5-1 and VEGF The outlying 
point is patient 8 who showed a massive increase m VEGF following tamoxifen 
therapy
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Number % Change 
VEGF
% Change 
TGFß-1
Age Type Stage ER Status
1 -39 14 -11 47 69 n/a n/a n/a
2 -60 60 -30 33 60 ductal T1 weak pos
3 -32 10 -5 95 54 lobular T3 pos
4 -10 29 -12 51 60 ductal T2 neg
5 -39 29 -23 84 65 ductal T2 neg
6 -12 68 2 28 59 ductal T1 neg
7 -16 64 -7 42 76 ductal T1 neg
8 540 79 -7 53 59 ductal T2 pos
9 -28 24 -78 39 74 ductal T3 neg
10 -50 80 -14 76 53 ductal T4 pos
11 1 05 42 24 63 n/a n/a neg
12 -13 30 -3 13 64 ductal T2 pos
13 -7 99 8 54 70 ductal T4 n/a
14 -60 65 -43 00 66 ductal n/a neg
15 0 26 0 26 59 ductal T1 neg
16 86 03 41 07 54 n/a n/a n/a
17 5 75 2 05 50 ductal T1 pos
18 -42 75 -8 38 57 ductal T4 neg
19 -4 57 8 73 79 n/a T4 n/a
20 -40 15 -8 37 52 ductal T2 neg
Table 5.1: Patient charactenstics The table shows the % change in VEGF and TGF(3- 
1, tumour type, tumour stage, ER status and age of patient n/a indicates that the data 
was not available A table showing the values of serum VEGF and TGF(3-1 prior to and 
after tamoxifen therapy is included in appendix 3
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5.2.3 BT474 cells and MDA-MB-231 cells do not express the oestrogen receptor
To examine the oestrogen receptor independent activities of tamoxifen, in vitro, BT474 
and MDA-MB-231 breast cancer cells and human microvascular endothelial cells 
(HMEC) were used ER negativity was established by immunocytochemistry 
Cytospms of these cells were stained by immunocytochemistry for presence of ER in 
the routine pathology lab in Beaumont Hospital Figure 5 7A represents a section of 
endometrial tissue and is used as a positive control that demonstrates positive nuclear 
staining for the ER Figure 5 7B, 5 7C and 5 7D, respectively, demonstrate that there 
was no positive nuclear staining for either the BT474, MDA-MB-231 or HMEC cells 
There is some non-specific cytoplasmic staining m Fig 5 7D In addition to 
immunocytochemistry results, a functional assay was earned out to determine whether 
growth of BT474 and MDA-MB-231 cells was oestrogen independent Cells were 
treated with 20 nM oestradiol, which has been shown to increase the proliferation of 
oestrogen receptor positive breast cancer cell lines (Iacobelli et a l , 1984), and the 
proliferation of each cell line was examined Figure 5 8 shows that neither the BT474 
or MDA-MB-231 cell lines showed a significant (unpaired students t-test, p > 0 05) 
increase in proliferation relative to control (100% vs 105 ± 6% and 100%) vs 97 ± 5% 
proliferation relative to control, respectively) with the addition of oestradiol
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Fig. 5.7: Examination of cells for ER status. The positive control (A) is a section of 
endometrial tissue and demonstrates positive staining. Cytocentrifuge preparations of 
BT474 (B), MDA-MB-231s (C) and HMEC (D) cells were stained
immunohistochemically for ER. There is some non-specific cytoplasmic staining in 
panel (D). Original magnification x 400.
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Fig. 5.8: Effect of 17P-oestradiol on the proliferation of BT474 (A) and MDA-MB-231 
(B) cells The bars represent control cells with no treatment (O) and oestradiol treated 
cells (20 nM for 48 hr) (□) Data is expressed as the mean proliferation relative to 
control cells ± SEM and is representative of 3 individual experiment earned out in 
tnphcate Statistical analysis was by unpaired students t-test, p = ns
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5.2.4 Effect of tamoxifen on breast cancer cell line production of VEGF
As tamoxifen decreased the serum levels of VEGF in a subpopulation of breast cancer 
patients, independently of ER status, the effect of tamoxifen on the production of VEGF 
by ER negative breast cancer cell lines, BT474 and MDA-MB-231, was examined 
Both cell lines were treated with base tamoxifen (0, 0 625, 1 25, 2 5,5 jig/ml) for 24 hr 
The tamoxifen doses chosen are similar to levels that have been found within breast 
tissue m patients receiving steady-state tamoxifen treatment (Lien et a l , 1991) The 
levels m tissue are higher than reported levels of tamoxifen m the serum indicating that 
the majority of tamoxifen is found m tissue (Lien et al 1991) This is most likely due 
to the poor solubility of tamoxifen in aqueous solution and its highly lipophilic nature 
As tamoxifen was originally solubilised m ethanol, cells were also treated with 0 5% 
(v/v) ethanol that is equivalent to the amount of ethanol present in the 5 |_ig/ml dose of 
tamoxifen Tamoxifen base at 2 5 and 5 jag/ml significantly (p < 0 05) increased VEGF 
levels m the conditioned medium of the BT474 cell line (1 37 and 1 29 pg/|a.g protein vs 
0 9 pg/|J.g protein, respectively) (Fig 5 9A) Tamoxifen did appear to be cytotoxic to the 
BT474 cells at these concentrations as observed by a more rounded morphology and 
increased presence of detached cells floating m the medium The apparent increase of 
VEGF m the conditioned medium may be due to release by cell lysis -Tamoxifen had 
no significant (p > 0 05) effect on the production of VEGF by the MD A-MB-231 cell 
line (Fig 5 9B)
5.2.5 Effect of 4-hydroxytamoxifen on VEGF production by breast cancer cell 
lines
Tamoxifen is readily metabolised to form a number of different metabolites including 4- 
hydroxytamoxifen This metabolite is only produced m small quantities but it binds 
with greater affinity to the ER and is more potently anti-oestrogemc than tamoxifen 
(Buckley and Goa, 1989) We examined whether this more potent metabolite, 4- 
hydroxytamoxifen, had any effect on the VEGF production by BT474 and MD A-MB- 
23 1 cell lines The doses chosen were similar to tissue levels m breast cancer patients 
(Lien et al 1991) Fig 510 shows that 4-hydroxytamoxifen (0 - 100 ng/ml) for 24 hr 
did not significantly (p > 0 05) alter the production of VEGF by either of these cell 
lines
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Fig. 5.9A: Effect of tamoxifen on VEGF production by the BT474 cell line Cells were 
exposed to tamoxifen or 0 5% (v/v) ethanol (EtOH) for 24 hr Data is representative of 
3 experiments done m duplicate and is expressed as mean ± SEM Statistical analysis is 
by ANOVA with a Scheffe post hoc *, p < 0 05 vs 0 |_ig/ml tamoxifen
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Fig. 5.9B: Effect of tamoxifen on VEGF production by the MDA-MB-231 cell line 
Cells were exposed to tamoxifen or 0 5% (v/v) ethanol (EtOH) for 24 hr Data is 
representative of 3 experiments done m duplicate and is expressed as mean ± SEM 
Statistical analysis is by ANOVA with a Scheffe post hoc *, p < 0 05 vs 0 |a,g/ml 
tamoxifen
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Fig 5.10A: Effect of 4-hydroxytamoxifen on VEGF production by the BT474 cell line 
Cells were exposed to 4-hydroxytamoxifen or 0 1% (v/v) ethanol (EtOH) for 24 hr 
Data is representative of 3 individual experiment earned out in duplicate and is 
expressed as mean ± SEM Statistical analysis was by ANOVA with Scheffe post hoc 
correction p = ns
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Fig 5.10B: Effect of 4-hydroxytamoxifen on VEGF production by the MDA-MB-231 
cell line Cells were exposed to 4-hydroxytamoxifen or 0 1% (v/v) ethanol (EtOH) for 
24 hr Data is representative of 3 individual experiment earned out m duplicate and is 
expressed as mean + SEM Statistical analysis was by ANOVA with Scheffe post hoc 
correction p = ns
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5.2.6 Effect of tamoxifen on the production of monocyte derived macrophage 
VEGF
Since tamoxifen did not decrease breast cancer cell line production of VEGF, the effect 
of tamoxifen on monocyte derived macrophage production of VEGF was examined 
Breast tumours can contain very high numbers of macrophages and macrophages have 
been shown to produce angiogenic factors Monocyte were isolated (2 2 8), matured to 
to macrophages and activated with 100 ng/ml IFNy for 24 hr Over this period 
monocytes increased m size and assumed a more macrophage like morphology (Figure 
5 11A and B) Monocyte derived macrophages were treated with various doses of base 
tamoxifen ( 0 - 5  [ag/ml) while m the presence of tumour conditioned medium and 
hypoxia to simulate tumour environment, conditions previously shown to upregulate 
macrophage production of VEGF (Harmey et al 1998) Figure 5 12 shows that there 
was no decrease in VEGF production by monocyte derived macrophages under these 
conditions Since macrophages isolated from different individuals express different 
amounts of VEGF the data was calculated as the change m VEGF production relative to 
the untreated controls for each individual Mean VEGF production m the untreated 
controls under these conditions was 10 5 ± 8 5 pg/|ag protein which is roughly 
equivalent to that produced constitutively by the breast cancer cell lines The amount of 
VEGF produced by monocyte derived macrophages was adjusted for the presence of 
VEGF m the tumour conditioned medium
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Fig. 5.11: Maturation and activation of monocyte derived macorphages. Monocytes 24 
hr after isolation (A). Mature monocytes (5 days) activated for 24 hr with 1,000U of rh- 
IFNy. Original magnification x 400.
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Fig 5.12: Effect of tamoxifen on monocyte derived macrophages production of VEGF 
m the presence of tumour conditioned medium and hypoxia Cells were exposed to 24 
hr of tamoxifen or 0 5% (v/v) ethanol (EtOH) Data is representative of experiments, 
earned out m tnplicate, using monocytes from 3 different male individuals Statistical 
analysis was by ANOVA with Scheffe post hoc conection p = ns
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5.2.7 Effect of tamoxifen on TGFp-1 stimulated production of VEGF by breast 
cancer cells
TGFp-1 increased VEGF production by both BT474 and MDA-MB-231 cells (4 2 4) 
High levels of TGFP-1 were found m the serum and tumour tissue of breast cancer 
patients and there was a correlation between the levels of these two factors Therefore, 
the effect of tamoxifen on TGFp-1 stimulated breast cancer cell line production of 
VEGF was examined The dose of TGFp-1 that maximally increased VEGF production 
was 5 ng/ml m the BT474 cells and 10 ng/ml m the MDA-MB-231 cells The effect of 
tamoxifen citrate (0, 2 5, 5, 7 5, 10 |_ig/ml) on TGFp-1 stimulated production of VEGF 
was examined Tamoxifen citrate is the salt form of tamoxifen and a slightly higher 
concentration of tamoxifen citrate is used so that it is stoichiometncally equivalent to 
the doses of base tamoxifen used The stoichiometric ratio for base tamoxifen to 
tamoxifen citrate is 1 1 2 Cells were treated for 24 hr with tamoxifen Tamoxifen did 
not significantly (p > 0 05) alter the TGFP-1 induced production of VEGF by either cell 
line (Fig 5 13)
5.2.8 Effect of tamoxifen on macrophage production of TGFp-1
Tamoxifen decreased serum VEGF levels in a subpopulation of breast cancer patients 
but did not decrease VEGF production by breast cancer cells in vitro indicating that 
tamoxifen may decrease VEGF by an indirect mechanism TGFp-1 was found to 
increase breast cancer cell production of VEGF Neither the BT474 nor the MDA-MB- 
231 cell line produced detectable levels of TGFp-1 Macrophages, however, can 
produce TGFP-1 and it is possible that infiltrating macrophages produce TGFp-1 which 
may then stimulate breast cancer cell production of VEGF The effect of tamoxifen 
citrate ( 0 - 1 0  p-g/ml) for 24 hr on the production of TGFp-1 by monocyte derived 
macrophages was examined Macrophages produced detectable levels of TGFP-1, mean 
production of TGFP-1 produced by untreated macrophages was 520 ±17  pg/|_ig protein 
Tamoxifen did not significantly (p > 0 05) decrease TGFp-1 production (Figure 5 14) 
Data is plotted as the relative change m TGFP-1 production compared to the untreated 
control for each individual experiment
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Fig. 5.13A: Effect of tamoxifen on VEGF production by BT474 cells stimulated with 5 
ng/ml and 10 ng/ml TGF(3-1, respectively Cells were exposed to tamoxifen for 24 hr 
Data is representative of 3 experiments earned out m duplicate and is expressed as mean 
± SEM Statistical analysis was by ANOVA with Scheffe post hoc correction p = ns
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Fig. 5.13B: Effect of tamoxifen on VEGF production by MDA-MB-231 cells
stimulated with 5 ng/ml and 10 ng/ml TGF(3-1, respectively Cells were exposed to 
tamoxifen for 24 hr Data is representative of 3 experiments earned out in duplicate and 
is expressed as mean ± SEM Statistical analysis was by ANOVA with Scheffe post 
hoc correction p = ns
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Fig 5.14: Effect of tamoxifen on monocyte derived macrophage production of TGFp-1 
Cells were exposed to tamoxifen or 1% (v/v) ethanol (EtOH) for 24 hr Data is 
representative of 3 experiments, earned out m tnplicate, using monocytes from 3 
different male individuals and is plotted as the % VEGF production relative to untreated 
control for each individual expenment ± SEM Statistical analysis was by ANOVA 
with Scheffe post hoc correction p = ns
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5.2.9 Effect of tamoxifen on VEGF production by breast cancer cells in hypoxia
It was established that breast cancer cell lines produce elevated levels of VEGF under 
hypoxic conditions (4 2 1) The effect of base tamoxifen (0, 0 625, 1 25, 2 5, 5 |ug/ml) 
for 24 hr on hypoxia induced production of VEGF by BT474 and MDA-MB-231 cells 
was examined Both cell lines produced elevated levels of VEGF m hypoxia than m 
normoxia (BT474 cells, 12 32 vs 3 19 pg/|ig protein and MDA-MB-231 cells, 52 17 vs 
15 64 pgVg protein) Tamoxifen at 5 |J.g/ml significantly (p < 0 05) increased VEGF 
production m both cell lines compared to the untreated control (BT474s, 15 99 vs 12 32 
pg/(a.g protein and MDA-MB-231s, 72 8 vs 52 17 pg/|ag protein) (Figure 5 15) This 
represents an increase of 29 8% and a 39 5% m the conditioned medium of the BT474 
and MDA-MB-231 cells, respectively Under these conditions however, tamoxifen 
appeared to be partially cytotoxic to these cells at these concentrations as seen by 
morphological changes and the detachment of cells from the surface of the flask This 
may account for the apparent increase m VEGF m the conditioned medium since dead 
cells will release their intracellular levels of VEGF
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Fig 5.15: Effect of tamoxifen on hypoxia-mduced VEGF production by BT474 (A) and 
MDA-MB-231 (B) cells Cells were exposed to tamoxifen or 0 5% (v/v) ethanol 
(EtOH) for 24 hr under hypoxic conditions Data is representative of 3 individual 
experiments performed m duplicate and are expressed as the mean ± SEM Statistical 
analysis is by ANOVA with Scheffe post hoc correction *, p < 0 05
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5.2.10 Effect of tamoxifen on microvascular endothelial cell migration
For angiogenesis to occur endothelial cells must migrate, into and withm the tumour, m 
response to binding of VEGF Human microvascular endothelial cells (HMEC) are 
endothelial cells derived from small dermal blood vessels and are more representative of 
the type of endothelial cells involved in capillary angiogenesis than other endothelial 
cells that are cultured in vitro Figure 5 16 shows a photograph of these cells m which 
the typical ‘cobblestone’ appearance of endothelial cells m culture is clearly visible 
The effect of base tamoxifen ( 0 - 5  (J-g/ml) on HMEC migration was assessed 
Migration was assessed by counting HMEC cells that moved from the upper layer of a 
membrane containing 8 p,m pores to the lower layer m response to VEGF over 48 hr 
20 ng/ml m the lower chamber increased HMEC migration (15 4 vs 2 7 counts/per field 
of view (pfv) in controls without VEGF) (Figure 5 17) Tamoxifen at 5|a,g/ml 
significantly (p < 0 05) reduced the number of cells that migrated to the underside of the 
membrane (3 2 vs 15 4 cells/pfv untreated control) This may have been partially due to 
a non-specific effect since there was a visible change m the morphology of these cells at 
this dose of tamoxifen Figure 5 18 shows representative photographs of cells that have 
migrated through the membrane into the lower compartment
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Fig. 5.16: Monolayer culture of HMEC cells. The cells can clearly be seen to grow 
with a cobblestone appearance that is typical of cultured endothelial cells.
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Fig 5.17: Effect of tamoxifen on HMEC migration Cells were exposed to tamoxifen 
or 0 5% (v/v) ethanol for 48 hr Data is representative of 3 independent experiments 
performed m duplicate and is expressed as the mean count ± SEM Statistical analysis 
is by ANTOVA with Scheffe post hoc correction &, p < 0 05 vs control with no VEGF 
*, p < 0 05 vs untreated control with VEGF
137
Fig. 5.18: Representative photographs of migrated endothelial cells. Positive control 
(A) is untreated cells with 20 ng/ml VEGF used as a chemoattractant while (B) 
represents migration of cells exposed to 2.5 |_ig/ml tamoxifen. The pores through which 
the cells migrate are clearly visible.
5.2.10 Effect of tamoxifen on monocyte transendothelial migration
Macrophages constitute an important source of breast tumour VEGF In order for 
tumours to recruit macrophages, monocytes must first cross the endothelial bamer The 
effect of base tamoxifen (2 5 |J.g/ml) on monocyte transendothelial migration was 
assessed (2 2 12) A single dose of tamoxifen was chosen because of restrictions m the 
number of samples that could be run, the dose chosen was the highest dose that could be 
used without cytotoxicity to the cells VEGF at 20 ng/ml is chemotactic for monocytes 
(Clauss et al 1996) Monocyte transendothelial migration was simulated in vitro by 
culturing a monolayer of HMEC cells on a collagen coated membrane containing 3 (im 
pores and adding VEGF (20 ng/ml) as a chemoattractant for monocytes to the medium 
m the bottom compartment A smaller pore size was used than that used for endothelial 
cell migration since monocytes are considerably smaller Monocytes are added to the 
top compartment and those that have migrated through the endothelial monolayer over 4 
hr are collected and counted Monocyte migration is considerably faster than 
endothelial cell migration Using 20 ng/ml VEGF as a chemoattractant in the bottom 
compartment significantly (p < 0 05) increased, by 4 fold, monocyte transmigration 
Tamoxifen at 2 5 |ig/ml significantly (p < 0 05) inhibited the VEGF induced migration 
of monocytes (70 4% migration vs 100% m untreated controls) (Figure 5 19) The 
ethanol control had no effect on VEGF induced migration
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Fig 5.19: Effect of tamoxifen on monocyte transendothelial migration Cells were 
exposed to tamoxifen or 0 25% (v/v) ethanol (ETOH) for 4 hr and the numbers of 
monocytes that migrated was counted 20 ng/ml VEGF was used as a chemoattractant, 
a plus sign indicates its use while a minus sign indicates that VEGF was not used Data 
is representative of 3 individual experiments performed m duplicate and is expressed as 
the relative migration compared to the control, that received no tamoxifen but did have 
VEGF as a chemoattractant, for each individual experiment ± SEM Statistics is by 
ANOVA with Scheffe post-hoc correction &, p < 0 05 vs no VEGF control *, p < 0 05 
vs VEGF control
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5.3 Discussion
The data presented in this chapter show that tamoxifen therapy (20 mg/day for 2 weeks) 
reduces serum levels of VEGF in a subset of cancer patients. Tamoxifen therapy 
reduced VEGF in serum and ascites fluid of a male patient with malignant ascites 
secondary to gastric cancer (Donovan et al., 1997). Tamoxifen reduced serum VEGF in 
15 of 20 breast cancer patients -  of these 53% (8/15) had ER negative tumours. These 
results suggest that tamoxifen reduces VEGF independently of the oestrogen receptor. 
This effect was achieved within 2 weeks of preoperative tamoxifen. Most patients are 
scheduled for surgery 2 - 3  weeks after initial clinic visit and it would have been 
unethical to delay surgery for a longer period. It is possible that if treatment was 
extended for a longer time period, and a steady state level of tamoxifen formed in the 
tissue, a greater decrease in serum VEGF levels may have been seen. However, in the 
male ascites patient tamoxifen therapy was for 4 weeks but the reduction in serum and 
ascites VEGF was observed within 2 weeks. Although reduced levels were maintained, 
there was little further reduction after 2 weeks.
Tamoxifen has been traditionally used as an adjuvant therapy following surgery. 
The reduction in serum VEGF observed in patients receiving tamoxifen therapy pre- 
operatively suggest that tamoxifen may be a useful perioperative therapy. As 
angiogenesis is critical for both tumour growth and metastases any agent capable of 
reducing VEGF levels should decrease tumour growth and metastasis by reducing 
angiogenesis. Antibodies against VEGF have already been shown to decrease tumour 
growth in animal models (Kim et al., 1993; Borgstrom et al., 1996). There is as yet no 
other pharmacological agent shown to decrease VEGF production. Reducing VEGF 
levels before surgery may be useful for temporarily halting tumour growth before 
commencing surgery. Surgery has been found to dislodge tumour cells and tumour cells 
have been found in the circulation following or during surgery (McCulloch et al., 
1995). VEGF causes hyperpermeability of blood vessels and tumour microvessels are 
known to be highly permeable. In addition, tumour blood vessels are known to be in a 
constant state of flux and are rarely properly formed vessels SUCh as WOUld be found in 
normal tissue. This may be in part due to the continual stimulation of endothelial cells 
by the many angiogenic factors that tumours produce. It is possible that the leaky, ill-
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formed, blood vessels withm tumours facilitate dissemination of tumour cells into the 
bloodstream during surgery Reducing VEGF levels before surgery may be useful for 
decreasing the permeability of blood vessels and therefore deny tumour cells access to 
the circulation before or during the surgical procedure A possible adverse effect of 
tamoxifen therapy could be impaired wound healing as angiogenesis is essential for 
wound healing In our study group no adverse effects on wound healing were observed 
and other data from this lab demonstrated increased anastamotic strength m rats treated 
with tamoxifen (McNamara, unpublished observations) Other studies have 
demonstrated reduced scar formation m rats treated with tamoxifen and this effect was 
ascribed to tamoxifen induction of TGFP-3
In the healthy adult VEGF is primarily produced for wound healing Surgical 
procedures involve extensive wounding of the tissue and under these circumstance 
VEGF is highly upregulated (Nissen et a l , 1998) Many surgical procedures do not 
remove every single tumour cell Cells that are left behind may be capable of utilising 
the abundant growth and angiogenic factors present at the site of the wound Tumours 
have been often been found to occur at porthole sites following laparoscopic surgery 
(Neuhaus et a l , 1998) Reducing VEGF levels penoperatively may inhibit the 
formation of stable metastasis following surgery Up to 50% of cancer patients already 
have metastases at time of diagnosis (Fidler and Ellis, 1994) Surgery has been found to 
alter the net balance of angiogenic signals for metastases that are present at the time of 
surgery Rapid growth of previously dormant metastases following surgical removal of 
a primary tumour is well documented (Holmgren et a l , 1995) Primary tumours 
produce angiostatm and endostatm that inhibit the growth of secondary tumours (Quinn 
et a l , 1993) By removing the primary tumour this may reduce anti-angiogenic signals 
and allow secondary tumour growth In an animal model where lung metastases were 
established by tail vein injection, surgical trauma has been found to increase metastatic 
growth (Pidgeon et a l , m press) As no primary was present the increase m growth 
cannot be ascribed to removal of the primary tumour derived angiostatm, thus surgery 
creates a permissive environment for tumour growth The increase of VEGF following 
surgery may provide an additional mechanism allowing growth of secondary tumours 
Pre-operative tamoxifen therapy may reduce this advantage by decreasing circulating
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VEGF and thereby reduce angiogenesis in the primary tumour before surgery and in 
secondary tumours after surgery.
The potential benefits of short term preoperative tamoxifen, as discussed above, 
are based purely on the effect we have noticed on serum levels of VEGF. The effect on 
serum VEGF is a quite modest decrease but could be of clinical significance. The use of 
perioperative tamoxifen, purely to reduce oestrogenic effects, has already been proposed 
(Jordan, 1994). If patients receiving preoperative tamoxifen also expressed the ER the 
additive benefits may be even greater and may possibly lead to revised surgery from a 
mastectomy to a wide local excision (Robinson et al., 1996). VEGF is thought to be 
regulated in some cases by oestrogen (McClure et al., 1994). Tamoxifen acts as an 
oestrogen agonist in the uterus (Boothe et al. 1994) and has been found to increase 
VEGF production in this tissue. Although we did not find any association with the ER 
in this study, the oestrogen antagonist activity of tamoxifen may have the reverse effect 
in the breast and decrease VEGF. Short-term preoperative tamoxifen has been shown to 
a be a safe use of this agent as it does not adversely affect tumour grade over this period 
(Robinson et al. 1996). We did not have the opportunity to look at long term effects of 
preoperative tamoxifen but it would be of great interest to see if this could extend 
survival figures for this disease.
We also found that tamoxifen reduced serum levels of TGF(3-1 in a large 
proportion of patients in this study. This is in contrast with other results which have 
tended to show that tamoxifen increased TGFp-1 levels (Butta et al., 1992; MacCallum 
et al., 1996). These measurements were made within the tissue while ours were 
measured in the circulation, however the primary source of plasma TGFp-1 in cancer 
patients is though to be from the tumour (Kong et al., 1995) so we are still in effect 
measuring tumour TGFp-1. TGFP-1 mRNA levels have been found to be reduced in 
patients who responded to tamoxifen treatment (Thompson et al., 1991). Patients on 
tamoxifen have been found to have a better quality of scar tissue which is a feature 
associated with reduced TGFP-1 levels and increased TGFP-3 levels (Ashcroft et al.,
1997). We also found there was a strong correlation between the reduction in TGFp-1 
and VEGF, a reduction in TGFp-lwas associated with a reduction in VEGF levels. 
Since we had shown before that TGFp-1 increased tumour cell production of VEGF it is 
possible that a reduction in serum VEGF is secondary to reduced TGFP-1 production.
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Neither the BT474 nor MDA-MB-231 cell line produced readily detectable amounts of 
TGFJ3-1 Macrophages are a known source of TGFp-1 (Assoian et a l , 1987) so the 
effect of tamoxifen on macrophage production of this factor was examined Tamoxifen 
did not reduce macrophage TGFp-1 It is possible that tamoxifen is reducing stromal 
cell production of TGFp-1 though tamoxifen was found to increase TGFp-1 production 
in stromal cells (Butta et a l , 1992)
As tamoxifen decreased circulating VEGF in a subpopulation of breast cancer 
patients, the direct effect of tamoxifen on the in vitro constitutive production of VEGF 
was assessed Tamoxifen did not reduce VEGF production by BT474 or MDA-MB-231 
breast cancer cells or macrophage VEGF production There was a slight elevation m 
VEGF production by the BT474 cell line m response to tamoxifen This may due to the 
fact that tamoxifen appeared to be cytotoxic to this cell line at lower doses (5 jag/rnl 
base tamoxifen) than any other cell line tested m the lab At these doses there is some 
cytotoxicity, as seen by morphological changes and detachment of cells, which probably 
results m lysis of the cell and release of intracellular VEGF into the conditioned 
medium We also looked at the effect of tamoxifen on the production of VEGF by 
BT474 and MDA-MB-231 cells exposed to TGFp-1 and hypoxia, both of which 
increase VEGF Tamoxifen did not inhibit VEGF production m stimulated cells There 
was again a slight increase m VEGF production m both the BT474 and MDA-MB-231 
cell line treated with hypoxia and tamoxifen This is most probably due to cytotoxicity 
when the cells are exposed to a double stress, namely tamoxifen and hypoxia, and 
intracellular VEGF is released into the conditioned medium
Tamoxifen apparently reduced endothelial migration Although tamoxifen at 5 
jag/ml was not cytotoxic to HMECs m a proliferation assay, there may have been a non­
specific effect during the migration assay since there was a visible morphological 
change m these cells at this dose While it was not statistically significant there was a 
visible trend for reduced migration at the lower doses of tamoxifen Tamoxifen 
significantly reduced monocyte transendothehal migration This experiment was earned 
out at a single dose of 2 5 |ag/ml but it would be of interest to examine this further using 
a greater range of doses. This result could explain, to some extent, the decrease of 
serum VEGF observed m patients m response to tamoxifen therapy Macrophages 
constitute a large proportion of the breast tumour mass, up to 50%, and produce large
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amounts of VEGF (O'Sullivan and Lewis, 1994). In an in vivo situation tamoxifen may 
stop monocytes from migrating from the circulation, through the endothelium, and into 
the tumour. By reducing macrophage recruitment into the tumour tamoxifen may 
reduce macrophage derived VEGF. Linomide has been found to reduce tumour growth 
by a similar mechanism, that is by reducing macrophage infiltration into the tumour 
(Leek et al., 1996). The mechanism by which tamoxifen reduced monocyte 
transendothelial migration is unknown. By inhibiting macrophage recruitment by the 
tumour other macrophage derived factors that aid angiogenesis, such as urokinase, EGF, 
TNFa, and TGFp-1 would also be reduced. Tamoxifen inhibited the adhesion of 
tumour cells to endothelium and invasion into basement membrane (Bliss et al., 1996). 
Tamoxifen has also been found to inhibit the binding of melanona cells and MCF-7 
breast cancer cells to components of the extracellular matrix (MacNeil et al., 1993). In 
this case the authors believe this effect was mediated through the effect of tamoxifen on 
intracellular calcium. It is possible that the effect of tamoxifen on calmodulin inhibits 
monocyte adhesion to components of the HMEC monolayer. Calmodulin antagonists 
inhibited the binding of B16 melanoma cells to the extracellular matrix (MacNeil et al.,
1992). Another mechanism through which tamoxifen may inhibit migration is by 
interfering with the VEGF signal by interacting with the VEGF receptors. VEGF is 
chemotactic for monocytes and binds to the VEGFR-1 receptor on these cells (Clauss et 
al., 1990). Tamoxifen inhibited VEGF stimulated proliferation of endothelial cells 
which could be explained by the interaction of tamoxifen with the VEGF receptor 
thereby reducing its mitogenic signal. The tamoxifen metabolite 4-hydroxytamoxifen 
inhibits the proliferation of EGF stimulated cells and the mechanism proposed was by 
alteration of the receptor functionality (Freiss et al., 1990). The EGF receptor is similar 
to the VEGF receptors in that it is also a tyrosine kinase molecule. Tamoxifen inhibits 
an autocrine IGF-I loop by interfering with a tyrosine kinase activity (Howe et al., 1996; 
Guvakova and Surmacz, 1997).
Tamoxifen has recently been found to reduce the risk of development of breast 
cancer in high risk women by nearly 50% (National Cancer Institute (NCI), 1998). 
There are probably multiple mechanisms involved in this effect but reducing tumour 
derived VEGF could possibly be one effect. Reducing tumour VEGF may maintain the 
tumour in an avascular state and chronically manageable. Tamoxifen is a well tolerated
145
drug that millions of patients throughout the world have taken for many years Its 
mechanisms of actions including its non-oestrogen mechanisms, however, are still 
poorly understood and are still under intense investigation This is evidenced by the fact 
that a great number of trials involving tamoxifen are still running From these results 
we suggest that a novel mechanism of action of tamoxifen is the reduction of tumour 
denved VEGF This may be achieved by the reduction of macrophage infiltrate into the 
tumour and reduced endothelial cell migration Further investigation of this property of 
tamoxifen may reveal exact mechanisms lead to the development of therapeutic agents 
that have a greater effect Until that time the use of preoperative tamoxifen should be 
further investigated
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CHAPTER 6
CONCLUDING DISCUSSION
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This thesis has demonstrated that VEGF is overexpressed in breast cancer Breast 
tumour cell lines were found to produce abundant VEGF protein and mRNA A 
breast cancer cell line derived from a pleural effusion, MDA-MB-231 cells, produced 
more VEGF protein and mRNA than a breast cancer cell line that was derived from a 
primary lesion, BT474 cells The metastatic MDA-MB-231 cells also produce a 
VEGF isoform, VEGFi89, that is not produced by the primary BT474 cell line and is 
capable of inducing a greater angiogenic response than the other VEGF isoforms 
Serum VEGF levels were increased in patients with malignant breast disease as 
compared to patients with benign fibroadenomas or healthy age-matched controls 
Though it was not statistically significant, most likely due to the low number of 
patients with disease of a higher stage, there was a visual trend for increased serum 
VEGF levels with increasing stage m breast cancer patients In addition, patients 
with metastatic disease had the highest levels of serum VEGF, commonly over 1000 
pg/ml Together with the data from the cell lines indicating that a metastatic cell line 
produced more VEGF this may indicate a role for VEGF m the development of 
metastases VEGF levels withm tumour tissue were substantially increased 
compared to normal breast tissue from the same patient Data from other labs has 
demonstrated that other breast cancer cell lines, including T47-D, MDA-MB-468 and 
MCF-7 cells, have also been found to produce VEGF protein (Bianco et a l , 1997, 
Hyder et a l , 1998, McLeskey et a l , 1998) These results indicate that VEGF is 
overexpressed by breast tumours
Since VEGF expression is elevated m patients with breast cancer it is 
important to know factors that regulate the expression of VEGF Several factors 
were examined for their effect on VEGF expression Factors were chosen based on 
evidence m the literature that they were relevant to breast cancer progression and had 
an association with the angiogenic phenotype Thus, the factors chosen were 
hypoxia, IGF-1 and TGFp-1 IGF-1 did not affect the expression of VEGF by 
BT474 or MDA-MB-231 cells Hypoxia induced a several fold increase in VEGF 
expression in both cell lines A positive association was found between the levels of
k
expression of TGFP-1 and VEGF in both tumour tissue and m pre-operative serum 
samples TGFp-1 increased VEGF expression in both the BT474 and MDA-MB-231 
cell lines Exogenous VEGF had no effect on the expression of TGFP-1 in either cell
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line Using a semi-quantitative assay for VEGF mRNA levels in cells it was 
demonstrated that TGFp-1 increased VEGF protein, m part, by increasing levels of 
VEGF mRNA TGF(3-1 increased VEGF production withm 12 hr and increase in 
expression was still detectable at 48 hr which is likely sufficient time to have an 
effect on angiogenesis Future work could focus on the exact mechanisms whereby 
hypoxia and TGFp-1 increase expression of VEGF in order to design strategies
r
aimed at disrupting the elevation of VEGF caused by these factors We examined a 
small subset of factors that play an important role m breast cancer and examined their 
effect on VEGF expression This was by no means a comprehensive study of all the 
factors that may be involved m the regulation of VEGF expression m breast cancer 
and it would be of great interest to examine other factors associated with the 
progression of breast cancer on the regulation of VEGF
Since it has been demonstrated that angiogenesis is a requirement for tumour 
growth and the development of metastases, the inhibition of angiogenesis has been 
recognised as a potential therapeutic target Tamoxifen, though it is traditionally 
used as an anti-oestrogen, has displayed several effects which are independent of the 
oestrogen receptor including the inhibition of angiogenesis m the chick egg 
chonoallanotoic membrane assay No mechanism has yet been described for the 
anti-angiogemc effects of tamoxifen As VEGF is a key angiogenic factor, the effect 
of tamoxifen on VEGF levels was examined Patients treated with 20 mg/day pre­
operative tamoxifen displayed a significant reduction m serum VEGF levels This 
reduction was independent of expression of the oestrogen receptor since there was no 
significant difference m change of serum VEGF levels in patients with ER positive 
or ER negative tumours Downregulation of VEGF is a potential mechanism 
whereby tamoxifen may inhibit angiogenesis Furthermore, since tamoxifen is a well 
tolerated and well studied drug, there exist opportunities for the expansion of it’s 
uses to other forms of cancer that express high levels of VEGF Since there was no 
association with reduction m VEGF and ER status tamoxifen may be of value m 
male patients to reduce VEGF levels, as demonstrated m a single male patient with 
high levels of serum and ascites fluid VEGF
In many of the patients that displayed a reduction m serum VEGF there was 
also a reduction m serum TGFp-1 and indeed there was a strong correlation between
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the changes m serum TGF(3-1 and VEGF While this correlation demonstrates that 
there is an association between the changes m the levels of these two factors it does 
not indicate the possible influence of one factor on the other Since we had 
previously demonstrated that TGF(3-1 increased breast cancer cell line production of 
VEGF it is possible that the reduction of serum TGFp-1 precedes the reduction of 
VEGF It would be of interest to monitor levels of both of these factors over shorter 
time intervals m order to determine the kinetics of this response to tamoxifen While 
the reduction m VEGF alone is of importance m breast cancer, the concomitant 
reduction of TGFP-1 could also be of great benefit There is considerable evidence 
to suggest that TGFp-1 expression in advanced tumours is associated with tumour 
growth By reducing both of these factors tamoxifen may play a dual role m 
inhibiting breast tumour growth
Various in vitro experiments were earned out to determine the 
mechanism through which tamoxifen reduced serum levels of VEGF Initially, the 
effect of tamoxifen on breast tumour cell line and monocyte denved macrophage 
VEGF production was examined, as these cells are the key producers of VEGF 
Tamoxifen did not directly lower VEGF production by either the BT474 or MDA- 
MB-231 breast cancer cell line or by macrophages Tamoxifen also did not reduce 
the production of VEGF by these cell lines when they were stimulated with TGFp-1 
and hypoxia This indicated that the mechanism through which tamoxifen reduced 
serum VEGF was an indirect mechanism Since TGFp-1 increases breast cancer cell 
line production of VEGF the effect of tamoxifen on production of TGFP-1 by cell 
lines and macrophages was examined In contrast to other breast cancer cell lines the 
BT474 and MDA-MB-231 cell lines did not produce significant amounts of TGFP-1 
which indicates that there was no autoenne stimulation of these cells Monocyte 
denved macrophages did produce large quantities of VEGF but this was not reduced 
by tamoxifen Concomitant research m the lab had indicated that the use of 
tamoxifen m rats may reduce endothelial migration Migration of endothelial cells is 
an important aspect of angiogenesis In addition, since there is a high macrophage 
content m breast tumours these cells must transmigrate from the circulation into the 
tumour stroma The migration of endothelial cells and the transendothelial migration 
of monocytes following exposure to tamoxifen was examined There was a visible
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trend for reduced migration of endothelial cells following exposure to tamoxifen and 
tamoxifen significantly inhibited the transendothehal migration of monocytes The 
inhibition of migration of these cells could explain the reduction of serum VEGF 
following tamoxifen treatment By reducing endothelial cell migration the overall 
level of angiogenesis would be reduced so that fewer VEGF producing tumour cells 
would be supported and the levels of VEGF would decline The inhibition of 
migration of monocytes would mean that there would be a decrease m the number of 
tumour associated macrophages within the tumour and therefore a reduction m 
VEGF producing cells The precise mechanism through which tamoxifen inhibits 
migration is unknown but should be the focus of further study Tamoxifen has been 
used as an anti-metastatic drug and it may reduce metastasis by reducing the 
migration of tumour cells which is an essential component of the metastatic cascade 
This thesis has clearly indicated that VEGF is elevated m breast 
cancer, several regulatory factors have been elucidated and a tamoxifen mediated 
inhibition of VEGF production in vivo has been illustrated Further study is 
warranted to discover other factors regulating the expression of VEGF The 
mechamsms through which tamoxifen reduces serum VEGF should also be further 
studied with the ultimate goal of producing a more potent therapeutic agent that 
further reduces VEGF production by tumours and further decreases tumour growth
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Appendix I - Representative standard curves.
VEGF (pg/ml)
A.
Representative standard curve from developed ELISA used for VEGF measurements m 
conditioned medium Regression coefficient, r2 = 0 988
180
VEGF (pg/ml)
B
Representative standard curve from commercial ELISA used for VEGF measurements 
m serum and tumour homogenates Regression coefficient, r2 = 0 998
181
TGFf3-l (ng/ml)
C.
Representative standard curve from commercial ELISA used for TGFp-1 measurements 
m serum, tumour homogenates and conditioned medium Regression coefficient, r2 =
0 998
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Appendix 2 -  Table of pre and post-tamoxifen serum VEGF and TGFJ3-1 levels in 
patients receiving 2 weeks pre-operative tamoxifen (5.2.2).
No. VEGF
(pre)
VEGF
(post)
TGFß-1
(pre)
TGFß-1
(post)
ER Stage Age Type
1 297 43 181 02 36 73 32 51 n/a n/a 69 n/a
2 199 27 78 52 55 32 38 54 pos T1 60 ductal
3 197 53 134 12 40 29 37 89 pos T3 54 lobular
4 109 79 98 50 36 00 31 49 neg T2 60 ductal
5 313 93 190 58 42 97 32 73 neg T2 65 ductal
6 465 95 406 88 60 55 61 94 neg T1 59 ductal
7 219 25 182 76 59 76 55 32 neg T1 76 ductal
8 318 28 1721 21 44 35 41 01 pos T2 59 ductal
9 158 03 113 40 72 30 15 63 neg T3 74 ductal
10 1330 29 654 39 76 90 65 55 pos T4 53 ductal
11 124 47 125 78 40 90 58 18 neg N/A 63 n/a
12 126 36 109 55 46 75 45 29 pos T2 64 ductal
13 316 22 290 94 42 52 46 15 n/a T4 70 ductal
14 68 26 26 86 48 60 27 70 neg N/A 66 ductal
15 49 81 49 94 49 81 49 94 neg T1 59 ductal
16 81 36 151 36 44 30 62 49 n/a N/A 54 n/a
17 347 27 367 27 51 24 52 29 pos T1 50 ductal
18 508 18 290 91 40 70 37 29 neg T4 57 ductal
19 725 00 691 82 45 72 49 71 n/a T4 79 n/a
20 544 55 325 91 48 50 44 44 neg T2 52 ductal
Pre = pre-tamoxifen, post = post-tamoxifen, n/a = not available, neg = negative, pos = 
positive
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